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THESIS ABSTRACT 
Hepatocellular carcinoma (HCC), the commonest primary liver tumour, is curable if detected 
early. It is often diagnosed late, carrying a devastating prognosis. In part, this is due to lack of 
accurate diagnostic markers. Using proton nuclear magnetic resonance (
1
H NMR) 
spectroscopy and ultra performance liquid chromatography mass spectrometry (UPLC-MS), 
metabolic profiles of plasma, serum and urine were generated from an animal model of HCC 
and  three cohorts of patients with HCC from Nigeria, Egypt and the UK. 
 
Plasma 
1
H NMR spectra from an animal model of HCC displayed decreases in lipoproteins, 
acetyl-glycoprotein, acetoacetate and glucose (p≤0.001). Blood 1H NMR studies of Nigerian 
and Egyptian patients with HCC compared to healthy controls and those with cirrhosis 
revealed alterations in levels of LDL (p=0.002, 0.12), VLDL (p=<0.001, 0.77), lactate 
(p=0.03, 0.12), N-acetylglycoproteins (p=<0.001, 0.001) and acetoacetate (p=0.52, 0.06). 
Using UPLC-MS blood profiling, lysophosphatidylcholine (24, 0, 0) (LPC), a major cell 
membrane component, was identified as altered between groups.  
 
Urine 
1
H NMR spectral profiles were distinguished in a Nigerian, mostly HBV-infected HCC 
cohort, with a sensitivity/specificity of 100%/93% and 89.5%/88.9% from healthy subjects 
and patients with cirrhosis. Urinary creatinine (p<0.001, 0.06), carnitine (p=0.04, <0.001) and 
creatine (p=0.05, 0.29) were contributory. In an Egyptian, mostly HCV-infected HCC cohort, 
sensitivity/specificity was 100%/94% and 81%/71%, displaying reduced creatinine (p=0.003, 
<0.001), glycine (p=<0.001, 0.88), trimethylamine-N-oxide (p=<0.001, 0.18), hippurate 
(p=<0.001, 0.66), citrate (p=<0.001, 0.12) and increased carnitine (p=0.29, 0.30) and creatine 
(p=0.12, 0.33) levels. In the UK cohort, sensitivity/specificity was 53.6%/96%. UPLC-MS of 
urine from the Nigerian HCC cohort identified elevated acetylcarnitine levels (p=0.07, 
<0.001). 
 
Both in blood and urine, HCC induces a metabolic profile change that can distinguish 
patients from healthy or cirrhotic controls. Furthermore, there exists some similarity between 
distinct populations. Underlying pathways may include heightened cellular proliferation, 
altered cellular, aberrant lipid metabolism and cancer cachexia.   
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1  INTRODUCTION 
1.1 HEPATOCELLULAR CARCINOMA  
Hepatocellular carcinoma (HCC) is the commonest primary tumour of the liver. It is likely to 
originate from hepatic stem cells, although the exact lineage remains not well established 
(Mishra et al., 2009; Sell, 2008). Internal and external stimuli, such as viral DNA integration, 
inflammation and fibrosis, are likely to induce alterations in tumour originator cells leading to 
apoptosis, cell proliferation, dysplasia and eventually, neoplasia. As with other malignancies, 
it is likely that genetic abnormalities give rise to uncontrolled cellular division through 
disruption of proliferative cellular pathways (Vogelstein and Kinzler, 2004). 
 
1.1.1  Epidemiology 
Hepatocellular carcinoma is the 3
rd
 most common cause of cancer-related death, worldwide, 
causing 695, 000 deaths in 2008 (World Health Organisation, 2008). There is a distinct 
geographical variation in HCC incidence with 85% of cases occurring in the developing 
world where hepatitis B virus (HBV) is endemic. The highest incidence rates occur in sub-
Saharan Africa and Southeast Asia. In 2008, there were 292, 966 cases in China alone (World 
Health Organisation,  2008) (Figure 1-1).   
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Figure 1-1. Estimated global age-standardised liver cancer incidence.  
Key: Rates per 100,000, Adapted from (World Health Organisation,  2008). 
 
In the developed world, the incidence of HCC, apart from in Japan (25,749 cases in 2008), is 
comparatively low, but there has been a steady overall increase across most western nations 
over the last two decades (World Health Organisation,  2008).    
 
1.1.2  Aetiology 
The prime risk factor for HCC is cirrhosis (Parkin et al., 2001; Parkin, 2001; Parkin, 2006; 
Shariff et al., 2009). Approximately 80 to 90% of HCCs occur on the background of chronic 
liver disease, although not all causes of cirrhosis carry the same risk. There is a 2:1 
preponderance of male incidence of HCC and risk rises with age, with cases below 40 years 
being rare (El-Serag, 2011; World Health Organisation,  2008).  
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1.1.2.1 Viral hepatitis 
Patients with viral hepatitis display heightened risk compared to other forms of chronic liver 
disease. Chronic HBV, in the presence of cirrhosis, increases the risk of HCC 1000-fold 
(Beasley et al., 1981). Currently, HBV accounts for 50% of cases of HCC worldwide and is 
now classed as the world’s most potent carcinogen after tobacco by the World Health 
Organisation (Parkin et al., 2001; Parkin,  2001; Parkin,  2006). Hepatocellular carcinoma 
may also occur on the background of HBV without the presence of cirrhosis, implicating 
other mechanisms of oncogenesis other than chronic hepatic damage. 
 
Chronic hepatitis C virus (HCV) causes cirrhosis in 30% of patients and 1 to 2% of these will 
develop HCC per year. Evidence of HCV infection are found in 80 to 90% of patients with 
HCC in Japan, 44 to 66% in Italy and 30 to 50% in the United States (El-Serag,  2011; El-
Serag and Rudolph, 2007). Hepatocellular carcinoma, related to HCV infection, has become 
the fastest-rising cause of cancer-related death in the United States (El-Serag,  2011).  
 
1.1.2.2 Aflatoxin B1 
Aflatoxin B1 (AFB1) is a mycotoxin produced by a fungus of the Aspergillus spp., which 
contaminates a number of tropical and subtropical region staple foodstuffs (grain, corn, 
peanuts and legumes) (Groopman et al., 1996; Qian et al., 1994). Areas of high HCC 
incidence and high aflatoxin intake correspond to areas where HBV is endemic. Hepatitis B 
virus and AFB1 are therefore likely to interact synergistically increasing carcinogenic risk. At 
the molecular level, once ingested, AFB1 is metabolised to AFB1 –exo- 8,9-epoxide which 
can bind to DNA and may initiate carcinogenesis through an inactivating mutation of the 
third base codon 249 of the p53 tumour suppressor gene. This mutation is found in 30-60% of 
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HCC tumours in aflatoxin endemic areas endemic areas (Bressac et al., 1991; Wild and 
Turner, 2002).  
 
1.1.2.3 Non-alcoholic fatty liver disease 
Non-alcoholic fatty liver disease (NAFLD), in the form of non-alcoholic steatohepatitis 
(NASH), has been implicated as a risk factor for HCC. This condition often occurs 
concurrently with features of the metabolic syndrome, including obesity, hypertension and 
diabetes mellitus. Studies from the United States have shown that historically no underlying 
risk factor for HCC was identifiable in 30-40% of cases, in the presence of so-called 
“cryptogenic” cirrhosis and it is likely that these cases were NASH associated (El-Serag and 
Rudolph, 2007).  A retrospective Italian study of 641 cirrhosis-associated HCCs, observed 
that 44 cases were associated with cryptogenic cirrhosis and in this group the prevalence of 
obesity and diabetes mellitus was significantly raised (Bugianesi et al., 2002). A Japanese 
cohort-study followed biopsy-proven NASH patients with advanced fibrosis and observed 
that the 5-year cumulative incidence of HCC was 7.6%. The burgeoning epidemic of 
worldwide obesity is likely to make NASH associated HCC a prevalent problem.   
 
1.1.2.4 Alcohol 
Heavy alcohol use (40 to 60g per day) is a risk factor for HCC (El-Serag,  2011). The risk is 
likely to arise through developing cirrhosis. Abstinence does not appear to affect HCC risk 
once cirrhosis is established, although alcohol has been shown to act synergistically, linearly 
increasing HCC risk, in the presence of other risk factors, particularly viral hepatitis (Donato 
et al., 2002). 
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1.1.3 Prognosis, surveillance and the importance of early tumour diagnosis 
The prognosis for patients with HCC remains poor, even in the developed world. In the 
United States, between 2001 and 2007, 5-year survival rates of those with a solitary HCC 
were 27%. This drops to 8.7% once the tumour has spread (U.S.National Institutes of Health, 
2008).  
 
Early diagnosis of HCC, when the tumour is amenable for surgical resection, ablation or liver 
transplantation, has been shown to vastly improve patient prognosis. Landmark trials by 
Mazzeferro and colleagues have established criteria for the selection of patients with HCC 
who benefit from orthotopic liver transplantation (OLT). If carefully selected, patients with 
early HCC carry similarly high post-transplant survival rates as for other indications for OLT  
(Mazzaferro et al., 1996; Mazzaferro et al., 2009).  The survival benefit results from smaller 
tumour size and burden as well as the absence of micro-vascular invasion.  
 
Population based studies have shown conflicting mortality benefit from HCC surveillance 
programmes. A Chinese study showed that the use of serum -fetoprotein (AFP) with liver 
ultrasound surveillance resulted in a 3-year cumulative survival rate of 36% for surveyed 
patients and 0% for non-surveyed patients (p<0.0001) (Yuen et al., 2000).  A randomised 
control trial of nearly 19,000 HBV-infected patients in China showed that 6-monthly serum 
AFP measurements and liver ultrasound resulted in a 37 % reduction in HCC-related 
mortality (Zhang et al., 2004).  A further randomised control trial of HBV infected patients in 
China was undertaken in 5000 patients but only using 6-monthly AFP. Tumours were 
diagnosed earlier but there was no mortality benefit (Chen et al., 2003). Nonetheless, 
international societies recommend 6-monthly screening by ultrasound (US) +/- serum AFP in 
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all patients with cirrhosis (Bruix and Sherman, 2005; Bruix and Sherman, 2011; Ryder, 
2003).  
 
1.1.4 Diagnosis 
Clinical symptoms and signs of HCC are often absent or non-specific. Most cases occur in 
patients with established cirrhosis and may cause hepatic decompensation, but equally, HCC 
may lie silent in those with compensated liver disease. The key and as yet, unmet need is to 
identify small tumours, amenable to curable treatments, in nodular cirrhotic liver 
parenchyma. In developing countries, medical advice is often sought late resulting in delayed 
presentation with end-stage signs of a palpable hepatic mass, haemoperitoneum or 
decompensation with portal hypertensive complications.  
 
Diagnosis is based on the fact that HCCs are highly arterialised, in contrast to the remainder 
of the liver. The most recent American Association for the Study of Liver Disease (AASLD)  
guidelines require the presence of features typical of HCC (arterial hypervascularity and 
venous phase washout) in just one imaging modality for lesions >1 cm (Bruix and Sherman, 
2011).   Previous guidelines suggested that  diagnosis was  made by the confirmation of two 
contrast-enhanced imaging modalities (ultrasound, computed tomography or magnetic 
resonance imaging) with characteristic features or one imaging modality suggestive of HCC 
with an AFP level of >400 ng mL
-1 
(Bruix and Sherman, 2005).   
 
Surveillance for HCC is recommended using US at 6 to 12 month intervals. The use of AFP 
for surveillance is not recommended unless US is unavailable according to the AASLD 
guidelines, although this remains controversial (El-Serag,  2011).  
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1.1.5 Serum markers of hepatocellular carcinoma 
1.1.5.1 Serum α-fetoprotein 
Serum AFP is the most widely used marker of HCC. It is a fetal glycoprotein which is 
synthesized in utero by the embryonic liver, cells of the vitelline sac and the fetal intestinal 
tract. Serum AFP is usually undetectable in healthy adults (Gomaa et al., 2009). The 
production of AFP by HCC cells has been seen as confirmation that the tumour arises from 
hepatic stem cells as a form of maturation arrest, akin to an embryonic state (Sell,  2008).  
The AFP gene is located on chromosome 4 (4q11 – 4q13) and is part of the albimunoid 
super-family of genes which includes the albumin gene (Debruyne and Delanghe, 2008). The 
function of AFP remains unclear, with some studies suggesting a role in transport of certain 
molecules such as bilirubin, fatty acids, retinoids, and others a role in immunosuppression 
(Debruyne and Delanghe, 2008).  
 
Not all HCCs secrete AFP and its diagnostic accuracy is variable. A meta-analysis of AFP for 
HCC surveillance found that it displayed a sensitivity of 39% to 65% and a specificity of 
76% to 94% for tumour diagnosis (Daniele et al., 2004). The cut-off level of AFP was 
important in determining the diagnostic power. A cut-off of 20 ng mL
-1
 resulted in a 
sensitivity of 64% and specificity of 91% (Sherman et al., 1995), while a cut-off of 400 ng 
mL
-1
 resulted in a sensitivity of 17% and specificity of 99% (Trevisani et al., 2001). Values 
of over 400 ng mL
-1
 are generally considered diagnostic of HCC, although only about 20% of 
patients with HCC display values this high. Furthermore, patients with chronic viral hepatitis 
may display a raised AFP during viral flares without the presence of HCC. In a study of 290 
Chinese patients with chronic HBV, 44 were found to have elevated serum AFP levels (>20 
ng mL
-1
) and only six (13%) had HCC. The remaining 38 had elevated serum AFP either due 
to viral flares or unknown causes (Lok and Lai, 1989). Trevisani and colleagues also 
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observed that an AFP elevation in non-infected patients could be more indicative of HCC 
when compared to infected patients (Trevisani et al., 2001).   
 
It would appear logical that if AFP is specific to HCC then targeted immunotherapy may be 
effective in selectively neutralising HCC cells. This, however, is not the case. Because AFP is 
a “self” antigen, usually secreted in utero, targeted therapy may result instead in 
autoimmunity. Furthermore, Butterfield and colleagues conducted two clinical trials of 
infused AFP immunostimulant peptides and AFP-stimulated dendritic cells (Butterfield, 
2007). Both were unsuccessful in showing any tumour-regressive effects, albeit in patients 
with advanced disease. In the latter study, there was serological evidence of increased 
interferon gamma producing AFP-specific T cells, perhaps suggesting that an AFP HCC 
vaccine is conceivable but immunomodulatory therapy remains unlikely.    
 
1.1.5.2 Lens culinaris agglutinin-reactive AFP 
Lens culinaris agglutinin-reactive AFP (AFP-L3) is a glycoform variant of AFP and is 
expressed as a percentage of the total AFP level. It can be detected in approximately one third 
of patients with small HCCs (<3cm) when cut-off levels of 10% to 15% are used. At higher 
cut-off levels of >15%, AFP-L3 displays a sensitivity of 75% to 96.9% and specificity of 
90% to 92% (Khien et al., 2001; Kumada et al., 1999). The usefulness of this marker is 
limited as studies have only been conducted in East Asian populations in whom AFP levels 
are already raised.  
 
1.1.5.3 Des gamma carboxyprothrombin 
Des gamma carboxyprothrombin (DCP) is an abnormal prothrombin protein and is also 
known as prothrombin induced by vitamin K absence II (PIVKA II). It is produced as a result 
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of an acquired defect in the post-translational carboxylation of the prothrombin precursor in 
malignant cells, the gene responsible being gamma-carboxylase (Grizzi et al., 2007). In 
several large studies, serum DCP was found to display poor diagnostic sensitivity (48% to 
62%) but good specificity (81% to 98%) for HCC (Grizzi et al., 2007; Marrero et al., 2003). 
A study comparing the performance characteristics of AFP, DCP and Lens culinaris 
agglutinin-reactive AFP in the diagnosis of HCC observed that DCP was significantly better 
than the other markers in differentiating HCC from cirrhosis, with a sensitivity of 86% and a 
specificity of 93% (Volk et al., 2007). There are conflicting reports, however, with a study by 
Nakamura and colleagues reporting that the efficacy of DCP was lower than that of AFP in 
the diagnosis of small tumours, although higher than that of AFP for large tumours 
(Nakamura et al., 2006).  
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1.1.5.4 Alpha-l-fucosidase 
Alpha-l-fucosidase (AFU) is a glycosidase found in cellular lysozomes and increased activity 
is found in patients with HCC. Studies of its diagnostic accuracy have displayed high 
sensitivity (82%) and specificity (70.7 – 85.4%) (Ishizuka et al., 1999; Tangkijvanich et al., 
1999; Wang and Cao, 2004). A comparative study of AFP and AFU in an Egyptian cohort 
found AFU to have a higher sensitivity (81.8% vs. 68.2%) but lower specificity (55% vs. 
75%) with a combined AFP + AFU sensitivity of 88.6% (el-Houseini et al., 2005). 
Unfortunately, AFU has been found to be elevated in other tumours and is therefore not 
specific to HCC (Gomaa et al., 2009).  
  
1.1.5.5 Glypican-3 
Glypican-3 (GPC3) is a heparin sulphate proteoglycan and has been shown to be capable of 
promoting the proliferation of tumour cells by modulating Wnt pathways and affecting 
cellular adhesion. As a tumour marker, GPC3 expression has been shown to be elevated in 
HCC tissue and in serum of 40 to 53% of patients with HCC (el-Houseini et al., 2005). A 
summary of the performance of the various serum markers is displayed in Table 1-1. 
 
 
Table 1-1. Diagnostic performance of serum markers of hepatocellular carcinoma.  
Serum marker Sensitivity (%) Specificity (%) 
AFP 39 – 65 79 - 94 
AFP-L3 75 - 97 90 - 92 
DCP 48 - 62 81 - 98 
AFU 82 71 - 85 
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1.1.6 Urinary markers of hepatocellular carcinoma 
The concept of urinary markers for HCC is not new and dates back to initial studies in the 
1970s. For any urine biomarker three central attributes are necessary for it to fulfil. First, the 
biomarker, if produced pre-renally, needs to be small enough and of the correct ionic charge 
to be filtered by the renal glomerulus and not re-absorbed by the tubules. Therefore, it has to 
be roughly less than 20 kDa in atomic weight. Second, the marker should be specific to the 
cancer in question and not secondary to the effects of cancer on general physiology. Finally, 
the marker should be secreted in adequate amounts for accurate, repeatable detection in early 
disease. Large, complex proteins are unlikely to enter the urinary stream, so are not 
candidates for urinary biomarkers.  
 
1.1.6.1 Nucleosides 
Studies in the 1970s observed elevated levels of the methylated purines 7-methylguanine, 1-
methylguanine, N-dimethylguanine, 1-methylhypoxanthine and adenine in the urine of 
patients with HCC. In 1976, it was found that urine levels of cyclic guanosine 3’:5’ 
monophosphate (cGMP) were elevated in rats with transplanted liver and renal tumours 
(Criss and Murad, 1976). In 1982, Dusheiko and colleagues, found parallels in human 
studies, observing elevated urinary cGMP levels in patients with HCC (Dusheiko et al., 
1981). In the same study, cGMP was also elevated in the urine of patients with liver disease 
and other non-HCC tumours, reducing the specificity of the marker considerably.  
 
In 1986, Tamura and colleagues observed that urinary levels of pseudouridine, a C-glycoside 
isomer of the nucleoside uridine, to be elevated in patients with HCC (Tamura et al., 1986). 
When combined with serum AFP, sensitivity for HCC detection was 83%. Disappointingly, 
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this marker was also non-specific and found to be similarly elevated in patients with other 
malignancies such as non-Hodgkin’s lymphoma.  
 
In a Taiwanese patient study it was observed that the urinary nucleosides adenosine, cytidine 
and inosine were elevated in patients with HCC (Jeng et al., 2009). When combined with 
serum AFP, sensitivity for tumour diagnosis was 80%. The study was flawed in that controls 
consisted of healthy patients with no liver disease and ideally the finding should have been 
confirmed in comparison to a group of patients with cirrhosis.   
 
1.1.6.2 Transforming growth factor α and β 
Transforming growth factor α and β (TGFα and β) have both been detected in the urine of 
patients with HCC. The first report was from 1990, observing elevated TGFα levels in urine 
(Katoh et al., 1990).  In 1991, a TGF-related protein was found in HCC patient urine and this 
was confirmed as TGFβ1 in 1997 by the same group (Chuang et al., 1991) (Tsai et al., 1997). 
In these studies, TGFβ1 correlated with prognosis and survival. A functional link was 
attractive as TGFs are known to stimulate non-transformed cells reversibly to grow as 
colonies in vitro.  
 
1.1.6.3 Neopterin 
In 1998, a study performed in Japan found neopterin, a protein now known to be released 
from macrophages following inflammatory stimulation, to be elevated in the urine of patients 
with advanced HCC (Daito et al., 1992; Kawasaki et al., 1988).  Similar to other potential 
markers, neopterin has since been shown to be elevated in a number of malignancies and pro-
inflammatory conditions such as human immunodeficiency virus (HIV) related disease, 
reducing its validity as a specific marker for HCC (Sucher et al., 2010).  
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1.1.6.4 Polyamines 
The polyamines, organic compounds containing two or more amine groups, include 
putrescine, spermine, and spermidine. Their exact cellular role is unclear but they are 
required for cellular proliferation. Putrescine acts on S-adenosylmethionine (SAMe), a 
methylating molecule, to produce spermine which in turn acts on further SAMe molecules to 
produce spermidine (Wishart et al., 2007). Antionella and colleagues reported increased 
urinary levels of free and acetylated polyamines using HCC patients compared to healthy 
controls and patients with cirrhosis (Antoniello et al., 1998), although the sensitivity of these 
markers was found not to be high enough for early tumour detection.   
 
1.1.6.5 Urinary trypsin inhibitor 
Urinary trypsin inhibitor (UTI) is a 25 kDa protein thought to be produced by hepatocytes. In 
2004, an ELISA-based study observed that urinary UTI was elevated in patients with HCC, 
albeit not significantly when compared to patients with cirrhosis (Lin et al., 2004). Follow-up 
studies have found correlations with severity of liver disease and patient prognosis in general 
but not specifically with HCC (Kikuchi et al., 2009).  
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1.1.7 The origin and pathogenesis of hepatocellular carcinoma 
Genetic profiling studies of HCC tissue have shown several genes to be disrupted through 
somatic mutations, chromosomal disruption and epigenetic aberration through methylation 
abnormalities including p53, Rb1, β-catenin, CMYC and survivin.  The WNT-β catenin 
pathway is the most commonly disrupted pathway, usually as a result of mutations in 
CTNNB1, AXIN1 genes, CDH1 epigenetic silencing and changes in expression of WNT 
receptors from the Frizzle Family (Minguez et al., 2009). Activation of the pathway induces 
translocation of β-catenin into the nucleus where it regulates specific oncogenes such as 
CMYC and CCND1. An initial somatic mutation in an oncogene or tumour suppressor gene is 
likely to generate a clonal expansion of cells which then have the potential, through further 
“proliferation advantageous” mutations and chromosomal disruptions, to develop into pre-
neoplastic lesions. These lesions, often <1 cm, have been identified in patients with cirrhosis 
and have been sub-classified into low or high grade dysplastic nodules (Fernandez et al., 
2009).  The former carry a low risk and the latter a very high risk, of malignant 
transformation.  
 
 
1.1.7.1 The “angiogenic switch” 
Dysplastic nodules are hypoechoic on ultrasound imaging and derive their blood supply from 
the portal vein. Established HCC displays typical arterial phase uptake on contrast imaging. 
At a critical point an “angiogenic switch” is activated which stimulates arterial neo-
vascularisation of the nodule and development of an established HCC (Figure 1-2). Japanese 
groups have identified this as a critical moment before which total cure with resection is 
likely and after which prognosis deteriorates rapidly (Takayama et al., 1998).   
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Certain factors may contribute to “neo-angiogenesis” of HCCs.  Vascular endothelial growth 
factor (VEGF) and platelet derived growth factor (PDGF) have been implicated as 
angiogenesis modulators. HCC cell lines may produce VEGF by themselves and increased 
concentration of VEGF in the serum of patients with HCC has been correlated with outcome 
after surgical resection (Armengol et al., 2004; Poon et al., 2004). Hypoxia inducible factor 
(HIF 1), a factor commonly expressed in HCC and heavily influential upon cellular 
metabolism, has been shown to induce expression of VEGF. A number of oncogenes have 
also been implicated in angiogenesis such as ras and myc (Vogelstein and Kinzler, 2004). 
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. The “angiogenic switch” in HCC. 
 
 
 
It has been shown that chemotherapeutics active against HCC such as the multikinase 
inhibitor sorafenib, exert their effects through inhibition of pro-angiogenic factors such as 
VEGF and PDGF, establishing neo-angiogenesis as a major therapeutic target in HCC 
(Fernandez et al., 2009).  With the onset of neo-angiogenesis, there is likely to be a rapid 
change in the metabolism of tumour cells and also the surrounding stroma (Fraisl et al., 
2008). The importance of the interaction between tumour and stromal cells is becoming 
increasingly recognised. Vizan and colleagues, studied the metabolic adaption of endothelial 
cells, to stimulation by VEGF and fibroblast growth factor (FGF). Glycogen synthesis, the 
pentose cycle and glycolytic pathways were shown to be essential for endothelial cell 
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proliferation and inhibition of these pathways decreased endothelial cell viability and 
migration (Vizan et al., 2009). The interaction of cellular metabolism and neo-angiogenesis is 
therefore crucial to tumour development.      
 
1.18 Treatment options 
Hepatocellular carcinoma is curable. The Barcelona Clinic Liver Cancer (BCLC) algorithm is 
the most widely recognised staging and treatment guidelines (Bruix and Sherman, 2011). 
Early tumours (single lesions or three lesions all less than 3cm) are amenable to resection, 
especially if in non-cirrhotic livers, or OLT, in those that are cirrhotic. Indeed, for those 
tumours less than 2cm, radio-frequency ablation has been shown to be curative (Livraghi et 
al., 2008). In those patients with intermediate stage multinodular tumours, trans-arterial 
chemoembolisation (TACE) is recommended. In resource poor settings, simpler, inexpensive 
techniques, such as ethanol injection, are highly effective in causing tumour necrosis. In those 
patients with advanced tumours, not amenable to any of the options above, sorafenib, an oral 
multikinase inhibitor has been shown to provide a survival benefit of 10.7 months versus 7.9 
months (Llovet et al., 2008).  
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1.2 ALTERED TUMOUR METABOLISM 
There is increasing evidence that altered metabolism in tumour cells is both a cause and 
effect of carcinogenesis. Tumour cells require increased amounts of energy and substrates for 
de novo synthesis of nucleotides, lipids, and proteins for rapid proliferation. Otto Warburg, in 
the 1920s, pioneered the theory of altered tumour metabolism. Recent evidence both supports 
and disputes his original conclusions.  
 
1.2.1 The “Warburg Effect” and glycolysis 
In 1924, Warburg, through placing a section of rat carcinoma in nitrogen-saturated Ringer’s 
solution (to simulate anaerobic conditions), observed that the tumour could be transplanted to 
a live donor if sugar was included in the Ringer’s solution, but not if the solution was left 
plain (Warburg et al., 1924). Following this work, Warburg discovered that even in the 
presence of oxygen, cancer cells preferentially metabolise glucose by glycolysis as oppose to 
oxidative phosphorylation, a vastly more inefficient route for energy production. He 
hypothesised that the increase in glycolysis under normal oxygen conditions arose from a 
deficiency in the mitochondrial oxidative phosphorylation (Warburg, 1958) (Figure 1-3). He 
thus established that tumour cells take up glucose at high rates to fuel heightened glycolysis. 
Indeed, it is upon this basis that tumours can be identified with glucose-labelled positron 
emission tomography (Ariff et al., 2009). Glycolysis generates adenosine triphosphate (ATP) 
with lower efficiency but at a faster rate than oxidative phosphorylation, which may be of 
benefit for rapidly dividing cells. The role of mitochondria in tumour cells is contentious. 
Primary defects in oxidative phosphorylation (which occurs within the mitochondrial 
membrane) have been invoked to explain the Warburg phenomenon because tumour 
mitochondria are often small, lack cristae and are deficient in the β-F1 subunit of the ATPase 
(Kroemer and Pouyssegur, 2008; Lopez-Rios et al., 2007). However, many groups have 
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demonstrated that tumour cell mitochondria are actually functional and even Warburg 
admitted that despite their high glycolysis rate, oxygen consumption by cancer cells is not 
diminished (Weinberg and Chandel, 2009). Furthermore, HCC is a highly vascular tumour 
that, certainly in the early stages, is likely to be adequately supplied with oxygenated blood. 
Importantly, glycolysis also provides intermediates for the pentose phosphate pathway and 
subsequent biosynthesis of nucleic acids. Which of these functions heightened glycolysis 
serves is, as yet, unresolved.  
 
 
 
Figure 1-3. Warburg theory of heightened glycolysis in tumour cells.  
Key: TCA, tri-carboxylic acid cycle; ATP, adenosine triphosphate; NAD, nicotinamide 
adenine dinucleotide.  
 
There is now some consensus that the major role of heightened glycolysis in tumour cells is 
to provide substrates to the pentose phosphate pathway for nucleotide synthesis, rather than 
energy provision in the form of ATP (Vander Heiden et al., 2009; Weinberg and Chandel, 
2009). In essence, the tumour is maximising production of cellular constituents for 
proliferation at the expense of energy production.  
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Glutamine, through entering the TCA cycle via a glycolysis-independent pathway, may also 
provide an alternative route to traditional oxidative phosphorylation for energy production. In 
vitro studies have identified the importance of glutamine as an important substrate for tumour 
and in particular, hepatoma cells. Reitzer and colleagues, in 1979, observed that glutamine 
and not glucose, was the major energy source for cultured HeLa cells (Reitzer et al., 1979). 
Glutamine is converted to α-ketoglutarate through glutaminolysis, to fuel the TCA cycle. It 
has also been shown that the higher the level of aspartate aminotransferase activity, a catalyst 
of glutaminolysis, the higher the rate of cellular proliferation (Sheid et al., 1965). 
Furthermore, Ehrlich rat hepatoma cells oxidise glutamine at higher rates than any other 
amino acid (Lazo, 1981; Weinberg and Chandel, 2009).  
 
Both in the presence of tumour and as a stimulant factor, altered lipid metabolism has been 
implicated. The rate of HCC occurrence in the presence of non-cirrhotic NAFLD is 
increasingly described, suggesting carcinogenic mechanism in the presence of cellular 
accumulated lipids other than fibrosis and inflammation. A possible mechanism for this is 
through TNFα activation, the major molecule involved in hepatic inflammation, which has 
been shown to promote hepatic insulin resistance which in turn promotes lipid accumulation. 
Furthermore, TNF and IL-6 are both involved in the activation of JAK/STAT and ERK 
pathways, which are both crucial in the development of HCC in an obese rat model 
(Bechmann et al., 2012).  
 
 
1.2.2 Molecular effectors and tumour metabolism 
Several oncogenes and tumour suppressor genes have been implicated in altered tumour 
metabolism. Sequential mutations are common in HCC and two effectors in particular, HIF 1 
and p53, may be responsible for some of the metabolic changes arising in HCC. 
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1.2.2.1 Hypoxia inducible factor  
Hypoxia inducible factor 1 is a heterodimeric protein complex transcription factor that is 
activated by hypoxic, inflammatory, metabolic and oxidative stress (Harris, 2002; Kroemer 
and Pouyssegur, 2008; Weinberg and Chandel, 2009). The HIF 1 heterodimeric complex 
(HIF 1α + HIF 1β) is stabilised at low oxygen levels, but degraded by the proteasome in 
normoxic conditions. The HIF 1 heterodimer stimulates glycolysis by increasing the 
expression of pro-glycolytic uptake enzymes and transport molecules, such as GLUT 1 and 
hexokinase (Weinberg and Chandel, 2009). HIF 1β deficient hepatoma cells grown as solid 
tumours in mice were found to have reduced rates of growth and glycolytic intermediates 
compared to wild type hepatoma cells (Griffiths et al., 2002). It would therefore appear that 
HIF 1 may play a central role in the Warburg model. However, HIF 1 is only stable in 
hypoxic conditions and Warburg’s model describes heightened glycolysis in normoxic 
conditions. Only a minority of cancers display aberrant HIF 1function in normoxia, such as 
renal cell carcinoma (Semenza, 2007). The role of HIF 1 in HCC is still under investigation 
but a number of recent studies, mostly in animal models, have observed high HIF 1 activity 
and its downstream counterparts, such as GLUT1, in hepatoma cells (Amann et al., 2009; 
Wang et al., 2009; Yao et al., 2009).  
 
 
1.2.2.2 p53 
Tumour suppressor genes, such as p53, have also been implicated in alterations in 
metabolism. Inactivation of p53 can cause the Warburg phenomenon. p53 positively 
regulates the expression of the protein synthesis of cytochrome c oxidase 2, which is required 
for the assembly of the oxidative phosphorylation enzyme, cytochrome c oxidase (Matoba et 
al., 2006) and also negatively regulates phosphoglycerate mutase,  a key glycolytic enzyme 
(Kondoh et al., 2005).  In addition, p53 transcriptionally activates  TP53-induced glycolysis 
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and apoptosis regulator (TIGAR) an inhibitor of phosphofructokinase activity which in turn 
lowers the level of fructose 1,6-biphosphate which acts as an allosteric activator of glycolytic 
enzymes (Bensaad et al., 2006).  
 
These examples illustrate the evidence that genetic alteration through tumour-driven mutation 
can affect metabolism. It is likely that many genes and proteins are involved in altered 
tumour metabolism, with a few taking a lead role.  
 
 
 
1.2.3 Metabolite effects on carcinogenesis 
Metabolites can affect carcinogenesis and may not be mere by-products of cellular reactions. 
Lactate, thought to be a “waste” product of glycolysis, may be such a signal. Lactate may 
stimulate HIF 1 independently of hypoxia (Hsu and Sabatini, 2008) and may condition the 
tumour environment and suppress anticancer immune effectors (Koukourakis et al., 2006; 
Kroemer and Pouyssegur, 2008; Swietach et al., 2007).  
 
HIF 1 can also be stimulated by the build up of TCA cycle intermediates, fumarate and 
succinate. This is evidenced through tumourogenic germline mutations of TCA cycle 
enzymes fumarate hydratase and succinate dehydrogenase, resulting in an accumulation of 
fumarate and succinate which competitively inhibit the α-ketoglutarate-dependent HIF-1 α 
prolyl hydroxylase, the enzyme that targets HIF 1 for destruction (Gottlieb and Tomlinson, 
2005).  
 
Through high-throughput liquid-and-gas-chromatography-based mass spectrometry of urine 
and plasma from patients with prostate carcinoma, Sreekumar and colleagues identified 
Sarcosine (Sreekumar et al., 2009), a metabolite derivative of glycine, as a marker of the 
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cancer. Furthermore, exogenous addition of sarcosine to tumour cells, or knockdown of 
sarcosine degrading enzymes, caused a shift of benign prostatic cells into a malignant 
phenotype. Although promising, sarcosine has not lived up to this promise in follow up 
studies by other groups. Jentzmik and colleagues found that urinary sarcosine could not 
reliably differentiate prostate carcinoma from benign prostatic disease after digital rectal 
examination (Jentzmik et al., 2010) and Struys and colleagues observed that serum sarcosine 
levels were not discriminatory between men with metastatic prostate cancer, those with an 
elevated prostate specific antigen (PSA) and healthy controls (Struys et al., 2010).  
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1.3 METABOLIC PROFILING 
Metabolic profiling is a general term encompassing “metabonomics”, which is the study of 
global metabolic responses to physiological, drug and disease stimuli (Nicholson and Lindon, 
2008) and “metabolomics”, which aims to characterise and quantify all the small molecules 
in biofluid sample (Fiehn, 2001). With careful attention to study design, true biomarkers of 
disease can be identified. It iswell recognised, however,  that gender, age, diurnal rhythm, 
diet and ethnicity can affect and bias metabolite profiles (Holmes et al., 2008; Psihogios et 
al., 2008; Slupsky et al., 2007). The largest study of urine metabolic profiles involved over 
4,500 volunteers from Japan, China, UK and the USA (Holmes et al., 2008). Geographical 
and dietary differences appeared to be highly discriminatory, above that of ethnicity and 
population. Indeed, recruits from the UK and USA were poorly distinguished while those 
from South East Asia and the Western population were easily distinguished. Furthermore, 
Japanese individuals domiciled in the US were well discriminated from those in native Japan, 
promoting the divergence of geography and diet and negating that of race. Vegetarians were 
also discriminated from non-vegetarians. Metabolites discriminatory in these studies included 
those closely linked to diet such as creatine and TMAO. Bearing this in mind, metabolic 
profiling study designs should try and compare dietary homogenous populations.   
 
The most commonly used methods of metabolite characterisation are proton nuclear magnetic 
resonance (
1
H NMR) spectroscopy and mass spectrometry (MS). These techniques are 
complimentary and each has advantages and disadvantages (Table 1-2). Sensitivity of MS is 
high, in some forms of gas chromatography (GC)-MS reaching femtomolar levels, but 
samples are degraded during the run and metabolite identification can be challenging (Want 
et al., 2005; Want et al., 2007). Nuclear magnetic resonance spectroscopy displays lower 
sensitivity (nano to milli-molar) but samples remain intact and NMR spectral profiles have 
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been extensively categorised making metabolite identification more straightforward (Holmes 
et al., 1997; Nicholson et al., 1995; Wishart et al., 2007).  
 
 
Table 1-2. Comparison of nuclear magnetic resonance and mass spectrometry.  
Variable NMR MS 
Sensitivity Lower than MS (nanomolar) Higher than NMR (picomolar) 
Sample degradation No Yes 
Reproducibility High Moderate 
Metabolite identification Well categorised Labour intensive 
 
 
 
 
1.3.1 Proton nuclear magnetic resonance spectroscopy  
Nuclear magnetic resonance refers to the behaviour of nuclei subjected to a magnetic field. 
Hydrogen is the most abundant atom in living organisms and using high power magnetic 
fields on in vitro samples high resolution metabolic spectra can be obtained with clearly 
defined metabolite peaks of small molecules (<2 kDa). Comprehensive metabolic profiles 
have been generated from biofluids including urine (Holmes et al., 2008; Williams et al., 
2009), serum (Bertini et al., 2009; Gao et al., 2008; Gao et al., 2009; Nicholson et al., 1995), 
bile (Khan et al., 2005) and intact tissue (Yang et al., 2007). 
 
 
1.3.1.1 Proton nuclear magnetic resonance spectroscopy and hepatocellular carcinoma  
There have been two human studies of HCC using in vitro
 1
H NMR spectroscopy of tissue 
samples. Yang and colleagues, using in vitro magic-angle spinning 
1
H NMR spectroscopy, 
observed that compared to normal adjacent liver tissue, HCC tissue had elevated levels of 
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lactate, glutamate, glycine, leucine, alanine, choline metabolites and 
phosphorylethanolamine, with reduced levels of triglycerides, glucose and glycogen (Yang et 
al., 2007). Soper and colleagues were able to distinguish normal liver tissue from HCC and 
cirrhotic tissue with an accuracy of 98% and 92%, respectively although no description of 
discriminatory metabolites was provided (Soper et al., 2002).  
 
Gao and colleagues utilised 600 MHz 
1
H NMR spectroscopy of serum to distinguish cirrhosis 
and HCC from healthy control specimens, observing that cirrhosis and HCC sera had higher 
levels of acetate, N-acetylglycoproteins, pyruvate, glutamine, alpha-ketoglutarate, glycerol, 
tyrosine, 1-methylhistidine and phenylalanine, together with lower levels of low-density 
lipoprotein, unsaturated lipids, isoleucine, valine, acetoacetate, creatine, choline and 
unsaturated lipids (Gao et al., 2009).  
 
1.3.2 Mass spectrometry 
Mass spectrometry has been utilised for metabolic profiling since the 1970s (Pauling et al., 
1971). Metabolites, or their constituent fragments, are detected and distinguished by their 
molecular weight and ionic charge. Due to their complex nature, biological fluids require 
separation prior to mass spectrometric analysis to achieve detection of as many metabolites as 
possible. The most common separation methods are GC or liquid chromatography (LC). Gas 
chromatography requires extensive sample pre-treatment and derivatisation steps. In contrast, 
LC requires minimal sample preparation and is immediately amenable to biofluid analysis. 
Ultra performance LC (UPLC) utilises separation columns with much smaller particle size 
packing material (1.4 -1.7μm) than traditional columns permitting the injection of liquids at 
pressures exceeding 10 000 psi thus allowing for improved metabolite resolution. Once 
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ionised, the particles are detected usually by a time-of-flight (TOF) analyser, which allows 
the detection of analytes over the range of m/z 50 – 1000 Da. 
 
1.3.2.1 Mass spectrometry and hepatocellular carcinoma 
Mass spectrometry has been widely used for metabolic profiling in cancer, including prostate 
(Sreekumar et al., 2009) and colorectal carcinoma (Qiu et al., 2009). Yin and colleagues 
identified dihydrosphingosine and phytosphingosine as potential serum metabolite 
biomarkers of HCC using reversed phase (RP) LC and hydrophilic interaction 
chromatography (HILIC) MS (Yin et al., 2009). Recently, Chen and colleagues analysed 
serum and urine samples from 82 patients with HCC and compared these profiles to patients 
with benign liver tumours and healthy volunteers (Chen et al., 2011). Forty three serum and 
31 urine metabolites were differentially present in samples of patients with HCC. These 
included bile acids, free fatty acids, inosine and histidine.   
 
Wu and colleagues reported a urinary GC-MS study of 20 HCC patients which identified a 
marker panel of 18 metabolites discriminating HCC and healthy Chinese controls (Wu et al., 
2009). This panel included octanedioic acid, glycine and hypoxanthine.  In the same year, 
Chen and colleagues utilised HILIC and RPLC in a comparison of 21 urine samples of 
patients with HCC to 24 healthy volunteer samples (Chen et al., 2009). In this set, 
hypoxanthine, creatinine, betaine, carnitine, acetylcarnitine, leucylproline and 
phenylacetylglutamine were altered between groups.   
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1.4 RATIONALE FOR STUDY 
1. Mortality from HCC remains extremely high, especially in the developing world 
where surveillance US is not affordable and patients subsequently present late with 
advanced, incurable disease. There is an urgent unmet need of effective and 
minimally invasive biomarkers of HCC. A urine test for HCC would be invaluable in 
this respect.  
 
2. There is limited evidence that HCC induces an altered metabolic phenotype which can 
be detected in the blood and urine of patients. Thus far, all metabolic profiling studies 
of HCC have been undertaken in patients from the same country and with the same 
aetiology of liver disease. Furthermore, the underlying mechanism of how and why 
the tumour causes these metabolic alterations is not clear.  
 
3. Biomarkers of HCC perform poorly and are confined to blood tests which may be 
prohibitively expensive and unavailable in parts of the developing world. Alterations 
in the urine metabolic profiles due to HCC may be amenable for development into a 
non-invasive test for HCC. 
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1.5 HYPOTHESES 
1. The presence of HCC results in altered blood and urinary metabolic profiles which 
can be characterised using 
1
H NMR and LC/MS. 
2. Metabolic blood and urine profiles of HCC can be modelled to allow accurate disease 
diagnosis.  
 
 
1.6 OVERALL AIMS 
1. To characterise blood 1H NMR and LC/MS metabolic profiles of the HCC in a Fisher 
rat model of HCC.  
 
2. To characterise blood 1H NMR and LC/MS metabolic profiles of HCC in 
aetiologically-and culturally-diverse human populations (Nigeria, Egypt and UK).  
 
3. To evaluate the diagnostic accuracy of blood and urine metabolic profiles in 
discriminating samples from patients with HCC from cirrhosis and healthy controls.  
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2 METHODOLOGY 
2.1 PRINCIPLES OF NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY  
2.1.1 Nuclear magnetic resonance and the property of spin 
Nuclear magnetic resonance refers to the behaviour of atoms subjected to a magnetic field, 
first described in 1946 by Bloch and Purcell (Gadian, 1995; Keeler, 2005). Atoms with an 
odd mass number such as proton (
1
H), phosphorus-31 (
31
P) and carbon-13 (
13
C) possess the 
quantum property of “spin” and behave as dipoles aligning along the axis of an applied 
magnetic field (Table 2-1). As hydrogen is the most abundant element in organic materials, it 
is the most commonly studied nuclei in human biofluid NMR.  
 
Table 2-1. Common nuclei studied using nuclear magnetic resonance spectroscopy.  
Nucleus Spin quantum number Natural abundance (%) 
1
H ½ 99.98 
13
C ½ 1.1 
19
F ½ 100 
31
P ½ 100 
 
2.1.2 Spin orientations and energy levels 
A spinning charge, such a proton, generates a magnetic field and the resulting “spin magnet” 
has a magnetic moment (μ) proportional to its spin. Nuclei with spin possess a certain number 
of orientations dependent on the formula: 2I+1; where I = overall spin. Therefore, hydrogen 
nuclei, with a ½ integer overall spin, will have two possible orientations. (Figure 2-1). In the 
presence of an external magnetic field (B0) the protons behave like tiny bar magnets and align 
along the field. Because the nuclei have spin and obey the laws of quantum mechanics, the 
magnetic moment of the nuclei will align parallel or anti-parallel to the applied field.  
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Figure 2-1. Nuclei with spin align to a magnetic field.  
 
If the proton spin is aligned parallel with the field, a lower energy state is required, +½, while 
those protons that spin anti-parallel to the field, -½, require a higher energy state. In the 
absence of an external magnetic field there is no overall magnetisation of the nuclei as an 
equal number of opposing spinning protons cancel each other out.  
 
The difference in energy states between the two orientations of the proton is very small and is 
proportional to the strength of the applied magnetic field (B0). If there is no magnetic field, 
the difference in energy states is zero, while the difference increases with the strength of the 
external field (Figure 2-1). Strong magnetic fields are required for high resolution magnetic 
resonance spectroscopy. Magnetic field strength is measured in Tesla (T) and the earth’s 
magnetic field is approximately 10
-4
 T at ground level. In comparison, magnetic resonance 
spectrometers use powerful magnets with field strengths from 1 to 20 T.  
 
 
  
 
 
B
0
 
 
 
B
0
 
+½ -½ 
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2.1.3 Precession and the Larmor frequency 
Because protons possess angular momentum, they do not align themselves completely and 
instead “precess” around an axis aligned with the field (Figure 2-2). The frequency with 
which the proton precesses depends on the strength of the magnetic field and the gyro-
magnetic ratio of the nucleus and is described by the Larmor frequency (LF), equation: 
ω0 = γB0; where ω0 is angular frequency (LF) and γ is the gyro-magnetic ratio.  
 
 
Figure 2-2. Precession of protons aligned to magnetic field (B0). 
 
Therefore, protons will precess faster with an increasing strength in the magnetic field. If the 
sample is irradiated with a radiofrequency pulse at the same frequency as LF, the protons 
absorb the energy and are promoted to the less favourable anti-parallel energy state (-½). This 
energy absorption is called “resonance” because the frequency of irradiation energy is the 
same as, or resonates, with that of the precession frequency.  
B
0
 
 
 
 
  
 
 
   
+½  
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Within a given experimental sample there will be a high number of protons, typically 10
18
 or 
greater. The process of NMR involves all of these protons. At room temperature, with no 
externally applied magnetic field, nuclei will be distributed evenly throughout all spin states. 
Since the energy difference between opposing spin states is comparatively small, energy from 
thermal collision will be enough to promote some nuclei into higher energy states. Therefore, 
the number of protons in each state will be almost equal, giving no net magnetisation of the 
sample. With the application of a magnetic field, even if very strong, the number of protons 
aligned with the field is only slightly greater than those opposing the field (Figure 2-3). This 
results in a net magnetisation of the sample in the direction of the field.  
 
 
Figure 2-3. Parallel and antiparallel orientation of protons. 
In the presence of B0, a small excess of protons align with the field than against it resulting in 
a net magnetisation in the direction B0. 
 
 
  
B
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2.1.4 Nuclear magnetic resonance systems 
Magnetic fields of the strength used for in vitro high resolution NMR spectroscopy can only 
be generated by superconducting magnets. The field is generated by passing a current through 
a wire coil. The wire is super-cooled to <6 K and is composed of filaments of one metal or 
alloy embedded in another (solenoid: typically tin, copper and niobium) which allows its 
conductive resistance to be reduced to almost 0, thereby allowing high currents to flow and 
perpetually persist. The wire coil is immersed in liquid helium which in turn is surrounded by 
a bath of liquid nitrogen (77 K) to prevent the helium from evaporating. Passing vertically 
through the centre of the machine is a room temperature zone into which the sample is placed 
(Figure 2-4).   
 
 
 
Figure 2-4. Schematic diagram of a nuclear magnetic resonance system.  
Key: A, outer shell; B, liquid nitrogen; C, liquid helium; D solenoid wire coil; E, shim coils; 
F, receiver and radiofrequency pulse coils; G, biofluid sample.  
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2.1.4.1 Shimming 
To obtain precision the magnetic field needs to be as homogenous across the sample as 
possible. The magnet alone, even though it generates a very strong field, is not able to 
achieve this. Shim coils are small wire coils placed strategically around the sample, through 
which current is transmitted, generating small, local magnetic fields which can be 
individually altered to provide a near homogenous field.  
 
2.1.4.2 Tuning and locking  
“Locking” the field is performed to compensate for small, undesired fluctuations in field 
homogeneity. This is achieved by continuous monitoring of a designated signal (usually 
deuterated hydrogen) and adjusting the field by small amounts to keep this signal at the same 
frequency.  
 
2.1.5 Signal generation 
Given that the net magnetisation of the sample is in the z-plane (B0), it is impossible to detect 
a signal as the NMR receiver coils lie in a different plane to that of the large, externally 
applied magnetic field. If the net magnetic moment component were tilted, for example by 
90
o, then a signal could be detected by a receiver coil. This “tilting” is achieved by irradiating 
the protons with a radiofrequency (RF) pulse at the LF (Figure 2-5). The absorption of 
energy has two effects. First, more protons are promoted to the higher energy state (opposing 
B0) and this therefore decreases net magnetisation in the direction of B0. Second, the RF 
pulse causes the protons to precess in phase, which results in the alignment of the charge and 
therefore a net magnetisation in the y-plane which can be detected by receiver coils inside the 
magnet.  
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Figure 2-5. Radiofrequency pulse causing transverse net magnetisation. 
 
 
2.1.6 Fourier transformation 
The signal generated is referred to as a free induction decay (FID) and contains all the time-
dependent proton resonances from the samples. This is not possible to interpret so is 
transformed from a time-dependent to a frequency-dependent signal through the 
mathematical process of Fourier transformation (Figure 2-6).  
 
 
 
Figure 2-6. Fourier transformation. 
Key: FID, free induction decay; FT, Fourier transformation.  
 
2.1.7 Chemical shift 
The molecular surroundings of each proton are different due to interactions from other 
protons, bonds and electron shielding. Thus, the resonance frequency of protons will also be 
different. After Fourier transformation, the proton resonances are measured according to their 
x 
y 
z 
  
RF pulse 
B
0
 
x 
y 
z 
 
B
1
 (following pulse) 
 
59 
 
frequencies. This is converted to a chemical shift parts per million (ppm) scale by subtracting 
a reference frequency (a molecule with a known, stable resonance frequency) and dividing by 
that frequency.  
 
2.1.8 Coupling 
Some molecules generate a single resonance (singlet). Protons may interact with other closely 
bonded protons to produce two or more resonances (doublets or multiplets). This feature, 
known as J-J coupling, can be used for metabolite identification, either through calculation of 
chemical structure depending on the coupling profiles or with known multiplet patterns 
occurring at particular resonances.  
  
2.1.9 Pulse sequences 
Characteristics of the molecular surrounding of the proton can also be manipulated by using 
certain RF pulse sequences and strengths. For example, a nuclear Overhauser enhancement 
spectroscopy (NOESY) sequence which uses three sequential 90º pulses will allow the 
detection of higher and lower molecular weight samples, while that of the Carr-Purcell-
Meiboom-Gill sequence (one 90º pulse and a repetitive loop of 180º pulses) suppresses larger 
weight molecular resonances and accentuates lower weight species.   
 
2.1.10 Proton nuclear magnetic resonance spectroscopy processing 
2.1.10.1 Phase correction 
Protons will resonate in the form of a sine wave and each of these waves will possess a phase. 
Not all the protons in the samples will possess the same phase. Therefore, when the FID is 
Fourier transformed, some resonances will display positive peaks, some will display negative 
peaks and some in between. By multiplying the spectrum by a phase correction, which can be 
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applied to the whole spectrum, all peaks can be corrected to positive and symmetrical line 
shapes. 
 
2.1.10.2 Baseline correction 
Baseline errors can be corrected using automated or manual software so that all spectra have 
a baseline starting at a y-value of 0.   
 
2.1.10.3 Exponential weighting or line-broadening functions 
To reduce the contribution of background noise in the spectrum, the FID can be multiplied by 
a weighting or “line-broadening” function. This has the effect of truncating the FID tail, so 
that resonances from noise are not Fourier transformed resulting in an increased signal to 
noise ratio.  
 
2.1.10.4 Zero-filling 
The NMR signal is collected as a series of data points by the receiver coil. By adding an 
equal number of zeros to the original number or data points (done simply by the computer) 
the number of data points increases, which in turn improves line shapes in the resultant NMR 
spectrum.  This manipulation has no effect signal resolution.  
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2.2 PRINCIPLES OF MASS SPECTROMETRY 
The premise of MS is simple: measure the weight of an ion to determine what it is. This is no 
different for high or low molecular weight MS. Thus the first principal is the generation of 
ions into a gaseous state from the compound of interest. Ions are generated so they can be 
manipulated by electromagnetic fields and passed through the MS instrument.  
  
2.2.1 The ion source 
The ion source serves to create ions. There are many different methods of ionisation 
including chemical, electrical, desorption and field. Some cause extensive compound 
fragmentations (hard ionisation) and some less so (soft ionisation). In liquid state samples, 
the liquid is introduced into the ion source as nebulised gas droplets which are subsequently 
ionised. For all the studies presented in this thesis, electrospray ionisation (ESI) was used. 
Electrospray ionisation, developed by Fenn (Fenn, 2002),  is well adapted to UPLC-MS and 
functions by passing a large voltage through the tip of an introducing nozzle through which 
the dissolved analytes pass. This effects the transformation of the liquid into charged droplets 
which evaporate solvent incrementally increasing the charge density across the particle. At a 
critical point like charges in the droplets repel resulting in the formation of ions. 
 
2.2.2 Mass analysers 
Once the ions are formed they need to be separated according to their masses. More 
accurately, the system bases this differential on the ion’s mass: charge ratio (m/z). All mass 
analysers use static or dynamic electric and magnetic fields alone or combined. The 
quadrupole analyser is made up of four rods arranged circumferentially around the ion path. 
Using the stability of trajectories in oscillating fields to separate the ions, the quadrupole can 
be manipulated to selectively allow ions of a particular m/z ratio through or selectively allow 
62 
 
lighter ions through before heavier ones. The TOF analyser is a flight tube in which there is 
no electro-magnetic field. Here, ions are separated according to their velocities after they 
have been accelerated by a preceding electric field. The mass analysers used in the 
experiments described in this thesis consisted of a quadrupole followed by TOF tube (Q-
TOF). 
 
2.2.3 Ion detectors 
The ions are detected at the end of the of the ion path once they discharge upon the detector. 
Many types of detector exist but all use the same principal of determination dependent on ion 
charge, weight or velocity. Therefore final readings are a measurement of total ion count.  
 
2.2.4 Tandem mass spectrometry 
Many metabolites may have the very similar masses, even to one decimal place. Tandem 
mass spectrometry, also known as fragmentation or MS-MS, can be undertaken to identify 
molecules. The instrument will contain a collision cell, usually placed after the quadrupole, 
which is filled with an inert gas such as argon. Ions can be selectively passed into the cell 
whereupon a variable voltage from 5 to 30 eV is applied which has the effect of fragmenting 
the ion into its constituent ions. Most ions will produce a signature fragmentation pattern 
which may be identifiable using databases or standards.   
    
2.2.5 Chromatography 
Chromatographic separation of a sample is usually performed prior to MS by passing the 
sample over a chromatographic column. The chemical attributes of the column cause certain 
molecules to stick and others to flow through. Inorganic and organic solvents are used at 
varying proportions to elute molecules at different times, generating a chromatogram of a 
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sample. The column can be very tightly packed with retention compounds allowing for higher 
injection pressures (high or ultra-high pressures) subsequently producing higher resolution 
chromatograms (Want et al., 2007).  Chromatographic separation also ensures a steady 
stream of molecules entering the ion source, rather than large batches. If too many molecules 
enter together then ionisation will be inefficient due to a limited amount of charge available 
to all species. This phenomenon is known as “ion suppression” and can have deleterious 
effects on sensitivity.  
 
2.2.6 Data pre-processing 
The datasets produced are complex. Each sample will provide both chromatographic 
retention time and mass spectrometry data. Prior to any form of comparative analysis it is 
essential that the data are aligned so that an analyte with a particular m/z and retention time 
has the same m/z and retention time in all the samples. Correction of m/z drift is 
straightforward with the continuous direct injection of a known reference standard, such as 
leucine-enkephalin, m/z 556.2771, utilised as a “mass lock”. Retention time drift, due to 
sample composition, column variability with time and environmental factors, is more difficult 
to correct for. Many software programmes are now available for data processing to resolve 
this problem. For these experiments the data processing software XCMS was used (Scripps 
Center for Mass Spectrometry, La Jolla, San Diego, California, USA) (Smith et al., 2006) 
(http://metlin.scripps.edu/download). XCMS performs three functions resulting in 
comparable data information: 
 
i. Peak detection. The algorithm used is based on cutting the data into slices a fraction 
of a mass unit (0.1 m/z) and operating on individual slices in the chromatographic 
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time domain. The signal is determined by taking the maximum intensity at each time 
point in the slice (Smith et al., 2006).  
 
ii. Peak matching. After identifying peaks they must be matched across all samples. 
Overlapping fixed-interval bins of 0.25 m/z width are generated to match peaks. 
Because the bins are overlapping, the algorithm counts the same peak twice and 
subsequently removes peak groups originating from overlapping bins resulting in a 
single peak per bin. Once peaks have been matched by mass, they are matched by 
retention time. This is performed by calculating the overall distribution of peaks in 
chromatographic time and identifying the boundaries of regions where many peaks 
have similar retention times. The distribution of peaks or “meta-peaks”  are defined in 
a fixed interval in which all peaks are placed into a group (Smith et al., 2006).  
 
iii. Retention time correction. From the initial grouping, the algorithm then identifies 
those peak groups in which very few samples have no peaks assigned and very few 
samples have more than one peak assigned.  The algorithm calculates the median 
retention time and deviation from median for every sample in that group. 
Consequently, a detailed, non-linear retention time deviation contour can be built for 
each sample and peak groups can be corrected for retention time differences (Smith et 
al., 2006). 
 
The resulting data matrix displays sample identification (observations) against unique mass 
(in Da) / retention time (“T” in sec) “features” (variables), each number corresponding to the 
intensity for that feature in a particular sample. The software also performs a simple 
univariate t-test between two selected groups identifying those features the levels of which 
65 
 
are significantly different between those two groups. The features are listed in order of 
significance and accompanying extracted ion chromatograms (EIC) are generated to aid 
visualisation. Ultra-performance liquid chromatography with XCMS data processing has 
been validated for use in metabolic profiling experiments (Nordstrom et al., 2006).  
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2.3 MULTIVARIATE STATISTICAL ANALYSIS 
The data generated by multi-sample NMR spectroscopy and LC-MS studies can generate 
30,000 variables (Figure 2-7). Much of these data, however, are collinear. As analyses are 
often untargeted, in that it is not known what differences may be present between groups, an 
alternative method of statistical comparison is required. Multivariate analysis allows the 
important differences between groups of data to be rapidly visualised reducing 
multidimensional data to two or three variables. Furthermore, the differences between patient 
groups may be characterised by a group of metabolite ratios rather than a single metabolite.  
 
Multivariate statistical analysis in the form of principal components analysis (PCA) and 
partial least squared discriminant analysis (PLS-DA) were used for analyses in the studies 
presented in this thesis (Trygg et al., 2007).  
 
 
 
Figure 2-7. Multiple variables are generated from metabolic profiling studies.  
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2.3.1 Principal components analysis and outlier exclusion 
Principal components analysis is an unsupervised analytical tool that provides an overview of 
complex data through an examination of the covariance structure, highlighting sample 
outliers and clustering. This is done by converting each sample into a coordinate in n-
dimensional space based on its metabolic profile and calculating the factors (which are 
combinations of these vector co-ordinates) which contribute to the greatest variation across a 
group of samples. Orthogonal factors, or principal components (PC), are then plotted against 
each other. Essentially, new variables (principal components) are created based on the 
variance between metabolite profiles between samples and the samples plotted as coordinates 
with the new variables acting as x, y and occasionally, z axes. In this manner, samples which 
are similar cluster and those that are different spread apart. A measure of distribution, akin to 
Gaussian distribution, can be overlaid to identify those samples that are outside of the 95% 
confidence level of distribution (the Hotelling’s or Mahalabonis’ distance). These samples are 
classed as outliers and it is likely that they contain an abnormally high or low level of a 
particular metabolite making them unrepresentative of the group. Furthermore, because PCA 
is a measure of variation, these samples are likely to influence multivariate analysis, heavily 
weighting principal components. It is therefore reasonable to exclude these samples on the 
basis of unfair bias. 
 
2.3.2 Partial least squared discriminant analysis 
Partial least squared discriminant analysis is a supervised analytical method which relates 
metabolite data to class membership, elucidating separation between the groups. As with 
PCA, each sample is placed in n-dimensional space based on its metabolic profile, but instead 
of variation between samples, variation between groups is modelled allowing the elucidation 
of variable differences between groups. Furthermore, models can be created to test the 
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accuracy of this multivariate model in predicting the origin of a new sample.  These statistical 
techniques can be applied to data matrices generated from 
1
H NMR and UPLC-MS. Both 
produce matrices with hundreds to thousands of variables whereby multivariate analyses 
allow visualisation of two or three variables (principal or partial least squared components), 
far more interpretable to the investigator. 
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3 PLASMA PROTON
 
NUCLEAR MAGNETIC RESONANCE 
SPECTROSCOPY PROFILING OF A RAT MODEL OF 
HEPATOCELLULAR CARCINOMA   
 
3.1 ABSTRACT  
Introduction: There are several rat models of HCC, however, only two studies have 
previously characterised the 
1
H NMR spectroscopic changes in HCC and these were of 
tumour tissue. There have been no reports of 
1
H NMR spectroscopy analysis of blood from 
rat models of HCC. Quinolones are known to reduce the inflammatory component of liver 
fibrosis reducing end-stage complications. The primary aim of this study was to characterise 
the blood metabolic profile of HCC in a rat model of HCC and the secondary aim was to 
evaluate the effect of the quinolone, norfloxacin on metabolic profiles. Methods: HCC was 
induced in 10 Fisher rats by administration of intra-peritoneal diethylnitrosamine (DEN) and 
oral N-nitrosomorpholine (NMOR) and plasma was collected upon sacrifice. Five of these 
rats were concomitantly administered oral norfloxacin. Six Fisher non-treated rats acted as 
healthy controls. Proton NMR spectra were acquired for all samples using a 600 MHz NMR 
system and results were analysed by visual comparison of median spectra and multivariate 
analysis. Results: Control animals were 120 g heavier than diseased counterparts. Proton 
NMR spectra from diseased rats displayed significant decreases in lipoproteins, unsaturated 
fatty acids, acetyl-glycoprotein, acetoacetate, and glucose (p ≤0.001). Plasma citrate and 
formate levels were increased (p = 0.02). Norfloxacin appeared to abrogate this effect 
slightly. Conclusion: The spectral profiles of plasma in rats with HCC display marked 
changes with relation to lipid metabolism and cellular turnover. Norfloxacin appears to 
moderate these metabolic alterations to a small degree.      
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3.2 INTRODUCTION 
Human 
1
H NMR spectroscopic studies of blood in patients with HCC have identified a 
number of altered metabolites, implicating changes in hepatic function, lipid metabolism and 
bile acid metabolism (Gao et al., 2008; Yin et al., 2009). Many rat models of HCC exist, 
however there are no reports of 
1
H NMR spectroscopic studies of rat serum or plasma. To 
characterise the serum or plasma metabolic changes in an animal model of HCC would 
provide valuable translatable information to human disease.  
 
There have been two reports of rat HCC tissue 
1
H NMR metabolite profiling studies. Tesiram 
and colleagues performed a meticulous study using 
1
H NMR spectroscopy to investigate the 
changes of lipid metabolites in a Fisher rat model of hepatic adenoma induced with a choline 
deficient diet (Tesiram et al., 2005). It was demonstrated that a substantial increase in 
glycerol backbone-containing phospholipids increased throughout adenoma development. 
Hepatocellular carcinoma did not develop in these animals but changes described in 
adenomas are likely to share similarities with HCC. A second 
1
H NMR spectroscopy study, 
performed in male Sprague-Dawley rats with DEN induced HCC, reported raised low, very 
low and high density lipoprotein (LDL, VLDL and HDL) levels in addition to alterations in 
branch chain amino acids, acetate, glutamine, choline, trimethylamine-N-oxide, glycine, 
glucose and glycogen (Wang et al., 2011). Whether these metabolic profiles are reflected in 
blood has not previously been investigated using 
1
H NMR spectroscopy.   
 
Quinolones are administered to patients with decompensated cirrhosis who develop 
spontaneous bacterial peritonitis in an antimicrobial capacity. It has also been reported that 
quinolones improve survival and decrease incidence of end-stage complications of liver 
disease, such as hepatorenal syndrome (Fernandez et al., 2007). Their effect might be 
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mediated through a decrease in gut bacterial translocation reducing the pro-inflammatory 
effectors of liver fibrosis (Gomez-Hurtado et al., 2011). 
   
3.2 AIMS 
The primary aim of this study was to ascertain whether altered metabolic profiles could be 
characterised in a rat model of HCC using 
1
H NMR spectroscopy. The secondary aim was to 
investigate the effect of the quinolone, norfloxacin, on HCC-induced 
1
H NMR plasma profile 
changes.    
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3.4 METHODS 
3.4.1 Fisher rat model of hepatocellular carcinoma 
All Fisher rat plasma samples were kindly provided by Dr Fatma Mohamed and Professor 
Rajiv Jalan, Royal Free Hospital, University College London. Hepatocellular carcinoma was 
induced by the administration of two potent carcinogens, DEN (Sigma-Aldrich, Gillingham, 
UK) and NMOR (Sigma-Aldrich, Gillingham, UK). This model was chosen owing to the 
rapid rate of development of HCC (14 weeks) allowing for rapid assessment of blood profiles 
of disease. Male Fisher rats had been divided into three groups: Group 1 (n = 5) consisted of 
rats which received 100 mg kg
-1 
intra-peritoneal DEN and NMOR at 80 ppm in drinking 
water ad libitum until sacrifice at 14 weeks; Group 2( n = 5)  also received the same doses of 
DEN and NMOR in addition to 20 mg kg
-1
/day gavaged norfloxacin (Dr Mohamed and 
Professor Jalan, who donated the plasma samples, are investigating the effects of antibiotics 
on liver inflammation); Group 3 (n = 6) received no treatment and acted as healthy controls 
(Table 3-1). All rats in groups 1 and 2 developed multifocal HCC, group 1 displaying a 
greater extent of liver inflammation than group 2. All rats in group 3 had normal liver 
histology. All animals were sacrificed at 14 weeks whereupon blood was venesected from the 
abdominal aorta into heparin containing tubes and livers extracted for histological analysis. 
All samples were centrifuged and snap frozen in liquid nitrogen and kept at -80 ºC until 
analysis.  
Table 3-1. Fisher rat groups and interventions; groups 1 and 2 developed HCC. 
Intervention Group 1  Group 2  Group 3 
n 5 5 6 
Diethylnitrosamine (DEN) 100 mg kg
-1 
 100 mg kg
-1
 0 
N-nitrosomorpholine (NMOR) 80 ppm in water 80 ppm in water 0 
Norfloxacin 0 20 mg kg
-1
/day 0 
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3.4.2 Sample preparation 
Samples were prepared according to standard validated protocols (Beckonert et al., 2007). 
Samples were thawed at room temperature and 200 μL were transferred into a 1.5 mL 
Eppendorf (Cambridge, UK) tube to which 400 μL NaCl / D20 (90% / 10%) were added. 
External reference standards, such as 3-trimethylsilyl-(2,2,3,3-
2
H4)-1-propionate (TSP), were 
not added, as in blood they may bind to protein resulting in a final NMR signal that is 
reduced and has a very broad line width. The mixture underwent centrifugation for 5 min at 
13, 000 rpm and 550 μL of supernatant were transferred to Norell, 5 mm 507-HP-7 NMR 
tubes (Norell, Landisville, New Jersey, USA) ready for 
1
H NMR analysis. 
 
3.4.3 Proton nuclear magnetic resonance spectroscopy 
All samples were run at the department of Biomolecular Medicine, Imperial College London 
Samples were run in a random non-grouped order under automation on a Bruker Ultrashield 
Plus
TM 
600 NMR system operating at 600.22 Hz 
1
H frequency (Bruker Biospin, Rheinstetten, 
Germany) fitted with a super-cooled probe head, containing the receiver and radiofrequency 
coils, cooled to almost 0 K by use of liquid helium (Cryoprobe
TM
, Bruker Biospin, 
Rheinstetten, Germany). The system was tuned, matched and frequency locked onto proton 
as the nucleus of interest. A representative sample was utilised to set shim gradients to ensure 
a homogenous magnetic field across the sample, a 90º pulse length and the water suppression 
offset parameters. These settings were saved and utilised for the whole sample set.  Pulse 
programme and acquisition parameters were set according to optimised protocols for blood 
from the department of Biomolecular Medicine, Imperial College London. Spectra were 
acquired using  NOESY and Carr-Purcell-Meiboom-Gill sequences at 300 K. One-
dimensional (1-D) NOESY pulse sequence was used  with water presaturation during the 
relaxation delay (RD) and mixing time (tm) using the following pulse programme: -RD-90º_t-
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90º-tm-90º-acquire; where RD = 2.0 s and tm = 0.1 s. For each sample, 64 free induction 
decays (FIDs) were collected into 32, 000 data points with a spectral width of 20 ppm. Proton 
NMR spectra were also acquired using a CPMG-presat sequence (Beckonert et al., 2007) to 
attenuate broad signals from macromolecules such as protein and lipid. For CPMG-presat 
experiments, the following pulse sequence was used: -RD-90º-(t-180º-t)n-ACQ, where t is the 
spin echo delay, n is the number of loops and 180º corresponds to a 180º RF pulse. Here, RD 
=  2 s , t = 0.0002 s , n = 160 , acquisition time = 2.73 s and for each sample, 128 FIDs were 
collected into 32, 000 data points with a spectral width of 20 ppm. A line broadening function 
of 0.3 Hz was applied prior to Fourier transformation. Proton NMR spectra were manually 
phased, baseline corrected and referenced to α-glucose at 5.23 ppm in TOPSPIN v2.0 (Bruker 
Biospin, Rheinstetten, Germany). Spectral peaks were assigned with reference to the 
literature (Holmes et al., 2008; Nicholson et al., 1995; Wishart et al., 2007).    
 
3.4.4 Spectral processing 
Proton NMR spectra were exported to MATLAB R2010 (MathWorks, Natick, 
Massachusetts, U.S.A) and to avoid influence on analyses from water suppression aberration, 
the water region from 4.5 - 6 ppm was excluded from all spectra. Data were normalised using 
median fold-change normalisation to remove the effect of inter-experimental variability. 
Median spectra for both groups were generated to allow direct visual comparison of average 
spectra and allow the selection of regions that were visually divergent, in addition to those 
identified by multivariate analysis, for peak integration.  
 
 
  
75 
 
3.4.5 Multivariate and univariate statistical analysis 
Full resolution data were used for analyses. Data matrices were generated in MATLAB 
containing ppm variables as columns and sample identities as rows. Matrices were exported 
to SIMPCA-P v12 (Umetrics, Umea, Sweden). After water exclusion, this amounted to a 
matrix, for both NOESY and CPMG experiments, of 31,181 variables and 16 observations. 
Data were mean-centred and PCA was performed first to model overall variation and identify 
outliers. Only mean-centred data were used for further analysis. After outliers were identified 
and excluded, PLS-DA was performed to identify the discriminant strength of the metabolite 
based model and to generate a loadings plot from which metabolites could be identified 
which most greatly contributed to differences between the groups. In SIMCA-P v12, PLS-DA 
models are generated through seven-fold cross validation. In this method, every 7
th
 sample is 
excluded (1
st
, 7
th
, 14
th
, 21
st 
and so on), a model generated from the remaining samples and the 
excluded “training set” predicted back into the model. This is repeated for all the samples 
(grouping the 2
nd
, 9
th
, 16
th
 and 3
rd
, 10
th
, 17
th
 and so on) until all the samples have been 
excluded once. The results are averaged to produce a model which is externally cross-
validated. Spectral peaks which contributed most to PLS-DA models and those visually 
different on median spectra comparison were selected for peak integration. Comparison of 
integrals was performed using GraphPad Prism (La Jolla, California, USA) using Mann-
Whitney non-parametric tests of significance, as normal Gaussian distribution could not be 
assumed, p-values of <0.05 were considered significant.  
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3.5 RESULTS 
3.5.1 Fisher rat weights 
Table 3-2 records the median weights of the three groups of rats. Healthy controls were 120 
g heavier than their liver disease counterparts. Macroscopic appearances of healthy and 
diseased liver of the groups are shown in Figure 3-1.  
 
 
Table 3-2. Fisher rat weights at time of sacrifice. 
 Group 1 (HCC) Group 2 (HCC + Norfloxacin) Control group 
Median weight (g) 336.0 335.5 455.5 
 
 
 
Figure 3-1. Explanted liver from healthy control and rat with HCC.  
Key: Arrows indicate areas of HCC nodularity. 
(Courtesy of Dr Fatma Mohamed). 
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3.5.2 Proton magnetic resonance spectral profiles 
Figure 3-2 displays the same plasma sample after NOESY and CPMG acquisitions. This 
highlights the effect of macromolecular suppression allowing smaller molecules to be 
detected. Figure 3-3 shows the effect of normalisation on a segment of spectra, reducing the 
effect of variability, not due to inherent sample qualities, but instead due to variability of 
experimental conditions.  
 
 
 
Figure 3-2. Fisher rat plasma proton nuclear magnetic resonance spectra highlighting 
macromolecular suppression.  
Top pane: NOESY and bottom pane: CPMG 
1
H NMR spectra. 
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Figure 3-3. Effect of median fold change normalisation on spectral data. 
Key: Different coloured spectra represent individual samples.  
 
 
Figure 3-4 displays the median spectra of animals which developed HCC (groups 1 and 2) 
compared to healthy controls (group 3). A number of spectral regions displayed high 
divergence between groups and these are recorded in Table 3-3. It is noteworthy that the 
same areas in NOESY and CPMG acquired spectra were altered. This is likely due to the fact 
that the dominant signals from certain molecules occur in both studies and are relatively 
unaffected by the macromolecular suppression from a CPMG pulse sequence.   
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Figure 3-4. Proton nuclear magnetic resonance spectra of rat groups. 
Key: Median spectra of HCC (Group 1); HCC + norfloxacin (Group 2); healthy controls 
(Group s. 
 
Table 3-3. Resonance identities in rat plasma spectra between 0.5 -4.5 ppm. 
Label Chemical shift (ppm) Multiplicity Molecule 
1 0.84 Multiplet (broad) Low density lipoprotein (CH3) 
2 0.87 Multiplet (braod) Very low density lipoprotein (CH3) 
3 1.22 Multiplet (broad) Low density lipoprotein (CH2) 
4 1.25 Multiplet (broad) Very low density lipoprotein (CH2) 
5 1.33 Doublet Lactate (CH3) 
6 1.46 Doublet Alanine 
7 1.57 Multiplet (broad) Lipid (CH2) 
8 2.04 Singlet Acetyl-glycoprotein 
9 2.23 Multiplet (broad) Lipid (CH2) 
10 2.69 Multiplet Lipid (CH2) 
11 3.24 - Glucose moeities and amino acids 
12 3.8 - Glucose moeties   
13 4.11 Quadruplet Lactate (CH) 
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3.5.3 Multivariate statistical analysis 
Multivariate analysis scatter plots are displayed in Figures 3-5 and 3-6 depict NOESY and 
CPMG studies. Clear clustering can be seen causing separation of rats with HCC (groups 1 
and 2) and healthy controls. This is interpreted as the greatest variation between samples 
(from all 3 groups) accounting for most of the variation between animals with HCC and those 
without. In alternative terms, those animals with HCC have more similar plasma metabolite 
profiles than those without. In both NOESY and CPMG studies, groups 1 (no norfloxacin) 
and 2 (norfloxacin) are poorly separated by multivariate analysis, implying that blood from 
these animals possess similar plasma profiles. Using the supervised method of PLS-DA, 
whereby models are generated to identify those multivariate components which describe most 
variation between groups, data were generated for CPMG and NOESY studies for combined 
groups 1 and 2 (those animals with HCC) versus group 3 (healthy controls) (Figures 3-5 and 
3-6). The R
2
 (goodness of fit) and Q
2
 (goodness of prediction) were greater than 0.95 in both 
studies, suggesting very different plasma metabolic profiles between HCC and non-HCC 
animals. This is reflected in the misclassification matrix and sensitivity and specificity of 
HCC diagnosis in Table 3-4, illustrating 100 % sensitivity and specificity of HCC diagnosis, 
for both NOESY and CPMG studies.  In keeping with the visual similarity between median 
spectral comparisons of NOESY and CPMG data, loadings plots of PLS-DA components 
identified the same spectral regions contributing most to multivariate models. As a result, 
only CPMG data were used for subsequent univariate analyses.  
 
 
Table 3-4. Misclassification matrix for PLS-DA prediction of disease. 
  Predicted as HCC Predicted as No HCC Total Sensitivity / Specificity 
HCC 10 0 10 100% / 100% 
No HCC 0 6 6  
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SIMCA-P+ 12.0.1 - 2011-09-11 12:32:00 (UTC+0) 
PLS 1 
PLS 2 
R2 = 0.97 
Q2 = 0.97
Figure 3-5A. Principal components analysis of rat plasma.  
 
Key: Data from NOESY analysis. A. Groups 1 (■), 2(●) and 3(●); B. Group 1 and group 3; 
C. Groups 1 and 2 combined and group3; D. Groups 1 and 2. PC = Principal Component 
 
 
 
 
Figure 3-5B. Partial least 
squared discriminant 
analysis of rat plasma.  
Key: Data from NOESY 
analysis. 
HCC + norfloxacin (■)  
and healthy controls (●). 
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SIMCA-P+ 12.0.1 - 2011-09-11 11:55:47 (UTC+0) SIMCA-P+ 12.0.1 - 2011-09-11 11:46:13 (UTC+0) 
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SIMCA-P+ 12.0.1 - 2011-09-11 14:04:15 (UTC+0) 
PLS 1 
PLS 2 
R2 = 0.96 
Q2 = 0.98
 
Figure 3-6A. Principal components analysis of rat plasma. 
 
Key: Data from CPMG analysis. A. HCC (■), HCC + norfloxacin (●) and healthy controls 
(●);PC = Principal Component. 
 
 
            
         
Figure 3-6B. Partial 
least squared 
discriminant 
analysis of rat 
plasma. 
Key: Data from 
CPMG analysis. 
HCC + norfloxacin 
(■)  
and healthy controls 
(●). 
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3.5.4 Univariate statistical analysis 
Variables from CPMG PLS-DA models and from visual comparison of median 
1
H NMR 
spectra that contributed most to variation between those animals with (groups 1 and 2)  and 
those without HCC (group 3), are tabulated and graphically illustrated below (Table 3-5) 
(Figure 3-7). Plasma LDL, VLDL, acetyl-glycoprotein, α-glucose and unsaturated fatty acids 
were all significantly reduced in rats with HCC (p = or <0.001). Plasma citrate and formate 
were significantly increased in animals with HCC (p = 0.02). 
 
Table 3-5. Median metabolite levels in healthy and diseased animals. 
Chemical 
shift (ppm) 
Molecule HCC  
 
HCC + 
Nor. 
Controls 
 
p-value 
 
      
0.80 – 0.85 LDL (CH3) 1.70 x 10
8
 1.48 x 10
8
 1.67 x 10
8
 
a
0.55, 
b
0.60 
0.86 – 0.89 VLDL (CH3)  9.58 x 10
7
 1.37 x 10
8
 6.41 x 10
8
 
a
0.03, 
b
0.004 
1.24 -1.28 LDL (CH2) 2.05 x 10
8
 2.66 x 10
8
 1.35 x 10
9
 
a
0.10, 
b
0.004 
1.28 – 1.31 VLDL (CH2) 1.48 x 10
8
 2.60 x 10
8
 1.09 x 10
9
 
a
0.03, 
b
0.004 
2.03 – 2.06 Acetyl-glycoprotein 1.41 x 10
7
 2.27 x 10
7
 3.51 x 10
8
 
a
0.06, 
b
0.004 
2.50 – 2.52 Citrate 6.14 x 10
8
 5.69 x 10
6
 5.01 x 10
6
 
a
0.15, 
b
0.13 
2.22 – 2.24 Acetoacetate 1.41 x 10
7
 2.27 x 10
7
 1.41 x 10
8
 
a
0.008, 
b
0.004 
5.22 – 5.24 α-glucose 1.27 x 10
8
 1.59 x 10
8
 1.50 x 10
8
 
a
1.0, 
b
0.004 
5.25 – 5.38 Unsaturated lipid 1.59 x 10
8
 6.32 x 10
8
 6.32 x 10
8
 
a
0.1, 
b
0.008 
8.44 – 8.45 Formate 570,230 512,847 429,393 
a
0.8, 
b
0.03 
Key: p-values calculated using Mann-Whitney non-parametric tests of significance, 
a
 and 
b
 
corresponds to HCC vs. HCC + Norfloxacin and HCC vs. Controls, respectively. Nor., norfloxacin; 
LDL, low density lipoprotein; VLDL, very low density lipoprotein. 
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Figure 3-7. Plasma relative intensities (integral values) of selected metabolites. 
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3.6 DISCUSSION 
The aims of this study were to investigate the plasma 
1
H NMR metabolite changes that occur 
in the presence of HCC, and also to evaluate the effect of norfloxacin upon these profiles. 
Certainly, the metabolite profiles of those animals with HCC differed greatly from healthy 
control animals, mainly with respect to lipid lipoprotein associated species, displaying clear 
separation on PCA plots and excellent classification by PLS-DA. The animals with HCC, 
however, were over 100 g lighter than healthy controls and this is clearly a significant factor 
which influences interpretation of the findings. It is not clear, however, how this weight 
difference explains the specific alteration in metabolites.  
 
Low density lipoprotein, VLDL and unsaturated fatty acids were significantly reduced in 
animals with tumours. This suggests several possible explanations. Firstly, the absorption of 
fat (via chylomicrons – see Figure 3-8) may be reduced, reducing the provision of lipid for 
production of VLDLs by the liver, although this would be unlikely as vastly reduced 
absorption would have been required to cause the results seen. Secondly, the findings may 
indicate cancer cachexia through an increased basal metabolic rate, which is defined as loss 
of skeletal muscle mass, with or without loss of body fat (Tisdale, 2010). Cancer cachexia is 
a complex condition likely to be cytokine mediated and indicative of end-stage disease 
(Tisdale,  2010). There are conflicting findings that support and argue against this: firstly, 
there is little evidence of increased muscle breakdown in rats with HCC, with no rise in 
plasma creatine or creatinine. Secondly, if fat were being actively metabolised it would be 
mostly through β-oxidation in mitochondria, a by-product of which is acetoacetate (acetic 
acid). Acetoacetate plasma levels were significantly reduced in animals with HCC which 
indicates reduces fatty acid metabolism, not in keeping with the use of fatty acids as an 
energy substrate. Ketoacids, however, are not definitive markers of fat metabolism and it may 
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be the case that fat is being mobilised for energy production in animals with higher basal 
metabolic rates, a hall mark of cancer cachexia. These results may also indicate deteriorating 
liver function. In addition to its multiple roles of coagulation cascade component, bile acid 
and vitamin production, the liver produces VLDL particles which are then circulated in the 
blood providing tissues with fatty acid substrates (Figure 3-8).  Given the complexity of lipid 
metabolism, it would be incorrect to presume that reduced production of VLDL particles 
results in reduced production of LDL particles. Low density lipoprotein is formed by the 
catabolism of VLDL but is dependent on several factors such as hepatic function and 
peripheral lipase activity.  It may be that the functional status of the liver, induced by tumour 
burden and inflammation caused by the carcinogens DEN and NMOR is reduced, causing the 
majority of lipid alteration in this model. It is also possible that the lipids are being used to 
fuel cellular division, providing the substrate for cell membranes in rapidly dividing tumours. 
If this were the case, then the by-products of fatty oxidation would not be raised as seen here. 
Finally, DEN is a potent carcinogen and its effect on lipid metabolism, aside from effects on 
liver inflammation, are not known. Animal studies have shown that DEN induces lipid 
peroxidation, which may be a factor in interpreting the results presented here (Jayakumar et 
al., 2011). The effects of NMOR on lipid metabolism are not known.  
 
The findings presented here do parallel those of a recent study undertaken by Wang and 
colleagues, where male Sprague-Dawley rat liver tumour homogenate, induced by DEN, 
were analysed using 
1
H NMR spectroscopy (Wang et al., 2011). A raised level of LDL, 
VLDL and choline was observed in tumours suggesting their increased incorporation into the 
tumour mass. Tesiram and colleagues observed substantial increases in glycerol backbone-
containing phospholipids in choline-deficient Fisher rats with hepatic adenomas (Tesiram et 
al., 2005). In this study, diseased rats were lighter than healthy controls but the growth 
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characteristics of both groups were similar suggesting an alteration in fat storage rather than 
muscle development.  
 
Acetylglycoproteins are known to be produced by hepatocytes and released in response to 
stressful stimuli and can be induced by a number of different inflammatory conditions 
including cancer (Baumann et al., 1983; Wang et al., 2006). Acetylglycoproteins were 
significantly reduced in animals with HCC which could also imply a decreased functional 
status of hepatocytes due to disease. The macroscopic appearance of the rat livers, almost 
completely infiltrated with multi-nodular tumour, would support the theory that less 
functional tissue remains to produce hepatic proteins.  
 
 
Figure 3-8. Lipid absorption and hepatic metabolism to lipoprotein.  
Key: VLDL, very low density lipoprotein; LDL, low density lipoprotein; HDL, high density 
lipoprotein; TGL, triglycerides. 
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Blood glucose levels, as measured in the glucose moieties (3.0 – 3.5ppm) and α-glucose 
(5.23ppm) were significantly reduced in animals with HCC. Hypoglycaemia is a well 
recognised paraneoplastic phenomena of HCC purported to be related to the secretion of 
insulin-like growth factors (Yamaguchi et al., 1998). It is also a manifestation of cancer 
cachexia of which these animals are likely to have been sufferers.   
 
The effect of norfloxacin on plasma NMR metabolic changes was modest, with phenotypes 
(all DEN/NMOR + norfloxacin treated animals also developed HCC) and metabolic profiles 
more similar to DEN/NMOR animals than controls. There is no presentable evidence that this 
slight alteration is due to reduced bacterial translocation and liver inflammatory status in this 
study. Furthermore, DEN is dependent upon the action of cytochrome P450 enzymes for 
conversion to its active metabolites (Salcido-Neyoy et al., 2009) and norfloxacin has been 
shown to suppress the activities of these enzymes (McLellan et al., 1996). The results 
observed here may therefore be due to enzyme inhibition rather than alterations in bacterial 
translocation.  
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3.7 CONCLUSIONS 
The spectral profiles of plasma in rats with HCC display marked changes with relation to 
lipid metabolism and cellular turnover. Norfloxacin appears to abrogate these effects slightly.     
The results of this study have provided an insight to the altered hepatic lipid metabolism in 
the presence of HCC. Interpretation must be cautious, given the small sample number. The 
1
H NMR changes in lipid profiles are likely due to a combination of cancer cachexia and 
reduced liver function although certain corroboratory findings, such as an increase in 
ketoacids, is missing. Further studies are required to characterise lipid subspecies. Low 
density lipoprotein, VLDL and unsaturated fatty acids cover a broad range of lipid subspecies 
and it would be important to identify whether any particular species is associated with HCC. 
For this, a more sensitive method of lipid analysis is required, such as liquid chromatography 
mass spectrometry LC-MS. Similar studies also need to be undertaken in the human 
population to test the translatability of findings.    
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4 THE PLASMA AND SERUM METABOLIC PROFILING OF 
HEPATOCELLULAR CARCINOMA IN A NIGERIAN AND EGYPTIAN 
COHORT USING PROTON NUCLEAR MAGNETIC RESONANCE 
SPECTROSCOPY 
4.1 ABSTRACT 
Introduction: Previous studies have observed alterations in the 
1
H NMR blood spectral 
profiles of patients with malignancy. No study has examined the blood metabolic profiles of 
HCC in two diverse populations. Presented here is a 
1
H NMR spectroscopy study of serum 
and plasma from patients recruited from Nigeria (mostly HBV infected) and Egypt (mostly 
HCV infected). The aim of this study was to identify differences that occur in the serum and 
plasma spectra of patients with HCC using 
1
H NMR spectroscopy. Methods: Patients with 
HCC (53) and cirrhosis (26) and healthy volunteers (19) were recruited from two countries: 
the University of Jos, Nigeria (2007 – 2008) and The National Liver Institute, Shebeen El 
Kom, Egypt (2004 – 2007). Participants provided serum or plasma samples. All samples were 
analysed as a group cohort using 600 MHz 
1
H NMR spectroscopy using NOESY pulse 
sequences. Comparison of median group spectra and multivariate analysis were performed to 
identify regions of difference. Results: Non-significant age differences were present between 
the HCC and healthy volunteer group (50 years versus 40 years, p=0.09) but not between 
HCC and cirrhosis groups (49.5 years, p=0.31). Alterations between patients with HCC, 
healthy volunteers and patients with cirrhosis were detected in levels of LDL (p=0.002 and 
0.12), VLDL (p=<0.001 and 0.77), lactate (p=0.03 and 0.12), N-acetylglycoproteins 
(p=<0.001 and 0.001) and acetoacetate (p=0.52 and 0.06). Conclusions: Differences were 
present in the serum and plasma of patients with HCC but whether this is due to confounding 
from age differences or complex alterations in lipid metabolism is debatable.  
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4.2 INTRODUCTION 
The previous chapter described the plasma 
1
H NMR spectral changes due to HCC in a Fisher 
rat model of the malignancy. Whether the same holds true for human disease remains poorly 
investigated. The vastly increased heterogeneity in genotype, diet, environment, co-morbid 
status and liver disease aetiological factors in man, may influence the ability to translate these 
findings to human disease.   
 
One previous study, performed in a Chinese population has utilised 
1
H NMR of serum to 
discriminate patients with HCC (n = 39) from patients with cirrhosis (n = 36) (Gao et al., 
2009). In this study, alterations were observed in levels of lipoproteins, amino acids, N-
acetylglycoproteins, ketoacids and lipids.   Unfortunately, no information was provided on 
age, gender or liver disease aetiology of the participants, which is particularly relevant when 
utilising this method to distinguish patients with cancer to those without. In 1986, Fossel and 
colleagues proposed using the line widths of methyl (CH3) and methylene ((CH2)n), measured 
by 400 MHz  
1
H NMR spectroscopy, as a sensitive test for cancer (Fossel et al., 1986). 
Levels of these metabolites were found to be significantly elevated in patients with a variety 
of tumours (n = 81). A number of validation studies performed on similar cohorts of patients 
using similar or higher magnetic field strengths, refuted this finding, citing age, triglyceride 
content and number of freeze thaw cycles as confounding variables that were likely to have 
contributed to Fossel’s original findings (Bell et al., 1988; Holmes et al., 1988; Okunieff et 
al., 1990; Wilding et al., 1988). 
 
The aim of the study presented here was to investigate whether serum and plasma 
1
H NMR 
profiles are different in patients with HCC compared to patients with cirrhosis and healthy 
volunteers.  
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4.3 METHODS 
4.3.1 Patient and healthy volunteer selection 
Subjects were recruited in two cohorts from Jos University Teaching Hospital (JUTH) and 
The National Liver Institute, Menoufiya University, Shebeen El Kom, Egypt. The Nigerian 
study protocol was approved by the research ethics committee of JUTH, Nigeria and the 
Egyptian protocol by Menoufiya University, Egypt. The metabolic profiling protocol was 
approved by the research ethics committee of Imperial College London, UK. All volunteers 
provided informed, signed consent.  
 
Hepatocellular carcinoma was diagnosed by radiological measures: US, computed 
tomography (CT) or magnetic resonance imaging (MRI). Cirrhosis was diagnosed on clinical 
findings, by the presence of portal hypertension (varices or ascites) and US or CT 
confirmation. Tumours were staged according to the Okuda system which includes tumour 
size, the presence of ascites, bilirubin and albumin levels as its criteria (Okuda et al., 1985). 
This scoring method was chosen out of necessity as other, more comprehensive scoring tools, 
such as the Barcelona Clinic Liver Cancer staging algorithm, require WHO performance 
status, presence of portal vein invasion and encephalopathy as criteria, which were not 
recorded for most of the patients in this study.  
 
4.3.1 Sample collection 
Nigerian blood samples were collected between 2007 and 2008 and Egyptian samples 
between 2004 and 2007. Random, non-fasted 5 mL blood samples were venesected into 
either plain serum or EDTA containing sterile tubes and placed immediately on ice or into a 
refrigerator at 4 ºC. Samples were centrifuged within 1 – 2 hrs at 4 ºC, 1000 rpm for 10 min. 
The supernatant was then transferred as 2 mL aliquots into 2 mL microvial tubes and stored 
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at -80 ºC undergoing no freeze thaw-cycles until analysis. Forty eight of 56 Nigerian samples 
were collected into tubes containing ethylenediaminetetraacetic acid (EDTA) as an 
anticoagulant. The remainder of samples were collected into plain serum tubes. All of the 
Egyptian samples were collected into plain serum tubes, with no additives. Previous studies 
have reported similar 
1
H NMR metabolic profiles from serum and plasma, allowing the two 
to be compared with relative assurance (Deprez et al., 2002; Teahan et al., 2006; Wedge et 
al., 2011). These studies highlight the fact that clinical differences between groups were 
profoundly more influential than spectral differences between EDTA plasma and plain serum 
samples.  
 
4.3.2 Blood laboratory tests 
For the Nigerian samples, serum urea, creatinine, alanine transaminase (ALT), alkaline 
phosphatase (ALP), total bilirubin and albumin levels were measured using automated 
techniques (Abbott™ Architect Ci16200 Analyser, UK) at St Mary’s Hospital, London. 
Serum AFP was measured using an automated Siemens™ Immulite 2500 Analyser, 
(Deerfield, USA). For the Egyptian samples, serum AFP, creatinine, ALT, AST, bilirubin and 
albumin were measured at the time of collection in Egypt using a Cobas Integer 400- 
Autoanalyzer, Roche, Germany. Median and interquartile ranges (IQR) were calculated for 
each assay and median levels were compared using unpaired Mann-Whitney tests of 
significance. 
 
4.3.3 Sample preparation 
Samples were prepared according to the same protocol outlined in Chapter 3, using NaCl / 
D20 solution. Samples were analysed on the same day as preparation.   
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4.3.4 Proton nuclear magnetic resonance spectroscopy 
All Nigerian samples were run in a random, non-grouped order on 29.10.2009. All Egyptian 
samples were run on 02.12.2010. Proton NMR spectroscopy has been found to display 95% 
concordance of results, even if different NMR systems are used (Keun et al., 2002). All 
samples were run at the department of Biomolecular Medicine, Imperial College London. 
Nigerian and Egyptian samples were run on two Bruker Ultrashield Plus
TM 
600 NMR systems 
operating at 600.29 - 600.44 MHz 
1
H frequency (Bruker Biospin, Rheinstetten, Germany). 
Spectral acquisition parameters, generation of 90º pulse and pulse sequences were as 
described in Chapter 3. Spectra were acquired using NOESY 1-D pulse sequence with water 
presaturation, during the relaxation delay (RD) and mixing time (tm) using the following 
pulse programme: -RD-90º_t-90º-tm-90º-acquire; where RD = 2.0 s and tm = 0.1 s. For each 
sample, 128 free induction decays (FIDs) were collected into 32, 000 data points with a 
spectral width of 20 ppm. A line broadening function of 0.3 - 1.0 Hz was applied prior to 
Fourier transformation. Spectra were manually phased, baseline corrected and referenced to 
the α-glucose doublet at 5.23 ppm in TOPSPIN v2.0 (Bruker Biospin, Rheinstetten, 
Germany). Spectral peaks were assigned with reference to the literature (Holmes et al., 2008; 
Nicholson et al., 1995; Wishart et al., 2007).    
 
4.3.5 Data pre-processing 
Spectra were exported to MATLAB R2010 (MathWorks, Natick, Massachusetts, U.S.A) and 
the water region from 4.5 - 6 ppm was excluded. As the concentration of EDTA varied 
between the serum and plasma samples, regions were excluded where it resonates to avoid 
modelling differences between EDTA concentrations between samples. In a recent analysis 
of the effect of EDTA on metabolic profiling information recovery, it was reported that the 
resonances EDTA obscures commonly resonate elsewhere in the spectrum with few 
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exceptions (Table 4-1). Furthermore, the effect of EDTA on other molecules, in terms of 
spectral resonance or peak shift, were found to be negligible (Barton et al., 2010). Peaks from 
EDTA are displayed in Figure 4-1, in comparison to an EDTA-free sample. Data were 
normalised to median fold-change and median spectra for all groups were generated to allow 
visual comparison of spectra and allow the selection of regions that were divergent for use in 
multivariate and univariate analyses.  
 
 
Figure 4-1. Resonances from EDTA compared to an EDTA-free serum sample. 
Key: EDTA plasma sample (-), EDTA free serum sample (-).  
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Table 4-1. Metabolite peaks obscured by EDTA resonances.  
Obscuring 
signal 
Chemical shift 
(ppm) 
Metabolites with peaks in 
this region 
Additional clear 
peaks (ppm) 
Free EDTA 3.6 Β-Aminobutyrate 1.33/2.5 
 Valine 0.99/1.04/2.28 
 Sarcosine 2.7 
 Acetylcarnitine Nil 
 γ-Hydroxybutyrate 2.2 
 Threonine 1.32 
 myo-Inositol 3.28 
 Glycerol 3.87 
Free EDTA 3.2 Glycerophosphorylcholine 3.95/4.30 
 Carnitine Nil 
 Choline 3.50/4.05 
 Anserine 7.1 
 Tyrosine 3.94/6.87 
 Arginine 1.73/1.92/1.68 
 Glucose 5.23 
 Histidine 3.98/7.02/7.73 
 Β-Alanine 2.50-2.60 
Ca-EDTA 3.06-3.017 Creatine 3.93 
 Creatinine 4.05 
 Tyrosine 3.94/6.87 
 Ornithine Nil 
 Cysteine 3.9 
 Β-Aminoisobutyrate 1.2/2.6-2.7 
 Citrulline 1.57/1.86/3.70 
 N-α-Acetylhistidine 7.08/7.83 
 3-Methylhistidine 7.01/7.61/7.77 
 cis-Aconitate Nil 
Mg-EDTA 2.7 Citrate Nil 
Adapted from (Barton et al., 2010).  
Metabolites with no other spectral resonances are in bold. 
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4.3.6 Multivariate analysis 
Median spectra of each group (HCC, cirrhosis and healthy volunteer) were compared in a 
combined analysis of Nigerian and Egyptian data. Regions that were visually divergent were 
selected for multivariate analysis. These areas are recorded in Table 4-2.  The integral areas 
of these regions were recorded in a data matrix and exported to SIMCA (Umetrics, Umea, 
Sweden) for PCA and PLS-DA as described in earlier chapters. All date were mean centred 
prior to multivariate analysis. Country specific and male only analyses were performed to 
ensure that findings were due to metabolite characteristics secondary to HCC and not due to 
population or gender disparities between groups. 
Table 4-2. Spectral regions selected for multi- and univariate analyses.  
 Region (ppm) Molecule Moeity 
    
1 0.8 – 0.85 Low density lipoprotein  CH3 
2 0.85 – 0.88 Very low density lipoprotein  CH3 
3 1.21 – 1.24 Low density lipoprotein  -(CH2)n- 
4 1.25 – 1.30 Very low density lipoprotein  -(CH2)n- 
5 1.31 – 1.32 Lactate CH3 
6 2.02 – 2.05 N-Acetylglycoproteins NHCOCH3 
7 2.22 – 2.23 Acetoacetate CH3 
8 4.098 – 4.108 Lactate  CH 
9 8.445 – 8.45 Formate CH 
 
4.3.7 Univariate analysis 
Data were exported to GraphPad Prism (La Jolla, California, USA) for univariate analysis in 
the form of Mann-Whitney t-tests comparison of medians between groups, assuming non-
parametric distribution of data and p-values of <0.05 were considered significant.  
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4.4 RESULTS 
4.4.1 Subject selection and demographics 
A total of 98 volunteers were recruited for study, 56 from Nigeria and 42 from Egypt (Table 
4-3). Subjects were recruited in three cohorts, 53 patients with ultrasound or computed 
tomography proven HCC (29 Nigerian + 24 Egyptian); 26 patients with clinically-confirmed 
cirrhosis with features of portal hypertension, but no HCC (12 Nigerian + 14 Egyptian); and 
19 healthy subjects with no history of liver disease (15 Nigerian + 4 Egyptian). All patients, 
except one, in the Nigerian HCC and cirrhosis groups were HBsAg positive (ELISA, 3
rd
 
generation). The single non-HBV patient with cirrhosis was also anti-HCV antibody negative 
and was therefore classified as having idiopathic liver disease. In the Egyptian cohort, all the 
patients with cirrhosis and 23/24 patients with HCC had chronic HCV. The single HCC 
patient without HCV had idiopathic induced liver disease. All healthy volunteers were 
HBsAg and anti-HCV antibody negative with no history of liver disease.  The Nigerian and 
Egyptian groups were combined as the number of healthy volunteers from Egypt was low (4). 
If country-specific analyses were undertaken the number of HCC and cirrhosis samples for 
the Egyptian group (24 and 14) would have vastly outnumbered the healthy controls leading 
to inevitable bias of results.  
 
Subject demographics are displayed in Tables 4-4 and 4-5. There was no significant 
difference between the ages of all three groups, although patients in the healthy volunteer 
group had a median age of 40 years, compared to that of 50 years for patients with HCC 
(p=0.09). There were fewer males in the healthy volunteer group (42% versus 70% in the 
HCC group, p=0.052).  Median serum AFP levels were significantly higher (1198 IU mL
-1
) 
in patients with HCC compared to those with cirrhosis and healthy volunteers (5.61 and 1.44, 
p<0.001). Of note, if an AFP cut off of 400 IU mL
-1
 was used for HCC diagnosis, 19 tumours 
would have not been diagnosed (64% sensitivity). Creatinine levels were comparable across 
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groups but serum ALT, bilirubin and albumin were deranged in the HCC and cirrhosis groups 
in comparison to healthy controls. Stages of HCCs are shown in Table 4-6.   
  
Table 4-3. Parameters of Nigerian and Egyptian cohorts. 
Parameter Nigerian cohort Egyptian cohort 
n 56 
HCC(29), Cirrhosis(12), Healthy(15) 
42 
HCC(24), Cirrhosis(14), Healthy(4) 
HBV HCC (29), Cirrhosis (12) 0 
HCV 0 HCC (23), Cirrhosis (14) 
Collection date 2007-2008 2004-2007 
Plain serum 8 42 
EDTA plasma 48 0 
NMR system 600 MHz 600 MHz 
Acquisition date 29.10.2009 02.12.2010 
 
 
Table 4-4. Nigerian and Egyptian patient and healthy volunteer demographics. 
Characteristic HCC Cirrhosis Healthy 
Controls 
p-value 
 
n 53 26 19 - 
Median Age (years) (range) 50 48.5 40 
a
0.09 and 
b
0.31 
Male (%) 37 (70%) 18 (69%) 8 (42%) 
ai
0.052 and 
bi
1.0 
Nigerian 29 12 15 - 
Egyptian 24 14 4 - 
Key: Mann-Whitney non-parametric comparisons of HCC versus healthy (
a
) and versus 
cirrhosis ( 
b) and Fisher’s exact test for categorical variables (ai and bi). 
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Table 4-5. Biochemical analysis of all patients. 
Test (range) HCC  Cirrhosis  Healthy 
Controls 
p-values 
(Mann-Whitney) 
Serum Samples (n) 53 26 19 - 
AFP (IU mL
-1
) 1198 5.61
+
 1.44
+ a and b
<0.001* 
Creatinine (mmolL
-1
) 63.0 82.5 70.0 
a
0.39 and 
b
0.04* 
ALT (IU L
-1
) 52.5
+
 32.5 22.0 
a
<0.001* and 
b
0.04* 
Bilirubin (μmol L-1) 29.0
+
 36.8 6.9 
a
<0.001* and 
b
0.43 
Albumin (g L
-1
) 26.6
+ 
23.8 45.7 
a
<0.001* and 
b
0.16 
Key: 
+
Some data missing. Mann-Whitney non-parametric comparisons of HCC versus 
healthy (
a
) and versus cirrhosis ( 
b
). 
 
 
Table 4-6. Okuda stages of patients with hepatocellular carcinoma.  
Stage Number 
1 8 
2 25 
3 16 
Unknown due to insufficient data* 4 
Total 53 
Key: *Due to samples not tested for bilirubin or albumin or no documentation of ascites. 
 
 
4.4.2 Proton nuclear magnetic resonance spectroscopy 
A representative NOESY plasma spectrum is displayed in Figure 4-2 with indication of 
which regions were excluded due to EDTA resonances. The area of exclusion is, therefore, 
relatively small in comparison to the whole spectrum. The resolution between the 
overlapping peaks of LDL at 0.8 ppm and 1.21 ppm and VLDL at 0.85 ppm and 1.25 ppm 
was poor, although could discernibly be distinguished. This was evident in median spectra 
(Figure 4-3).  
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Figure 4-2. Representative plasma spectrum with EDTA exclusion.  
Key: 1 and 2 - LDL/VLDL, 3 - lactate (CH3), 4 - alanine, 5 – N-acetylglycoproteins, 6 – 
acetoacetate,  8 and 9 - citrate, 10 – creatinine, 11 – glucose resonances, 12 – lactate (CH) 
and 13 – albumin and albumin –bound fatty acids (Nicholson et al., 1995). Purple bars 
indicate areas of EDTA resonance exclusion.    
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Figure 4-3. Selected spectral regions of difference between median hepatocellular 
carcinoma, cirrhosis and healthy volunteer group spectra from combined Egyptian and 
Nigerian cohorts. 
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4.4.3 Multivariate statistical analysis 
Principal components analysis and PLS-DA was performed on the data matrix consisting of 
those spectral regions that appeared most divergent between patient and control groups. Nine 
regions were identified, which are tabulated (Table 4-2). Principal components analysis of all 
groups (Figure 4-4A) displays clustering of healthy and patient groups suggesting that that 
variance between the groups accounts for most variance between these metabolite regions. 
Supervised PLSD-DA was undertaken and is displayed for HCC and healthy volunteer and 
HCC and cirrhosis groups in Figures 4-4B and 4-4C. Clustering can certainly be seen and 
goodness of fit of the models was good (R
2
=0.87 and 0.7). Goodness of prediction or Q
2
 
levels was low: 0.22 and 0.25.  Figure 4-5 displays the separate multivariate analyses for the 
Nigerian and Egyptian cohorts. These analyses confirm that the combined analyses reflect the 
country-specific results, with metabolites such as LDL, VLDL, N-acetylglycoproteins and 
acetoacetate as contributing most to discrimination between patients and healthy volunteer 
groups. Finally, male only analyses were performed using both Nigerian and Egyptian data. 
This is represented in a PCA plot in Figure 4-6.  The data displayed similar clustering to 
combined plots and the metabolites contributing most to discrimination between group  
remained very similar, confirming that gender disparities between disease and healthy 
volunteer groups were not confounding multivariate results.  
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Figure 4-4. Multivariate analyses of combined Nigerian and Egyptian samples.  
A. PCA scatter plot of all groups; B. PLS-DA scatter plot of HCC and healthy volunteer 
samples; C. PLS-DA scatter plot of HCC and cirrhosis samples.   
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Figure 4-5. Multivariate analysis plots of Nigerian and Egyptian data.  
A and B: PCA and PLS-DA loadings plot of Nigerian data; C and D: PCA and PLS-DA 
loadings plot of Egyptian data. 
SIMCA-P+ 12.0.1 - 2011-09-20 10:47:57 (UTC+0) 
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
P
L
S
 1
SIMCA-P+ 12.0.1 - 2011-09-20 10:51:28 (UTC+0) 
LDL/VLDL
Acetoacetate
Acetyl-glycoprotein
C
D
SIMCA-P+ 12.0.1 - 2011-09-20 11:03:30 (UTC+0) 
-0.10
0.00
0.10
0.20
0.30
P
L
S
 1
SIMCA-P+ 12.0.1 - 2011-09-20 11:07:40 (UTC+0) 
LDL/VLDL
Acetyl-glycoprotein
Acetoacetate
A
B
PC 1
PC 2
PC 1
PC 2
106 
 
 
Figure 4-6. Principal components analysis of male volunteer samples. 
 
 
4.4.4 Univariate statistical analysis 
Univariate analyses, using the spectral integral values of one peak, which corresponds to one 
metabolite, were performed (Figure 4-7 and Table 4-7). The most prominent spectral peaks, 
arising from LDL and VLDL molecules, showed significant difference between the groups. 
Low density lipoprotein levels were reduced in patients with HCC compared to both healthy 
volunteers (p=0.28 and 0.002) and cirrhosis (p=0.12 and 0.05). Very low density lipoprotein 
levels were raised in patients with HCC compared to compared to healthy volunteers 
(p=0.004 and <0.001) but not when compared to patients with cirrhosis (p=0.77 and 0.62). 
Lactate levels, both at 1.31 ppm (doublet) and 4.11 ppm (quadruplet), were significantly 
raised in patients with HCC compared to healthy controls (p=<0.001 and 0.03), but not when 
compared to patients with cirrhosis (p=0.06 and 0.12). N-Acetylglycoproteins levels were 
significantly raised in patients with HCC compared to both healthy volunteers and patients 
with cirrhosis (p=<0.001 and 0.001), while acetoacetate was non-significantly raised (p=0.52 
and 0.06). Finally, formate levels, although visually appearing altered between group median 
spectra, displayed no significant differences between the groups.  
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Figure 4-7. Univariate analysis of discriminatory metabolites.  
Key: p1 = p-value of HCC versus healthy control analyses; p2 = p-value of HCC versus 
cirrhosis analyses. Mann-Whitney tests of significance used for generation of p-values. 
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Figure 4-7 continued. Univariate analysis of discriminatory metabolites.  
Key: p1 = p-value of HCC versus healthy control analyses; p2 = p-value of HCC versus 
cirrhosis analyses. Mann-Whitney tests of significance used for generation of p-values. 
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Table 4-7. Metabolite differences between groups. 
Metabolite Moiety Chemical 
shift (ppm) 
HCC vs. 
Healthy 
HCC vs. 
Cirrhosis 
Pathway 
LDL  CH3 0.8 – 0.85   ↓* ↓ 
Lipid 
production/use 
LDL  -(CH2)n- 1.21 – 1.24 ↓    ↓ 
VLDL  CH3 0.85 – 0.88   ↑* ↑ 
VLDL  -(CH2)n- 1.25 – 1.30   ↑* ↑ 
Lactate CH3 1.31 – 1.32   ↑* ↓ 
Inflammation 
Lactate  CH 4.098 – 4.108   ↑* ↓ 
N-Acetyl-
glycoproteins 
NHCOCH3 2.02 – 2.05   ↑*   ↑* 
Acetoacetate CH3 2.22 – 2.23  ↑   ↑* Lipid metabolism 
Formate CH 8.445 – 8.45  ↑ ↑ 1-carbon pathway 
Key: ↑↓Indicates increased or decreased in patients with HCC, *indicates p-value <0.05. 
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4.5 DISCUSSION 
This is the first study to characterise the metabolic changes in serum and plasma due to HCC 
in two diverse populations. Multivariate analysis displayed reasonable separation of disease 
and healthy groups and comparison of median group spectra combined with univariate 
analyses identified several metabolites elevated or reduced in the blood of patients with HCC. 
Furthermore, combined analyses, of subjects from Nigerian and Egypt, revealed similar 
results to country-specific analyses. Given that the majority of patients from Nigeria were 
HBV infected and those from Egypt were HCV infected, this would suggest that blood 
metabolite profiles in the presence of HCC are dependent on the tumour effects rather than 
aetiology of liver disease. To test this, it would have been revealing to compare the 
metabolite profiles of Nigerian patients with HCC to those of Egyptian patients with HCC, 
but this was not done because of the significant effect that diet, which is quite different in 
these two countries, would have on resultant data  (Holmes et al., 2008).   
 
Gao and colleagues utilised 
1
H NMR of serum from patients with HCC in comparison to 
patients with liver cirrhosis and healthy volunteers (Gao et al., 2009), the results showing 
some similarities to those reported here (Table 4-8). The report of this study did not clarify 
the patient age, genders or aetiology of liver disease. The metabolites identified in the study 
reported here and from this study infer a significant influence of HCC upon lipid metabolism. 
Blood VLDL levels were elevated in patients with HCC, both in comparison to cirrhosis and 
healthy states. 
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Table 4-8. Metabolite alterations between groups: comparison to previous studies. 
Metabolite Moiety Chemical shift (ppm) HCC vs. 
Healthy 
HCC vs. Healthy 
(Gao et al., 2009)  
LDL  CH3 0.8 – 0.85   ↓*   ↓* 
LDL  -(CH2)n- 1.21 – 1.24 ↓      ↓* 
VLDL  CH3 0.85 – 0.88   ↑*   ↓* 
VLDL  -(CH2)n- 1.25 – 1.30   ↑*   ↓* 
Lactate CH3 1.31 – 1.32   ↑* - 
Lactate  CH 4.098 – 4.108   ↑* - 
N-Acetyl-
glycoproteins 
NHCOCH3 2.02 – 2.05   ↑*   ↑* 
Acetoacetate CH3 2.22 – 2.23  ↑   ↓* 
Formate CH 8.445 – 8.45  ↑ - 
Key: ↑↓Indicates increased or decreased in patients with HCC, *indicates p-value <0.05. 
 
Low density lipoprotein levels, conversely, were reduced. Acetoacetate, a by-product of fatty 
acid oxidation, was elevated in patients with HCC. These results, however, must be 
interpreted with extreme caution. Previous studies by Fossel and colleagues (Fossel et al., 
1986)  observed strong correlation of the methyl and methylene line width resonances of 
lipoproteins and malignancy, originally proposed as a “blood test for cancer”. When matched 
for age and triglyceride levels (which affect the line width of VLDL and LDL resonances) no 
difference could be found on follow up studies by other groups (Bell et al., 1988; Holmes et 
al., 1988; Okunieff et al., 1990; Wilding et al., 1988). In the study presented here, age was 
higher in the cancer group compared to healthy volunteers, albeit not significantly (40 years 
versus 50 years, p=0.09). Although not significant, the p-value of 0.09 indicates a trend and 
age may certainly have influenced lipoprotein resonances and confounded results. The 
cirrhosis and HCC groups were well matched for age (48.5 years and 50 years, p=0.32), so it 
112 
 
is unlikely that age plays a role in explaining discrimination between lipoprotein levels in this 
group, although none of the univariate comparisons of levels between HCC and cirrhosis 
groups reached statistical significance. Unfortunately, triglyceride levels were not measured 
in these subjects so cannot be correlated with results. Given this background, it is unwise to 
attribute the changes seen in VLDL and LDL levels, which are similar to those observed by 
Fossel and colleagues, wholly to the presence of HCC, without exclusion of confounding by 
age and triglyceride levels. If, however, this is a true reflection of HCC, then it is worth 
exploring the possible mechanisms by which these alterations may occur.  
 
It is increasingly recognised that the liver, as a central hub of lipid metabolism, may alter its 
production of VLDL as a result of disease (Bassendine et al., 2011). This is of particular 
importance in the presence of HCV particles which utilise altered VLDL particles as a 
transport and translocation facilitator thereby affecting blood levels. It is less well 
documented how HCC may affect this pathway. Intuitively, it would be expected that as a 
tumour grows in an already diseased cirrhotic liver, functionality decreases and lipid 
production does so as well. This is likely to be the explanation for vastly reduced lipoprotein 
levels in the Fisher rat model of HCC described in the previous chapter (Chapter 3). The 
results in this study are therefore counter-intuitive, with raised VLDL and reduced LDL 
levels. Gao and colleagues offer little explanation of why this would occur in their study, 
stating that HCC and cirrhosis merely enhance lipid metabolism. The genetic changes that 
occur in HCC are diverse and can affect many pathways (Wurmbach et al., 2007).  It is 
possible that one of these affected pathways may affect lipid metabolism and promote the 
production of VLDL. A candidate may be PPARα, a nuclear transcription factor, which, if 
activated, is known to decrease hepatic VLDL secretion and enhance clearance (Shah et al., 
2010). It is also plausible that peripheral VLDL breakdown, via the lipolytic pathway, is 
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reduced. If this were the case then less LDL would be formed, as seen here. This may be 
effected through  a down regulation of lipolytic enzymes such as hepatic or lipoprotein lipase, 
the interplay of which is highly complex in lipid metabolism (Bassendine et al., 2011). The 
rise in acetoacetate is also difficult to explain. If peripheral lipolysis is decreased and thus 
tissue is taking up less triglyceride for energy or storage demands, then it would also be 
expected that fatty acid oxidation, of which acetoacetate is a by-product, would be reduced. 
In combination with raised VLDL and reduced LDL, it is not clear why acetoacetate should 
be elevated.  
 
Lactate was significantly increased in patients with HCC compared to healthy controls. This 
finding is not unexpected given that stress induced anaerobic respiration is likely to occur in 
patients with cancer compared to healthy volunteers.  
 
N-Acetylglycoproteins were increased in patients with HCC. These represent “acute phase 
protein” fragments of glycoproteins such as α1-acid glycoprotein, haptoglobin, transferrin and 
fibrinogen. This finding is in disagreement with a reduced level of this molecule in the Fisher 
rat HCC model (Chapter 3). Hepatocytes are known to secrete this molecule under a number 
of different stressful stimuli including cancer (Baumann et al., 1983; Wang et al., 2006). A 
study by Bell and colleagues comparing patients with different malignancies to matched 
healthy controls, observed this resonance to display large variations in amplitude in the blood 
of cancer patients compared to healthy volunteers (Bell et al., 1988). In the human model, it 
may be that hepatic function is preserved to an extent so as to secrete this molecule upon 
stressful stimulation. It is noteworthy that glucose levels were not a discriminatory factor 
between groups. This is in contrast to the rat studies were animals with HCC displayed lower 
blood glucose levels. It may be that the influence of liver fibrosis and cirrhosis on insulin 
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resistance has a moderating effect on glucose levels. None of the patients in the study 
displayed very low glucose levels, hypoglycaemia, known to be an occasional paraneoplastic 
phenomenon in the presence of HCC (Yamaguchi et al., 1998).  
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4.6 CONCLUSIONS 
This study has produced results which, if interpreted with caution, may provide insight into 
the altered lipid pathways induced by HCC. Follow up work would begin by more 
comprehensively characterising the lipidome of patients with HCC. This may be possible 
with 
1
H NMR, as certain centres have developed an expertise in this lipid profiling method in 
attempt to characterise risk of coronary heart disease (Soininen et al., 2009). With the method 
from these centres, which uses a similar pulse sequence to the study described here, VLDL, 
LDL, HDL and IDLs can be differentiated. It would also be helpful to analyse the samples for 
routine lipid profiles (which would include cholesterol and triglycerides). This, unfortunately, 
was not possible given the small volumes of sample remaining in storage.  
 
Limitations of the study include the contamination of EDTA in Nigerian samples. Data 
recovery was reasonable despite this, but to maximise the chance of identifying biomarkers, 
samples should not contain EDTA or other storage molecules that display 
1
H NMR 
resonances. It would also be essential to compare to a contemporaneously collected sample 
set of patients with non-liver tumours to assess whether changes are cancer related or HCC 
specific.  
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5 BLOOD LIPID PROFILING OF HEPATOCELLULAR 
CARCINOMA USING ULTRA-PERFORMANCE LIQUID 
CHROMATOGRAPHY MASS SPECTROMETRY 
5.1 ABSTRACT 
Introduction: The liver is a hub of lipid metabolism and previous studies have shown liver 
disease and HCC to be associated with altered blood lipid profiles. The primary aim of this 
study was to examine the lipid profile of HCC, using MS-based techniques, in an animal 
model and compare observations made in human populations.  Traditional lipid extraction 
protocols involve the use of chloroform, a toxic chemical, the use of which is diminishing. 
The secondary aim of this study was to optimise the lipid extraction using dichloromethane 
instead of chloroform. Methods: Plasma samples were obtained from a Fisher rat model of 
HCC and healthy littermate controls (n=7 and 8). Serum and plasma samples were obtained 
from patients with HCC and cirrhosis from UK (n=3 and 4) and Nigerian (n=5 and 5) 
cohorts. All samples were analysed using UPLC-MS, optimised using dichloromethane lipid 
extraction protocols. Data were processed using multivariate analysis to identify lipids most 
discriminatory between disease groups. Results: In the rat model, multivariate statistical 
modelling was robust in classifying animals with HCC from healthy controls. In the human 
studies, multivariate analyses of lipid profiles were poor in distinguishing HCC from 
cirrhosis. Features M496 T104 and M759 T776 were identified as most contributory to 
multivariate models. M496 T104 is likely to represent lysophosphatidylcholine (24, 0, 0) 
(LPC), a major cellular membrane component. Conclusions: Altered global lipid profiles 
were robust in discriminating HCC from healthy controls in a Fisher rat model but poor in 
parallel human studies. Differences in LPC (24, 0, 0) were present in all studies which may 
indicate altered cellular turnover as a result of HCC.     
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5.2 INTRODUCTION 
Lipids are a diverse group of molecules, ranging from fatty acids, the building block of most 
lipids, to glycerolipids and sphingolipids. They are defined by their insolubility in water and 
solubility in organic solvents. They can be variously involved in energy production, cell 
membrane synthesis and cell signalling cascades (Fahy et al., 2009) (Table 5-1). The liver is 
a central regulator of lipid turnover, synthesising most endogenous lipids, cholesterol and 
apolipoproteins.  
 
Table 5-1. Lipids (Fahy et al., 2009). 
Lipid Example Function(s) 
   
Fatty acyls Palmitic acid Building blocks of major lipids 
Glycerolipids Triglyceride Fat storage molecule in mammalian systems 
Glycerophospholipids Phosphatidylcholine, 
phosphaethanolamine 
Cell membrane substrate, binding site for 
intra- and extra-cellular proteins 
Sphingolipids Sphingosine, ceramide Cell membrane substrate, signalling cascade 
Sterols Cholesterol Cell membrane substrate, hormone synthesis 
Prenols Caretenoid Vitamin precursors 
 
 
Cox and colleagues,  using phosphorous-31 in vitro MRS, observed that HCC tumour tissue 
displayed raised phosphoethanolamine (PE) and phosphocholine (PC) and reduced 
glycerophosphoethanolamine (GPE) and glycerophosphocholine (GPC) levels, providing an 
insight into the altered metabolism of lipids in HCC (Cox et al., 1992).  Serum 
1
H NMR 
spectroscopy and LC-MS studies of patients with HCC from China, described reduced levels 
of lysophosphatidylcholine, sphingosines, unsaturated fatty acids and low density 
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lipoproteins indicating that HCC-induced altered lipid metabolism could be detected in the 
blood (Gao et al., 2009; Yin et al., 2009).  
   
In the previous chapter 
1
H NMR spectroscopy of serum and plasma revealed broadly altered 
lipid profiles in patients with HCC. Resolution of lipid species was poor in these studies, 
allowing only a broad estimation of lipoproteins to be made. Liquid chromatography with MS 
is a validated method of analysing blood lipid profiles (Quehenberger et al., 2010) and if 
ultra-pressure systems are employed, acquisition of high resolution data is possible.   
  
Traditional lipid extraction protocols involve the use of chloroform (CHCl3) and methanol 
two phase extraction regimens, whereby lipids are soluble and retained in the lower organic 
layer. These methods were introduced by Folch and colleagues in the 1950s when attempting 
to optimise extraction protocols for brain tissue (Folch et al., 1957). Chloroform, however, is 
toxic and potentially carcinogenic, European regulations allowing only a 2 ppm workplace 
atmospheric concentration. Dichloromethane (CH2Cl2) is less toxic, regulations allowing a 50 
ppm atmospheric concentration and has been shown, albeit in plant and seed lipid extraction 
experiments, to be as efficient as chloroform in extracting lipids (Cequier-Sanchez et al., 
2008).  
 
The initial aim of this study was to optimise lipid extraction techniques and examine the 
effectiveness of dichloromethane lipid extraction.  The main aim was to examine the lipid 
profiles of HCC in a small sample of human and rat subjects, as a proof of principal, that lipid 
extraction coupled with UPLC-MS could be a fruitful method of lipid profiling.  
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5.3 METHODS 
5.3.1 Lipid extraction optimisation 
Standard rat plasma was used to evaluate the extraction efficiency of dichloromethane and 
methanol, versus methanol alone, to establish a protocol which could be applied to all blood 
samples. Standard lyophilized rat plasma (Sigma-Aldrich, Poole, UK), constituted from 
pooled rat blood with 3.8% trisodium citrate additive as anticoagulant, was reconstituted with 
1 mL H20. Test samples were prepared as described below and run using a high strength 
silica (HSS) T3 Acquity
TM
 UPLC-MS 2.1 x 150 mm, 1.8 μm column (Waters Ltd, Elstree, 
UK) in a Waters Acquity
TM
 Autosampler (Waters Ltd, Elstree, Herts, UK). Based on superior 
chromatographic results (Figure 5-1) dichloromethane and methanol extraction was utilised 
for all further experiments.  
 
5.3.2 Fisher rat model of hepatocellular carcinoma 
Induction of HCC, venesection and sample storage were the same as described in Chapter 3.  
 
5.3.3 Patient selection 
UK patients were recruited from outpatient and inpatient settings at St Mary’s Hospital, 
Imperial College NHS Trust, Paddington, London, UK between October 2008 and March 
2011. All patients gave written informed consent in accordance with local Research Ethics 
Committee approval. Nigerian patients were recruited from Jos University Teaching Hospital 
(JUTH), Jos Nigeria and all provided informed consent, signed HCCs were diagnosed in both 
populations by radiological measures (US, CT or MRI) and cirrhosis in the UK population 
diagnosed by biopsy, US, MRI or CT confirmation and in Nigeria, clinically, by the presence 
of portal hypertension (varices or ascites) and US or CT confirmation.  
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5.3.4 Blood laboratory tests 
Serum ALT, total bilirubin and albumin were measured using automated techniques 
(Abbott™ Architect Ci16200 Analyser, UK) at St Mary’s Hospital, London. Serum AFP was 
measured using an automated Siemens™ Immulite 2500 Analyser, (Deerfield, USA). Given 
the low number of samples in each group, median levels were not statistically compared as 
results would have been prone to bias.  
 
5.3.5 Sample collection 
Random, non-fasted 5 mL blood samples were venesected into either plain serum or EDTA 
containing sterile tubes and placed immediately on ice or into a refrigerator at 4 ºC. Samples 
were centrifuged within 1 – 2 hrs at 4 ºC, 1000 rpm for 10 min. The supernatant was 
transferred as 2 mL aliquots into 2 mL microvial tubes and stored at -80 ºC until analysis.   
 
5.3.6 Sample preparation 
All solvents were HPLC grade, 99.9% pure and purchased from Sigma-Aldrich, Poole, UK. 
All samples were thawed at room temperature and 100 μL transferred into 3.5 mL glass vials 
to which 267 μL methanol were added. Using a glass syringe, 1.2 mL dichloromethane were 
added and the sample was vortexed for 5 s to encourage mixing of sample with solvents. The 
mixture was centrifuged at 1,400 rpm for 5 min at room temperature which resulted in a two 
layer product, the bottom layer containing the lipid fraction. Using a glass 150 mm Pasteur 
pipette (VWR International, Pennsylvania, USA) the bottom layer was transferred into clean 
3.5 mL glass vials. The solution was evaporated to dryness using a Concentrator Plus
TM
 
evaporator (Eppendorf, Hamburg, Germany) under vacuum at room temperature for 1 hr. The 
resultant concentrated dried lipid fraction was re-suspended in 100 μL methanol (final 1: 1 
ratio of sample: methanol), placed in an ultrasonic bath for 10 min (Grant Instruments, 
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Cambridge, UK), vortexed for 30 s and centrifuged at 1,400 rpm for 5 min at room 
temperature. The supernatant was transferred into 150 μL glass vial inserts (Waters Ltd, 
Elstree, UK) and capped with pre-slit polytetrafluoroethylene/silicone septated caps, ready 
for UPLC-MS analysis.   
 
5.3.7 Chromatographic conditions 
All chromatography was performed using a HSS T3 Acquity UPLC-MS 2.1 x 150 mm, 1.8 
μm column (Waters Ltd, Elstree, UK) in a Waters Acquity AutosamplerTM (Waters Ltd, 
Elstree, UK). Mobile phase solvents were made up as follows: mobile phase A consisted of 
290 mL H20, 200 mL acetonitrile and 10 mL ammonium acetate buffer (pH 5); mobile phase 
B consisted of 440 mL isopropanol, 50 mL acetonitrile and 10 mL ammonium acetate buffer 
(pH 5). As lipids avidly adhere to this column, isopropanol was used for mobile phase B as it 
possesses the correct miscibility to allow lipid elution from the column. The column 
temperature was high, 65 ºC, which also encourages lipid elution. Injection volume was 3 μL 
and the flow rate set at 500 μL min-1. The mobile phase gradient (A / B) was set as 60 % / 
40% for 10.5 min, 0 / 100% for 2.1 min, 60% / 40% for 4..4 min (total run time 17 min).  
 
5.3.8 Mass spectrometry 
Mass spectrometry experiments were performed on a Micromass LCT Premier™ quadrupole 
time of flight (Waters MS Technologies, Manchester, UK) with electrospray ionisation (ESI). 
Data were collected in positive ion centroided mode. The mass spectrometer was operated 
with a capillary voltage of 3 kV, cone voltage of 50 V, nebulizer gas flow of 800 L/h, 
desolvation temperature of 400 °C, and source temperature of 120 °C. The instrument was set 
to acquire over the mass range m/z 50-1000 with acquisition time of 5 scans s
-1
 and an 
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interscan delay of 0.02 s. The analyser was run in V mode and the lock mass used was 
leucine encephalin (556.2771 Da).  
 
 5.3.9 Data pre-processing 
Datasets generated are complex, each sample generating chromatographic retention time and 
mass spectrometry data. Prior to comparative analysis it is essential that the data are aligned 
so that an analyte has the same mass: charge ratio (m/z) and retention time in all samples. 
Correction of m/z drift is straightforward with the use of a known reference standard (leucine-
enkephalin, m/z 556.2771) utilised as a mass lock. Retention time drift, due to sample 
composition, column variablity with time and environmental factors, is more difficult to 
correct for. For these experiments the data processing software XCMS was used (Scripps 
Center for Mass Spectrometry, La Jolla, California, USA) (Smith et al., 2006). XCMS 
performs three functions resulting in comparable data information: 
i. Peak detection. The algorithm is based on cutting the data into slices a fraction of a 
mass unit (0.1 m/z) and operating on individual slices in the chromatographic time 
domain. The signal is determined by taking the maximum intensity at each time point 
in the slice (Smith et al., 2006).  
ii. Peak matching. Overlapping fixed-interval bins of 0.25 m/z width are generated to 
match peaks. Because bins are overlapping, the algorithm counts the same peak twice 
and subsequently removes peak groups originating from overlapping bins resulting in 
a single peak per bin. Once peaks have been matched by mass, they are matched by 
retention time. This is performed by calculating the overall distribution of peaks in 
chromatographic time and identifying the boundaries of regions where many peaks 
have similar retention times. The distribution of peaks or “metapeaks”  are defined in 
a fixed interval in which all peaks are placed into a group (Smith et al., 2006).  
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iii. Retention time correction. From the initial grouping, the algorithm then identifies 
those peak groups in which very few samples have no peaks assigned and very few 
samples have more than one peak assigned.  The algorithm calculates the median 
retention time and deviation from median for every sample in that group. 
Consequently, a detailed, non-linear retention time deviation contour can be built for 
each sample and peak groups can be corrected for retention time differences (Smith et 
al., 2006). 
 The resulting data matrix displays sample identification (observations) against unique mass 
(in Da) / retention time (“T” in sec) “features” (variables), each number corresponding to the 
intensity for that feature in a particular sample. The software also performs a simple 
univariate t-test between two selected groups identifying those features the levels of which 
are significantly different between those two groups. The features are listed in order of 
significance and accompanying extracted ion chromatograms (EIC) are generated to aid 
visualisation. UPLC with XCMS data processing has been validated for use in metabolic 
profiling experiments displaying excellent data preservation and high sensitivity and 
resolution of data (Nordstrom et al., 2006).  
 
5.3.10 Multivariate analysis 
The data matrix was exported to SIMCA (Umetrics, Umea, Sweden) for PCA and PLS-DA as 
described in earlier chapters. All date were mean centred prior to multivariate analysis.   
 
5.3.11 Univariate analysis 
Data were exported to GraphPad Prism (La Jolla, California, USA) for univariate analysis in 
the form of Mann-Whitney t-tests comparison of medians between groups, assuming non-
parametric distribution of data.  
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5.4 RESULTS  
5.4.1 Patient and rat demographics 
Patient demographics are displayed in Tables 5-2 – 5-4. Body mass indices were similar for 
patients with HCC and cirrhosis, however, all of the HCCs in the Nigerian group were AFP 
secreting, while those in the UK cohort were not. The aetiologies in both groups were 
diverse, including HCV, HBV, alcohol and NASH. The average Okuda stage was higher in 
the Nigerian group (2.4), compared to the UK group (2.0).  
 
Table 5-2. Patient demographics of UK and Nigerian cohort. 
Characteristic UK group Nigerian group 
 HCC Cirrhosis HCC Cirrhosis 
     
n 3 4 5 5 
Median age (range) (years) 61.0 65.5 48.0 57.0 
Male n (%) 3 (100%) 2 (50%) 4 (80%) 4 (80%) 
Median body mass index (kg/m
2
) 24.1 28.6 Not recorded Not Recorded 
AFP (IU mL
-1
) 23.9 4.3 8,877 5.97 
ALT (IU L
-1
) 44.0 23.5 29.0 37.0 
Bilirubin (μmol L-1) 10 46.5 7.1 26.4 
Albumin (g L
-1
) 32.0 33.5 22.6 27.8 
 
 
Table 5-3. Aetiologies of hepatocellular carcinoma and cirrhosis cohorts. 
Aetiology HCC Cirrhosis 
 UK Nigerian UK Nigerian 
HCV 1 0 0 0 
HBV 2 5 1 5 
Alcohol 0 0 2 0 
NASH 0 0 1 0 
Total 3 5 4 5 
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Table 5-4. Okuda stage of patients with hepatocellular carcinoma. 
Stage UK Nigerian 
I 1 0 
II 1 3 
III 1 2 
Mean score 2 2.4 
Total 3 5 
 
 
 
Median rat group weights at sacrifice (14 weeks) are displayed in Table 5-5, displaying that 
control rats were 103.5 g heavier than those with HCC. 
 
Table 5-5. Fisher rat weights at time of sacrifice. 
 HCC group Control group 
n 7 8 
Weight at 14 weeks upon sacrifice (g) 340.5 444.0 
 
 
5.4.2 Lipid extraction optimisation 
Total ion chromatograms of the same standard rat plasma using different extraction methods 
are displayed in Figure 5-1. Several areas in the chromatogram are highlighted where 
dichloromethane with methanol extraction resulted in superior lipid recovery to methanol 
alone.  
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Figure 5-1. Total ion chromatograms of the rat standard plasma after 
dichloromethane/methanol or methanol only extraction.  
Top pane: dichloromethane/methanol extraction; lower pane: methanol only extraction. 
Areas in red highlight improved recovery of lipid species.  
 
 
5.4.3 Positive mode lipid chromatograms 
Figure 5-2 displays a positive mode total ion chromatogram from a Fisher rat with HCC. In 
comparison, chromatograms from patients from the UK and Nigerian group are also 
displayed. Similarities between the chromatograms are observed suggesting similar lipid 
profiles overall.  
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Figure 5-2. Nigerian, UK and rat serum and plasma total positive ion mode 
chromatograms following lipid extraction. 
 
 
5.4.4 Multivariate statistical analysis 
Figure 5-3 displays PCA scatter plots for rat plasma as well as those for parallel UK, 
Nigerian patients’ serum and plasma samples, of HCC versus cirrhosis for human studies and 
HCC versus healthy controls for the rat studies. Clustering of groups was poor in the human 
studies, although in the rat studies, it was more obvious. PLS-DA of the rat data revealed a 
good R
2
 value (0.88), or goodness of fit, and good Q
2
 value (0.74), goodness of predictability. 
For Nigerian and UK human studies: R
2
 = 0.68 and 0.52, Q
2
 = both negative, suggesting 
good model fitting but poor discrimination between HCC and cirrhosis based on global lipid 
profiles.  PLS-DA loadings plots were examined for those features that contributed most 
greatly to PLS components in both models. Table 5-5 displays these features in all three 
groups, documenting certain features that were identified in two or more of the cohorts.  
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Table 5-6. Discriminatory features identified by multivariate analysis.  
 Nigerian plasma and serum UK serum Rat plasma 
Feature 
M759 T366 M496 T104 M496 T104 
M849 T585 M522 T114 M269 T776 
M821 T573 M520 T87 T759 T366 
M187 T776 M187 T776 M873 T577 
Text in green indicates features that were discriminatory in two or more groups. 
 
5.4.5 Lipid feature identification 
Those features that were discriminatory in two or more cohorts were selected for 
identification. M187 T776 was represented in all three cohorts, however, when the 
chromatographic data were analysed, it was apparent that at this retention time there was no 
Figure 5-3. Principal components 
analysis of human and rat positive mode 
data.  
Key: ■= Hepatocellular carcinoma 
samples; ●= cirrhotic controls in human 
studies or healthy controls in rat studies.   
PC2 
SIMCA-P+ 12.0.1 - 2011-09-02 14:07:27 (UTC+0) 
SIMCA-P+ 12.0.1 - 2011-09-01 10:43:35 (UTC+0) 
SIMCA-P+ 12.0.1 - 2011-09-01 10:27:39 (UTC+0) 
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clear chromatographic peak, nor would it be likely at such a late time point (12.95 min), 
which is at the end of the run after the majority of ions have been eluted. XCMS had 
therefore erroneously labelled background noise as a peak. This feature was discounted from 
further analysis.  
 
Representative extracted ion chromatograms for masses 496 Da (exact mass 496.34 Da) and 
759 Da (exact mass 758.57) from the human and animal study HCC groups are displayed in 
Figures 5-4 and 5-5.  These chromatographic data confirm the presence of true elution peaks 
for these masses. Mass spectra of these peaks from the human and animal studies are 
displayed in Figure 5-6 and 5-7.  Reference to online databases (http://metlin.scripps.edu) 
identified this feature as likely to be a lysophosphatidylcholine (LPC) (24, 0, 0) 
(C24H50NO7P) a lysophospholipid that can have variable fatty acid chain lengths (Wishart et 
al., 2007) and is a major plasma lipid (Figure 5-9). In addition, in some spectra, a co-eluting 
mass at 184.07 Da is observed, which may represent a phosphocholine head group, a 
fragment of LPC (24, 0, 0) (Figure 5-6).  Feature M759 T366 could not be identified from 
databases.  
 
5.4.6 Univariate statistical analysis 
Figures 5-8 display scatter plots of the relative intensity of each of these masses in each 
disease group. Feature M496 T104, likely to represent LPC (24, 0, 0), was reduced in patients 
with HCC compared to cirrhosis, although not to a level of significance (p=0.4). In the 
Nigerian cohort there was no significant difference (p=0.69). This was mirrored in the Fisher 
rat study where there was no significant difference between levels of M496 T104 between 
animals with HCC and healthy controls (p=0.96).  
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Figure 5-4. Extracted ion chromatograms for mass 496.34. 
 
Figure 5-5. Extracted ion chromatograms for mass 758.57. 
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Figure 5-6. Mass spectra of feature M496 T104. 
 
 
Figure 5-7. Mass spectra of feature M759 T366. 
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Figure 5-8. Relative intensities of features M496 T104 (likely to be lysophosphatidylcholine (24, 0, 0)) and M759 T366 in UK, Nigerian 
and rat cohorts. (p values generated from Mann-Whitney tests of median values)
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5.5 DISCUSSION 
Proton NMR spectroscopy studies described in the previous chapter, highlighted altered lipid 
profiles in animal and human studies. The aims of the study presented here were to optimise 
lipid extraction techniques using dichloromethane instead of chloroform and to characterise 
the lipid species altered in HCC. Optimisation experiments were successful in confirming 
that dichloromethane / methanol extraction, while lengthy, does efficiently extract lipids. 
Classification of disease based on lipid profiles using multivariate statistical analysis was 
good in Fisher rat models (R
2
=0.88 and Q
2
=0.74), but poor in human models (R
2
=0.52 – 0.68 
and Q
2
 negative). Multivariate analysis accounts for global lipid profiles and given that there 
was a 100 g difference in rat weight between the controls and HCCs, it is unsurprising that 
lipid differences were detected in this group. The human studies were of small number, but 
well matched groups, both for disease severity and BMI. It is probably this reason that 
accounts for the similarity in global lipid profiles resulting in poor multivariate classification. 
Furthermore, there is a far higher degree of genetic diversity in humans which will almost 
certainly have an effect on lipidomic profiles. It is more illuminating, however, that certain 
lipids contributed more to multivariate models than others. Indeed, very little is present in the 
literature on the specific lipid changes in patients with HCC and with greater knowledge of 
the functional and signalling role of lipids, this study produced some results of note. Feature 
M496 T104, likely to represent lysophosphatidylcholine (24, 0, 0), was a discriminating 
factor in multivariate models. The rat model did not display significantly different levels of 
LPC between animals with tumour and healthy controls. None of the human univariate 
analyses reached significantly different results between subjects with HCC and controls and 
trends were different in both the human cohorts. In the UK population, levels of this molecule 
were higher, while this was not the case in the Nigerian cohort.   Lysophosphatidylcholine is 
a major plasma glycerophospholipid which can possess variable fatty acid chain lengths, the 
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most common containing 16 carbons in the fatty acid chain (Wishart et al., 2007). LPC 
transports metabolites such as fatty acids, choline and phosphatidylglycerol between tissues. 
It is derived from surface phosphatidylcholine of lipoproteins or cell membrane-derived 
phosphatidylcholine as a result of phospholipase A2 (Schmitz and Ruebsaamen, 2010).   A 
proportion of LPC has been shown to be secreted from the liver in rats (Sekas et al., 1985). 
The main role of LPC is thought to be as a cell membrane constituent, although it is 
increasingly recognised that it may have a role in cell signalling, cell proliferation, and even 
tumour cell invasiveness (Fukushima et al., 2001). Alterations in levels of plasma LPC have 
also been observed in neurological diseases and carcinomas (Schmitz and Ruebsaamen, 
2010). Cox and colleagues, observed increased PC and PE and decreased GPC and GPE 
levels in seven in vitro tumour extracts, three of which were from HCC, using 
31
P magnetic 
resonance spectroscopy. They hypothesised that this may be due to increased synthesis and 
decreased breakdown of phospholipids in tumours, presumably to fuel the cell membrane 
substrate requirements (Cox et al., 1992). Yang and colleagues, in 2007, using 
1
H MRS of 17 
HCC tissue specimens, also detected increased choline levels, concluding that this was due to 
high cell turnover (Yang et al., 2007). Two studies from China, in HBV infected patients 
with HCC, using MS and 
1
H NMR techniques, observed reduced LPC levels and choline 
levels in patients’ blood (Gao et al., 2009; Yin et al., 2009). It is therefore likely, that a 
similar explanation underlies the results observed in this UK study: lower LPC (24, 0, 0) 
levels in the blood indicating consumption of this molecule by the tumour to fuel its growth. 
Why similar results are not seen in the Nigerian cohort may be due to a number of reasons. 
First, biometric data are not available for the group and it may that there is a vast difference 
in BMI between the HCC and cirrhosis groups. If this were the case, then, global lipid 
profiles would be altered, likely due the effect of nutritional and cachexia status, rather that 
specific tumour-related lipid changes. Second, the tumours in the Nigerian group were more 
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advanced (median Okuda stage 2.4) and may not be directly comparable to the UK group 
(median Okuda stage 2.0). Thirdly, dietary influence may play a role in influencing lipid 
profiles. Unfortunately, no dietary history was recorded for the Nigerian patients, but the 
staple food in this area of central Nigeria consists of maize products and little meat due to its 
high cost. This contrasts to the protein rich Western diet which UK patients are likely to 
consume.  
 
To account for these findings as being specific to HCC would be false without validation 
experiments in other tumours. Cox and colleagues found similar changes in PE / PC and GPE 
/ GPC ratios in adenocarcinoma liver metastases and it is likely that any tumour may display 
these findings as all require building blocks to synthesis cell membranes. Caution should also 
be taken in interpretation of results given the small numbers in each group. This study has 
proved a principle that lipid profiles are altered in HCC compared to similarly matched 
controls; however, much larger studies are needed to confirm this. Furthermore, identification 
of all lipids, which display altered levels in patients with HCC, is required for full 
characterisation of the tumour “lipidome”. UPLC-MS, while exquisitely sensitive, does pose 
difficulties in species identification and future work would have to include tandem mass 
spectrometry fragmentation experiments and standard authentication in a larger disease group 
including other non-HCC tumour types as well.   
 
Figure 5-9. Schematic structure of lysophosphatidylcholine (C24H50NO7P). 
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5.6 CONCLUSIONS 
This study has confirmed that dichloromethane is a valid alternative to chloroform for the 
purposes of lipid extraction. Using this method, blood lipid profiling of HCC identified 
altered metabolites in both human and animal models of the disease. Altered global lipid 
profiles were robust in discriminating HCC from healthy controls in a Fisher rat model but 
poor in parallel human studies, probably due to the low sample numbers in study groups.  
Differences in LPC (24, 0, 0) were present in all studies which may indicate altered cellular 
turnover as a result of HCC.    
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6 THE URINARY METABOLIC PROFILING OF 
HEPATOCELLULAR CARCINOMA USING PROTON NUCLEAR 
MAGNETIC RESONANCE SPECTROSCOPY IN A NIGERIAN 
PATIENT COHORT 
 
6.1 ABSTRACT  
Introduction: There have been few studies of the urine metabolic profile of HCC and none 
using urinary 
1
H NMR spectroscopy in an African population. This study is the first to 
analyse the urinary 
1
H NMR metabolic profiles of patients with HCC from Jos in Nigeria, in 
an attempt to identify metabolic changes due to the tumour.  Methods: Using a 500 MHz 
NMR system, urine was analysed from three well-matched subject groups, collected at Jos 
University Teaching Hospital (JUTH), Nigeria. Multivariate statistical analyses were 
performed PCA and PLS-DA. All patients were of Nigerian descent: 18 hepatitis B surface 
antigen (HBsAg)-positive patients with HCC; 10 HBsAg positive patients with cirrhosis; and 
14 HBsAg negative healthy Nigerian volunteers. Results: Urinary 
1
H NMR spectral profiles 
from HCC patients were distinguished from healthy controls, and from patients with 
cirrhosis, with sensitivity: specificity of 100%: 93% and 89.5%: 88.9%, respectively. 
Metabolites that most strongly contributed to the multivariate models were creatinine, 
carnitine, creatine and acetone. Compared to patients with HCC, healthy volunteer and 
cirrhosis patient urine displayed reduced creatinine (p<0.001and 0.06) and elevated carnitine 
(p=0.04 and <0.001) and creatine  (p=0.05 and 0.29) levels.  Conclusions: Urinary 
1
H NMR 
spectroscopy with multivariate statistical analysis was able to differentiate patients with HCC 
from normal subjects and patients with cirrhosis permitting the notion that a urinary test for 
HCC is possible.  
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6.2 INTRODUCTION 
Urine contains a wealth of information. Small metabolites (<1000 Da) are able to pass 
through the renal glomerulus, evade tubular re-absorption and be excreted and can form a 
metabolic fingerprint of the host physiology. These metabolites, which may include amino 
acids, peptides, nucleotides and lipid fragments can be detected using techniques such as 
1
H 
NMR spectroscopy and mass spectrometry. Several recent studies have highlighted the value 
of 
1
H NMR spectral urinary profiling in the diagnosis of lung cancer (Carrola et al., 2011), 
bladder cancer (Srivastava et al., 2010), pneumonia (Slupsky et al., 2009) and inflammatory 
bowel disease (Williams et al., 2009). 
 
Hepatocellular carcinoma is prevalent in sub-Saharan Africa (Shariff et al., 2009) due to the 
high rate of chronic HBV infection. In resource poor settings, such as rural sub-Saharan 
Africa, tests to diagnose HCC such as ultrasound and serum AFP are not available owing to 
their high cost and infrastructure requirements. A urine test for HCC would be invaluable in 
this setting as it would be non-invasive, robust (urine does not need immediate centrifugation 
as there are no erythrocytes to lyse) and cheap to collect (no phlebotomy equipment 
required).  
 
There have been three studies in Oriental patient cohorts of the urinary metabolic profiles of 
HCC using MS-based techniques (Chen et al., 2009; Chen et al., 2011; Wu et al., 2009). 
These studies have revealed a number of urinary amino acid, peptide and bile acid signatures 
of HCC. It is therefore clear that either directly or through changes in host metabolism, HCC 
can cause metabolic changes detectable in urine. This is the first urinary 
1
H NMR 
spectroscopy study of HCC to be undertaken (Shariff et al., 2010).  
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The aim of this study was to test the hypothesis that HCC-induced metabolic changes can be 
detected and categorised using 
1
H NMR spectroscopy of urine in an African population. The 
secondary aim was to test the accuracy of detected alterations in discriminating urine between 
patients with HCC from that of healthy volunteers and patients with cirrhosis.   
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6.3 METHODS 
6.3.1 Patient selection 
The study protocol was in concordance with the ethical guidelines of the 1975 Declaration of 
Helsinki and approved by the research ethics committee of the University of Jos, Nigeria, 
while the metabolic profiling protocol was approved by the research ethics committee of 
Imperial College Healthcare NHS Trust, London, UK. All subjects provided informed, signed 
consent. 
 
6.3.2 Sample collection 
Samples were collected and processed for storage by Dr Nimzing G. Ladep, JUTH, Nigeria. 
Random, non-fasted, urine samples were collected and centrifuged at 13,000 rpm for 10 min 
to remove any precipitates and stored at -80
o
C until analysis. Samples were thawed and 
prepared according to standard methodology (Beckonert et al., 2007; Williams et al., 2009). 
400 μL of urine were mixed with 200 μL of phosphate buffer solution (0.2 M Na2HPO4/0.2 
M NaH2PO4, pH 7.4), and 60 μL of 3-trimethylsilyl-(2,2,3,3-
2
H4)-1-propionate (TSP) / D2O 
solution (final concentration of TSP = 1mM) were added. The TSP served as an internal 
chemical shift reference (0.00 ppm) and the D2O provided a nucleus field lock. The buffered 
urine sample was left to stand for 10 min and then centrifuged at 13,000 rpm for 10 min. 
550μL of supernatant were transferred into a 5mm diameter glass NMR tube (Wilmad 
LabGlass
TM
, New Jersey, USA) for 
1
H NMR spectroscopy. 
 
Blood was venesected  from each subject for parallel metabolite profiling studies (Chapters  
4, 5 and 9) and  for measurement of serum urea creatinine, ALT, ALP, bilirubin and albumin 
levels, measured using automated techniques (Abbott™ Architect Ci16200 Analyser, UK). 
Serum AFP was measured using an automated Siemens™ Immulite 2500 Analyser, 
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(Deerfield, USA). Median and interquartile ranges (IQR) were calculated for each assay and 
median levels were compared using unpaired Mann-Whitney tests of significance, p-values of 
<0.05 were considered significant. 
 
6.3.3 Proton magnetic resonance spectral processing 
Samples were run in a randomised order over one session. Proton NMR spectra were 
acquired using a pulse-collect sequence with water presaturation (JEOL 500 MHz Eclipse+ 
NMR spectrometer). The 16 data collects were summated. A 90
o
 pulse angle was used with a 
total repetition time of 18.7 s, so that fully-relaxed data were acquired. The acquisition time 
was 8.7 s. MR spectra were processed using the KnowItAll™ Informatics System v7.8 (Bio-
Rad, Philadelphia, USA). Free induction decays were zero-filled by a factor of two and 
multiplied by an exponential window function with a 0.3 Hz line-broadening factor, prior to 
Fourier transformation. All MR spectra were phased and a baseline correction applied. All 
spectra were referenced to TSP (0.00 ppm) and methyl creatinine peaks were aligned to 3.05 
ppm. MR spectral resonances were assigned according to literature (Holmes et al., 1997; 
Nicholson et al., 1995; Wishart et al., 2007). MR spectral analysis included the range 0.20 – 
10.00 ppm, excluding the region 4.50 – 6.40 ppm, to remove the residual water signal and 
variation in urea signal due to exchange of protons with the solvent.  
 
6.3.4 Multivariate statistical analysis 
Magnetic resonance spectra were divided into smaller regions or “buckets” of 0.02 +/- 0.01 
ppm, representing specific metabolites (Psihogios et al., 2008; Walsh et al., 2006; Williams 
et al., 2009) using the “intelligent bucketing” algorithm in the KnowItAll Informatics System 
v7.8. These regions were then integrated, normalised to the sum of the total spectral integral 
and the data mean-centred prior to multivariate analysis. This created a data matrix of 
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samples against variables (ppm bins) which was transferred to KnowItAll Informatics System 
v7.8 for PCA and exported to Pirouette v4.0 (Infometrix, Washington, USA) for PLS-DA. 
The data filtering technique of orthogonal signal correction (OSC) was used to remove 
variation in the spectra not directly related to the physiological condition being studied and to 
minimise the possible influence of inter-individual variation (Psihogios et al., 2008; 
Westerhuis et al., 2008). The discriminatory power of each model was validated using two 
techniques. First, leave-one-out cross validation, whereby each sample in turn was excluded 
from the analysis, a model created from the remaining samples and the class membership of 
the excluded sample predicted (Mahadevan et al., 2008). Second, full external validation in 
which models were created from training sets (70% of the samples, selected at random) and 
their predictive power tested using independent “test” sets (the held-back 30% of the 
samples). For both techniques, the R
2
 and Q
2
 values and misclassification matrix of the model 
described the number of correctly predicted samples, and from this the sensitivity and 
specificity of the model could be calculated. 
 
6.3.5 Univariate statistical analysis 
The metabolites which contributed most to PCA and PLS-DA discrimination were identified 
through analysis of the loadings plots. Using KnowItAll Informatics System v7.8, these areas 
were integrated and normalised to the sum of the total spectral integral. Values were 
expressed as percentage index, relative to the total spectral integral. Using GraphPad Prism 
v5.01 (California, USA), differences between the HCC, cirrhosis and healthy control groups 
were analysed using the Mann-Whitney tests of significance, p-values <0.05 were considered 
significant. 
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6.4 RESULTS  
6.4.1 Subject demographics 
Forty-two Nigerian subjects were recruited for study. These consisted of 18 patients with 
ultrasound or computed tomography diagnosed HCC; 10 patients with clinically diagnosed 
cirrhosis with features of portal hypertension; and 15 healthy Nigerian healthy volunteers. 
Subject demographics are shown in Table 6-1. Median age of the HCC group was 46.5 years 
and that of the healthy and cirrhosis groups 37 years. Mann-Whitney tests of median values 
did not find this to be a significant difference (p=0.47 and 0.19). Twelve of 18 (66.7 %) 
patients in the HCC group were male, 8 of 10 (80 %) in the cirrhosis group and 7 of 14 (50 
%) in the healthy group. Fisher’s exact (chi-squared) of categorical variables of HCC versus 
healthy and HCC versus cirrhosis groups revealed these proportions not to be significantly 
different (p=0.30 and 0.67). Seventeen of the patients (94%) in the HCC group and all of 
those with cirrhosis were HBsAg positive (ELISA 3
rd
 generation). The only HBsAg negative 
patient in the HCC group was also HCV serum antibody negative and therefore diagnosed as 
having idiopathic liver disease. HCCs were classified according to the Okuda staging system 
(Okuda et al., 1985) (Table 6-1). All HCCs were reasonably advanced at stage II (n=8, 
though in 2 of these 8 subjects, stage was based only on the tumour size (>50% of liver size) 
and detectable ascites, as there was insufficient serum collected to measure albumin and 
bilirubin levels) or stage III (n=10). Healthy volunteers were of Nigerian descent, from the 
medical faculty of JUTH, and were HBsAg negative with normal hepatic function.  
 
On direct questioning, none of the subjects admitted to taking prescribed or non-prescribed 
medication, nutrient or vitamin supplements, but analysis of subsequent MR spectra revealed 
the presence of paracetamol (acetaminophen) metabolites acetaminophen glucorunide and 
acetaminophen sulphate (Clayton et al., 2009) (Figure 6-1), in a sample from a healthy 18 
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year old female healthy volunteer. These metabolites were not present in any other spectra. 
The first PCA score plot for HCC and healthy controls identified this sample as a clear 
outlier. As this spectrum unfairly biased the principal components it was excluded from 
further analysis. Paracetamol metabolites produce marked spectral resonances which heavily 
influence multivariate analysis. This subject was therefore excluded from all further data 
analyses, reducing the healthy volunteer group to 14 in total. 
 
Table 6-1. Nigerian subject demographics. 
Characteristic HCC Cirrhosis Healthy p-value 
 
N 18 10 14 - 
Median age (range) 
(years) 
46.5 (25–85) 37 (23–62)  37 (27–80) a0.47, b0.19 
Male n (%) 12/18 (66.7%) 8/10 (80%) 7/14 (50%) 
+a
0.30, 
+a
0.67  
Ethnicity Nigerian Nigerian Nigerian - 
HBsAg +ve 17/18 (94.4%) 10/10 (100%) 0/14  
+
<0.0001 
Okuda stage (n) I=0, II=8, III=10 - - - 
p-values: 
a
 and 
b
 denote Mann-Whitney tests of HCC versus healthy and HCC versus 
cirrhosis, respectively. 
+
 denotes Fisher’s exact test of categorical variables. 
*2 of 8 classified as Stage II on the basis of >50% tumour size and detectable ascites, though 
insufficient serum to obtain albumin and bilirubin levels. 
 
 
 
Figure 6-1. Urine magnetic resonance spectra displaying paracetamol metabolites. 
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6.4.2 Serum biochemical analyses 
Serum AFP was significantly raised in the HCC group (median 12,474 IUL
-1
), compared to 
healthy controls (median 1.66 IUL
-1
, p<0.001) and patients with cirrhosis (median 5.97 IUL
-1
, 
p<0.001). Using a serum AFP level cut-off value of 20 IUL
-1
, 2/10 (20%) patients with 
cirrhosis would have produced false positive results and 2/18 (11%) patients with HCC 
would have been classified as false negatives. For this group of subjects, AFP, with a cut-off 
value of 20 IUL
-1
 had a sensitivity: specificity of 100%: 83.3% for HCC versus healthy 
controls and 88.9%: 77.8% for HCC versus patients with cirrhosis. Serum urea and creatinine 
levels were not significantly different between groups (p=0.27 - 0.93). Serum ALT levels 
were significantly raised in the HCC group compared to healthy controls (48 IUL
-1
 and 23 
IUL
-1
, p=0.006), but not compared to patients with cirrhosis and patients with cirrhosis (37 
IUL
-1
, p=0.59). Bilirubin and albumin levels were also significantly altered compared to 
healthy volunteers but not compared to patients with cirrhosis (Table 6-2).  
 
Table 6-2. Serum biochemical analyses. 
 
HCC  
Median (range) 
Cirrhosis 
Median (range) 
Healthy 
Median(range) 
p-values 
 N 
18* 9** 9*** - 
AFP IUmL
-1 
12474 (944-30000) 6.0 (3.3-24.9) 1.7 (1.4-3.4) a,b≤0.001 
Urea mmolL
-1  4.8 (4.1-6.5) 4.3 (3.6-6) 4.9 (3.6-7.89) a0.27 ,b0.41 
Creatinine 
mmolL
-1 
75.5 (44-110.3) 76 (56.5-102) 76.0 (61-101.5) a0.62 ,b0.93 
ALT IUL
-1 48 (30-107) 37 (25.5-69.5) 23 (17.5-26.0) a0.006 ,b0.59 
ALP IUL
-1 11.5 (6.6-17.7) 11.6 (9.3-270.6) 8.0 (5.85-69.6) a0.77 ,b0.42 
Bilirubin μmolL-1 29.9 (22.6-87.5) 36 (25.9-52.2) 4.7 (3.3-30.3) a<0.001 ,b0.98 
Albumin gL
-1 29.6 (20.6-40.5) 29.4 (26.5-37.4) 49.3 (46.3-52.4) a0.002 ,b0.98 
Key: *HCC group- 2 samples insufficient volume for ALT, ALP, bilirubin and albumin 
assays, **Cirrhosis group– 1 serum sample missing, ***Healthy control group– 5 serum 
samples missing. p-values: 
a
 and 
b
 denote Mann-Whitney tests of HCC versus healthy and 
HCC versus cirrhosis, respectively. 
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6.4.3 Proton nuclear magnetic resonance spectroscopy 
Representative urine 
1
H NMR spectra are displayed in Figure 6-2 and Figure 6-3.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2. Representative magnetic resonance urine spectra. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-3. Magnetic resonance urine spectra (expanded region 3.0–4.2 ppm).  
Key: A. Healthy volunteer (A), patient with cirrhosis (B) and with HCC (C). 
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6.4.4 Multivariate data analysis 
Principal components analysis was performed following the exclusion of the outlying sample 
containing paracetamol metabolites, as described above. The subsequent three component 
PCA scores plot is displayed in Figure 6-4 and highlights clustering of healthy controls, 
clearly separated from patients with HCC. Also displayed is the three component PCA scatter 
plot of HCC and cirrhosis samples, again displaying clustering of cirrhosis samples separated 
from HCC samples (Figure 6-4).    
 
Partial least squares discriminant analysis models were constructed to investigate the ability 
of this technique to distinguish between HCC, healthy controls and patients with cirrhosis. 
Table 6-3 displays the values of validity (R
2
 and Q
2
) and sensitivities and specificities of 
PLS-DA in discriminating subject cohorts using a leave-one-out paradigm (Man et al., 2004). 
Hepatocellular carcinoma and healthy control subjects were discriminated with a sensitivity 
of 100% and specificity of 93% (leave-one-out cross-validation). Full external validation 
separated the groups with 100% sensitivity and 87.5% specificity. HCC and cirrhosis cohorts 
were distinguished with sensitivity: specificity of 89.5%: 88.9% and 62.5%: 100% using 
leave-one-out and full external validation paradigms, respectively (Table 6-3).  
 
Resonances that contributed most strongly to both models of HCC and healthy volunteer and 
HCC and cirrhosis samples, were identified as creatinine (methyl and methylene singlets at 
3.05 and 4.07 ppm) carnitine (methyl singlet at 3.23 ppm), creatine (methylene singlet at 3.05 
ppm) and acetone (methyl singlet at 2.24 ppm) (Holmes et al., 1997; Nicholson et al., 1995; 
Slupsky et al., 2007; Wishart et al., 2007).  
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Figure 6-4. Principal components analysis scores plots. 
Key: HCC (●) versus healthy volunteer (●) and versus cirrhosis samples (●).  
PC = principal component. 
 
 
 
Table 6-3. Validity values of partial-least squares discriminant analyses and diagnostic 
sensitivities and specificities. 
 R
2
 Q
2
 Sensitivity Specificity 
HCC vs. Healthy 0.88 0.74 100 % 93 % 
HCC vs. Cirrhosis 0.85 0.55 89.5 % 88.9 % 
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6.4.5 Univariate statistical analysis 
Urinary creatinine levels (expressed as % normalized total spectral integral) were 
significantly reduced in the HCC cohort compared to the healthy controls (p<0.001) and 
reduced, approaching significance compared to the cirrhosis samples (p=0.06); median levels 
[IQR] for HCC = 6.12 [4.11 – 7.41]; for healthy = 9.81 [7.95 – 10.94] and for cirrhosis = 7.53 
[6.28 – 9.62] (Figure 6-5). Urinary carnitine levels were significantly elevated in the HCC 
compared to the cirrhosis cohort (p<0.001) and elevated, approaching significance compared 
to healthy volunteers (p=0.05) median levels [IQR] for HCC = 0.86 [0.34 – 1.62]; for healthy 
= 0.31 [0.1 – 1.01] and for cirrhosis = 0.16 [0.07 - 0.24] (Figure 6-5). Urinary creatine levels 
were significantly raised in the HCC cohort compared to the healthy control cohort: 0.90 
[0.68 – 1.39] and 0.57 [0.47 – 0.97] (p=0.04); but not compared to the cirrhosis cohort: 0.72 
[0.62 – 0.95] (p=0.29) (Figure 6-5). Urinary acetone levels were not significantly different 
between groups: median levels for HCC = 0.35 [0.26 – 0.78]; for healthy = 0.64 [0.31–1.85] 
and for cirrhosis = 0.39 [0.14–1.56] (p=0.28 and 0.70) (Figure 6-5).  These results illustrate 
that it is the combination of metabolites, the values of which may be statistically different 
between groups, rather than a single metabolite that contributes to the multivariate 
discriminatory model.   
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Figure 6-5. Univariate analysis of discriminatory metabolites creatinine, carnitine, 
creatine and acetone. 
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6.5 DISCUSSION 
This is the first study to use 
1
H NMR spectral metabolite profiling of urine to characterise 
patients with HCC in an African population (Shariff et al., 2010). In this study, a urinary 
biomarker panel composed of creatinine, carnitine, creatine and acetone successfully 
discriminated patients with HCC from healthy controls and patients with cirrhosis. Using 
PLS-DA “leave-one-out” cross-validation algorithms, the sensitivity and specificity of correct 
group classification of HCC from healthy controls and from cirrhosis were 100%: 93.3% and 
88.9%: 80%, respectively. This compares favourably to serum AFP, which for this group of 
subjects, using a cut-off value of 20 IUL
-1
, displayed a sensitivity: specificity of 100%: 
83.3% for HCC versus healthy controls and 88.9%: 77.8% for HCC versus patients with 
cirrhosis. 
 
Urine creatinine levels were significantly reduced in patients with HCC compared healthy 
controls. Creatinine is a breakdown product of muscle creatine phosphate and is eliminated in 
urine. Renal impairment will cause a rise in serum creatinine and a concomitant rise in urine 
creatinine. Serum creatinine levels were similar between subject groups. A high muscle bulk 
and turnover may also lead to high serum and urine creatinine levels suggesting no renal 
impairment was present. The muscle mass of the Nigerian subjects was not recorded as 
owing to lack of resources, formal anthropometric assessments were not possible. It is likely 
that the “dry weight” of patients was reduced, as most subjects with HCC were visibly 
cachectic to some degree (personal communication from Dr Nimzing Ladep, JUTH). It is 
therefore reasonable to attribute lower urinary creatinine levels to reduced muscle mass. A 
previous study of urinary creatinine in the US population observed that lower muscle mass 
was a major contributing factor to lower urinary creatinine levels (Barr et al., 2005).  
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Urinary carnitine levels were higher in patients with HCC compared to other groups. 
Carnitine is a hydrophilic molecule that plays an essential role in mitochondrial metabolic 
pathways. It is either absorbed from the diet or synthesised in the liver, kidney and testis and 
renally reabsorbed. Meat, poultry and dairy products are the main dietary sources of carnitine. 
Unabsorbed carnitine is mostly degraded by micro-organisms in the large intestine. In health, 
only a small fraction (usually <5%) of filtered carnitine is excreted (Rebouche, 2004). As 
healthy kidneys efficiently reabsorb carnitine, a high urinary level may correspond to excess 
carnitine ingestion, biosynthesis or poor reabsorption. The subjects in this study were not 
administered nutritional supplements, nor was their diet likely to be rich in meat products, 
which are sparse in this area of Nigeria. Carnitine is indispensable for energy metabolism, 
enabling fatty acids to enter the mitochondria for β-oxidation. Furthermore, carnitine is 
involved in the transfer of the products of peroxisomal β-oxidation, including acetyl-CoA, to 
the mitochondria for oxidation to carbon dioxide and water (Vaz and Wanders, 2002). With 
elevated metabolic activity and high cell-turnover, it may be hypothesised that elevated urine 
carnitine levels reflect tumour overproduction of carnitine to fuel mitochondrial activity and 
maintain rapid growth. 
 
Urinary creatine levels were raised in subjects with HCC, significantly compared to healthy 
volunteers but not compared to patients with cirrhosis. Creatine is a nitrogenous organic acid, 
synthesised mainly in the liver from its component parts arginine, glycine and methionine and 
stored in muscle as phosphocreatine. It has a direct function in cellular energy transport, 
interacting directly with adenosine triphosphate (ATP) to produce phosphocreatine and 
adenosine diphosphate (ADP). It is therefore likely that creatine, an essential component of 
the energy transfer process, is elevated in rapidly growing cells, such as in HCC. A study by 
Pang and colleagues observed elevated levels of ubiquitous creatine kinase, the catalyst of the 
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phosphate transfer between phosphocreatine and ATP, in prostate cancer cell lines suggesting 
heightened metabolic states (Pang et al., 2009).   
 
There were a number of limitations to the study, but given the resources in Jos, the study was 
carried out with care. The number of subjects included was low and therefore multivariate 
analyses results, in particular PLS-DA, should be interpreted with caution as prediction can 
be over-optimistic when sample sizes are low (Brereton, 2006). Studies in other populations, 
where other disease aetiologies other than HBV predominate and with larger samples sizes 
are required to validate these findings. It may be that other risk factors for HCC, such as 
HCV, alcohol-induced cirrhosis and aflatoxin will display different patterns of metabolic 
derangement. Urine metabolite characteristics are also dependent on interacting factors 
including diet and nutrition (Holmes et al., 2008), and it would therefore be crucial to attain 
accurate dietary histories and anthropometric measurements to exclude this as a possible 
confounding factor. The medical provenance of the samples is also vitally important in 
metabolic profiling studies. The diagnosis of cirrhosis was made on clinical and radiological 
grounds on the basis of the presence of signs of portal hypertension, such as ascites, gastro-
oesophageal varices and portal hypertensive gastropathy. These findings correlate well with 
underlying cirrhosis, although the distinction would ideally have been made with histological 
confirmation, as patients may occasionally display signs of portal hypertension, for example 
with portal vein thrombosis, without the presence of cirrhosis (although this is unlikely in the 
context of chronic viral hepatitis).   
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6.6 CONCLUSIONS 
This study has provided insight into the urinary changes in metabolites that may reflect the 
underlying effect HCC has on host physiology. It is the first to utilise urinary 
1
H NMR 
spectroscopy with multivariate statistical analysis in a cohort of patients with HCC (Shariff et 
al., 2010). Multivariate models were able to differentiate patients with HCC from normal 
subjects and patients with cirrhosis with high accuracy, comparable to that of AFP, 
permitting the notion that a urinary test for HCC is possible. Larger, more diverse studies are 
required for validation of these findings.  
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7 THE URINARY METABOLIC PROFILING OF 
HEPATOCELLULAR CARCINOMA IN AN EGYPTIAN POPULATION 
USING PROTON MAGNETIC RESONANCE SPECTROSCOPY 
 
7.1 ABSTRACT 
Introduction: The previous chapter identified a set of discriminatory urinary metabolites 
comprising creatinine, creatine, carnitine and acetone, in Nigerian, HBV-infected, patients 
with HCC. The study presented here, undertaken in an Egyptian, mainly HCV-infected 
patient group, served to validate or refute these findings.  Methods: Urine samples were 
collected from Egyptian subjects with HCC (16), cirrhosis (14) and healthy volunteers (17) 
and metabolite profiles were generated using a 
1
H NMR spectroscopy. Data were analysed 
using multivariate and univariate statistical analysis. Results: Using multivariate models, the 
sensitivity and specificity of the technique for distinguishing patients with tumours from 
healthy controls and patients with cirrhosis was 100%: 94% and 81%: 71%, respectively. 
Discriminatory metabolites between HCC and healthy and HCC and cirrhosis groups 
included creatinine (p=0.003 and <0.001), carnitine (p=0.29 and 0.30), glycine (p=<0.001 
and 0.88), trimethylamine-N-oxide (p=<0.001 and 0.18), hippurate (p=<0.001 and 0.66), 
citrate (p=<0.001 and 0.12) and creatine (p=0.12 and 0.33). Conclusions: This metabolic 
profile bears some similarity to profiles identified in the Nigerian cohort, in the form of 
altered urine creatine, carnitine and creatinine levels. These metabolites may be indicative of 
tumour effects on physiology, energy production and aberrant chromosomal methylation.  
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7.2 INTRODUCTION 
In the previous chapter the urinary metabolic profile of HCC was characterised in a small set 
of Nigerian HBV infected patients with HCC and cirrhosis and a control set healthy 
volunteers. Multivariate analysis was able to discriminate the 
1
H NMR urine profiles of HCC 
from healthy and cirrhosis with high sensitivity and specificity (Shariff et al., 2010).  The 
metabolites creatinine, creatine, carnitine and acetone were found to contribute most to 
multivariate models and may signify an alteration in muscle mass status, energy 
consumption, fatty acid oxidation and respiration in patients with tumours. The study 
presented here, in an Egyptian, mostly HCV infected patient population, was performed to 
validate these findings (Shariff et al., 2011). 
  
Egypt has the highest prevalence of HCV worldwide, with population estimates ranging 
between 6% - 28%, largely owing to the use of unsterilised needles in a widespread 
schistosomiasis treatment programme in the 1950s-1970s using intravenous tartar emetic 
(Williams, 2006). HCV has been estimated to be the main aetiological factor of HCC in 40% 
- 50% of cases (Lehman and Wilson, 2009).  
 
All previous reported studies of the metabolic profiles of HCC have been undertaken in 
single indigenous populations where there is usually a single aetiological pathogen of liver 
disease and HCC (Chen et al., 2009; Chen et al., 2011; Wu et al., 2009). As HCC occurs on 
the background of multiple aetiologies, these results may not hold true for other populations 
or aetiologies.  
 
The aims of this study were to 1. Identify differences in metabolic profiles between HCC, 
cirrhosis and healthy volunteer samples using urine 
1
H NMR spectroscopy combined with 
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multivariate analysis, and 2. Evaluate the robustness of these models in differentiating disease 
groups.     
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7.3 METHODS 
7.3.1 Subject selection 
Urine and serum samples were collected from patients attending the National liver Institute, 
Menoufiya University, Shbeen El Kom, Egypt. Ethical approval was granted by the research 
ethics committees at the National Liver Institute, Menoufiya University and Imperial College 
London.  
 
Subjects were recruited between 2005 and 2006 with HCC (diagnosed by two imaging 
techniques showing early arterial enhancement and rapid washout in portal phase or one 
characteristic imaging modality with serum AFP >400 ngmL
-1
); or with clinically or 
histologically confirmed cirrhosis, as disease controls. Healthy volunteers, with no liver 
disease, were recruited as healthy controls. Staging of HCC was according to the Okuda 
system (Okuda et al., 1985), as previously described (Chapter 4). Principal components 
analysis was used to identify outlying samples for exclusion as detailed in the results section.  
 
7.3.2 Urine sample collection 
Random, non-fasted, 5 mL urine samples were collected into plain containers and stored at -
80 °C, 2 to 4 hrs after collection in Egypt until transportation by air on dry ice.  Samples were 
thawed prepared according to standard methodology described in Chapter 6. 
 
7.3.3 Serum biochemical tests 
Serum AFP, creatinine, ALT, AST, bilirubin and albumin levels were measured at the time of 
urine sample collection in Egypt using a Cobas Integra 400- Autoanalyzer, (Roche, Rotkreuz, 
Switzerland). These data are also presented in Chapter 4.  
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7.3.4 Magnetic resonance spectral acquisition and processing 
Samples were run in a random, non-grouped order. Proton NMR spectra were acquired using 
a pulse-collect sequence with water presaturation (JEOL 500 MHz Eclipse+ NMR 
spectrometer). The 16 data collects were summated. A 90
o
 pulse angle was used with a total 
repetition time of 18.7 s, so that fully-relaxed data were acquired. The acquisition time was 
8.7s. Data were collected into 64K points. Proton NMR spectra were processed using the 
KnowItAll™ Informatics System v7.8 (Bio-Rad, Philadelphia, USA). Free induction decays 
were zero-filled by a factor of two and multiplied by an exponential window function with a 
0.3 Hz line-broadening factor, prior to Fourier transformation. All NMR spectra were phased, 
a baseline correction applied and referenced to TSP (0.00 ppm) and the methyl-creatinine 
peak was aligned to 3.05 ppm. Spectral resonances were assigned according to literature 
(Holmes et al., 1997; Lindon et al., 1999; Wishart et al., 2007). The region 4.50 – 6.40 ppm 
was excluded to remove the residual water signal and variation in urea signal due to exchange 
of protons within the solvent.  
 
7.3.5 Multivariate statistical analysis 
Principal components analysis and PLS-DA were used for initial analysis. Orthogonal signal 
correction (Chapter 6) was used to remove variation in the spectra not directly related to the 
physiological condition being studied. The discriminatory power of each model was validated 
using leave one out and full external validation models as previously described (Chapter 6). 
Samples lying outside the Hotelling’s distance were excluded as these unfairly influence the 
principal components and are not representative of the group. 
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7.3.6 Univariate statistical analysis 
The most important discriminatory metabolite resonances, as determined by PLS-DA 
loadings plots were integrated and normalised to the sum of the total spectral integral. Using 
GraphPad Prism v5.01 (California, USA), median value differences between groups were 
analysed using the Mann-Whitney test for non-parametric data and p-values <0.05 were 
considered significant. 
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7.4 RESULTS 
7.4.1 Subject recruitment, exclusion and demographics 
Fifty-eight subjects were recruited for study between 2005 and 2006. This included 18 
patients with HCC; 20 patients with cirrhosis; and 20 healthy Egyptian volunteers. Eleven 
samples were identified as outliers by PCA and excluded from further analysis. Outlying 
samples included two from the HCC cohort, one of which displayed dominant glucose 
resonances (probably indicating underlying undiagnosed diabetes mellitus) and the other 
which could not be phased adequately (Figure 7-1). Six spectra were excluded from the 
cirrhosis cohort, three of which displayed marked glucose metabolites, one which could not 
be phased adequately, one with dominant lactate peaks and one which displayed pronounced 
unidentified peaks at 1.45 ppm and 1.60 ppm which strongly affected multivariate analyses. 
Three spectra were excluded from the healthy control group all of which displayed dominant 
glucose metabolites.  These samples were excluded from further analysis as detailed below. 
This left 16 samples in the HCC group, 14 in the cirrhosis group and 17 in the healthy control 
group. 
 
Figure 7-1. Urinary spectra of a 
sample containing glucose (pink) 
compared to normal (black).  
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Subject demographics are displayed in Table 7-1. The median age of the HCC group (51.5 
years) was significantly older than that of the healthy controls (41 years) (p=0.01) but not 
when compared to that of the cirrhosis group (54 years) (p=0.37). There were significantly 
more males in the HCC group (15/16 = 94%) than the healthy control group (9/17 = 53%) 
(p=0.02), but not when compared to the cirrhosis group (11/14 = 79%) (p=0.32). One of the 
HCC subjects had stage I, 10 had stage II and 5 had stage III disease (Table 7-1). The 
majority of patients with HCC and 50% of patients with cirrhosis were HCV antibody 
positive: 11/16 (69%) and 7/14 (50%), respectively. The remaining patients with HCC or 
cirrhosis had diverse aetiologies (Table 7-2). All healthy controls were of Egyptian origin. 
  
Table 7-1. Egyptian subject demographics. 
Characteristic HCC Cirrhosis Healthy p-value 
n 16 14 17 - 
Median age (yrs) 51.5 54.0 41.0 
a
0.01, 
b
0.37 
Male n (%) 15/16 (94%) 11/14 (79%) 9/17 (53%) 
a+
0.02, 
b+
0.32 
Ethnicity Egyptian Egyptian Egyptian - 
HCV Ab+ 11/16 (69%) 7/14 (50%) 0 - 
Okuda stg. (n) I (1), II (10), III (5) - - - 
Key: p-values: 
a
 and 
b
 denote Mann-Whitney tests of HCC versus healthy and HCC versus 
cirrhosis, respectively. 
+
 denotes Fisher’s exact test of categorical variables. 
 
Table 7-2. Aetiology of liver disease in Egyptian patient cohorts. 
Aetiology HCC Cirrhosis 
HCV 11 7 
HBV 0 1 
Idiopathic cirrhosis with 
schistosomiasis 
0 4 
Budd Chiari syndrome 0 2 
Idiopathic 5 0 
Total 16 14 
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7.4.2 Serum biochemical analysis 
Median values for serum AFP, creatinine, ALT, AST, bilirubin and albumin of study subjects 
are displayed in Table 7-3. Serum AFP levels were only measured in the cirrhosis and HCC 
groups. median serum AFP levels were significantly higher in HCC patients (745 IU mL
-1
 
versus 77 IU mL
-1
, p<0.001). The lowest serum AFP in the cirrhosis group was 20 IU mL
-1
 
and using a cut-off of 20 IU mL
-1
, all cirrhosis patients would have been falsely classified as 
HCC, based on serum AFP levels (sensitivity 100%, specificity 0%). If a cut-off value of 400 
IU mL
-1
 was used, specificity improved to 100% and sensitivity fell to 88%. The HCC 
diagnostic performance of AFP, using a cut-off value of >200 IU mL
-1
, was therefore good in 
these patients. Median serum creatinine was significantly higher in the HCC group, compared 
to controls (106 mmol L
-1
 versus 62 mmol L
-1
, p<0.001), but not when compared to that of 
the cirrhosis subjects (106 mmol L
-1
 versus 150 mmol L
-1
, p=0.16). Serum ALT, AST and 
bilirubin levels were all significantly higher in the HCC group compared to healthy controls, 
but not compared to cirrhosis subjects. Serum albumin was significantly lower in the HCC 
group compared to healthy controls but not compared to cirrhosis subjects.   
 
 
Table 7-3. Serum biochemistry profiles of subject cohorts 
 HCC  
Median (range) 
Cirrhosis  
Median (range) 
Healthy 
Median (range) 
p-values  
Serum Samples (n) 16 14 17 - 
AFP (IU mL
-1
) 745 (174-5000) 77 (20-174) - b<0.001 
Creatinine (mmol L
-1
) 106 (44-318) 150* (97-229) 62 (44-80) a<0.001and b0.16 
ALT (IU L
-1
) 56 (11-164) 30 (16-119) 12 (9-18) a<0.001and b0.36 
AST (IU L
-1
) 79 (22-224) 51 (31-190) 15 (11-20) a<0.001and b0.44 
Bilirubin (μmol L-1) 63 (17-547) 48 (14-156) 12 (0.7-19) a<0.001 and b0.19 
Albumin (g L
-1
) 30 (19-34) 29 (23-35) 40 (38-44) a<0.001and b0.79 
Key: *Two samples did not have serum creatinine levels measured. p-values: 
a
 and 
b
 denote 
Mann-Whitney tests of HCC versus healthy and HCC versus cirrhosis, respectively. 
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7.4.3 Proton nuclear magnetic resonance spectroscopy 
Representative urine 
1
H NMR spectra from a healthy volunteer and patients with HCC and 
cirrhosis are displayed in Figure 7-2 and resonances tabulated in Table 7-4.  
 
Figure 7-2. Representative Egyptian subject urine spectra  
Urine MR spectra from a healthy volunteer (A), a subject with cirrhosis (B) and a subject 
with HCC(C). Key: TMAO, trimethylamine-N-oxide.  
 
 
Table 7-4. Urine magnetic resonance metabolite resonances. 
 Region (ppm) Molecule (multiplicity) Moeity 
1 2.57 Citrate ( double doublet) CH2 
2 3.05, 4.07 Creatinine (singlets) CH3, CH2 
3 3.23 Carnitine (singlet) CH3 
4 3.27 TMAO (singlet) CH3 
5 3.57 Glycine (singlet) CH2 
6 3.93 Creatine (singlet) CH2 
7 3.95 Hippurate (doublet) CH2 
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7.4.4 Multivariate statistical analysis  
Principal components analysis scores plots of the resulting groups displayed clustering of 
HCC, healthy volunteer and cirrhosis samples (Figure 7-3). Analyses using OSC-PLS-DA 
distinguished HCC and healthy control cohorts with 100% sensitivity and 94% specificity 
using a leave one out algorithm (R
2
=0.8, Q
2
=0.74) (Table 7-5). Using a full external 
validation paradigm, discriminatory sensitivity was 100% and specificity 93%. Resonances 
contributing most to the PLS-DA components were glycine (3.57 ppm), trimethylamine-N-
oxide (TMAO) (3.27 ppm), hippurate (δ 3.96 ppm), citrate (2.66 ppm), creatinine (3.05 ppm), 
creatine (3.93 ppm) and carnitine (3.23 ppm). Analyses using OSC-PLS-DA distinguished 
HCC and cirrhosis cohorts with 81% sensitivity and 71% specificity using a leave one out 
algorithm (R
2
=0.54, Q
2
=0.25) (Table 7-5). Using a full external validation paradigm, 
discriminatory sensitivity was 75% and specificity 67%. Resonances contributing most 
strongly to PLS-DA discrimination were TMAO (3.27 ppm), creatine (3.93 ppm) and 
carnitine (3.23 ppm).  
 
 
 
 
Figure 7-3. Principal components analysis scores plots Egyptian subject groups. 
A.HCC subjects (●) versus healthy controls (●) and B.HCC (●) versus cirrhosis subjects (●).  
A B 
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Table 7-5. Validity values of partial-least squares discriminant analyses.  
 R
2
 Q
2
 Sensitivity Specificity 
HCC vs. Healthy 0.8 0.74 100% 94% 
HCC vs. Cirrhosis 0.54 0.25 81% 71% 
Calculated using “leave one out” external validation models.  
 
7.4.5 Male only comparisons 
Male only analyses were undertaken to confirm that findings were due to the effects of HCC 
rather than gender variation between groups. Male HCC urine could be discriminated with 
100% sensitivity and 93% specificity from healthy control urine and with 80% sensitivity and 
55% specificity from urine of patients with cirrhosis. Discriminatory metabolites were similar 
to combined gender comparisons: glycine, TMAO, hippurate, citrate, creatinine, creatine, and 
carnitine. 
 
7.4.6 Univariate statistical analysis 
Univariate analyses are displayed in Figure 7-4. Urinary creatine levels were significantly 
elevated in HCC subject urine compared to healthy controls and cirrhosis subjects: 1.5 [0.92 
– 3.32]; 0.54 [0.04 – 1.28] and 0.26 [0.12 -0.39] (p=0.003 and p<0.001, respectively). 
Urinary carnitine levels were non-significantly elevated in HCC subjects, compared to 
healthy controls and cirrhosis subjects: 1.16 [0.25 – 2.59]; 0.58 [0.36 – 0.86] and 0.39 [0.29 – 
0.97] (p=0.29 and p=0.30). Urinary glycine levels (expressed as % normalized to total 
spectral integral) were significantly reduced in HCC subjects urine, compared to healthy 
controls: median [interquartile range] 0.46 [0.24 - 0.71] and 2.41 [1.30 - 2.95] (p<0.001), but 
were not significantly reduced compared to cirrhosis subjects: 0.53 [0.13 – 1.27] (p=0.88). 
Urinary TMAO levels were significantly reduced in HCC subject urine, compared to healthy 
controls: 1.17 [0.47 – 1.56] and 3.98 [2.69 – 4.67] (p<0.001), but non-significantly reduced 
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compared to cirrhosis subjects: 2.03 [0.47 – 3.07] (p=0.18). Urinary hippurate levels were 
significantly reduced in HCC subjects, compared to healthy subjects: 0.53 [0.23 – 0.98] and 
1.62 [1.08 – 1.88] (p<0.001), but not significantly different compared to cirrhosis subjects: 
0.66 [0.0 – 0.89] (p=0.65). Urinary citrate was significantly reduced, compared to healthy 
subjects: 0.04 [0.0 – 0.84] and 1.68 [1.06 – 2.74] (p<0.001), with a reduced trend towards 
significance compared to cirrhosis subjects: 0.91 [0.09 – 1.36] (p=0.12). Urinary creatinine 
levels were reduced in HCC urine, compared to healthy control and cirrhosis subjects, but not 
to a level of significance: 13.7 [11.59 – 18.69], 17.49 [13.82 – 24.11] and 17.71 [11.78 – 
22.28] (p=0.12 and 0.33, respectively). 
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Figure 7-4. Univariate metabolite statistical analysis. 
Key: p-values generated through Mann-Whitney non-parametric tests of significance.  
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Figure 7-4. Univariate metabolite statistical analysis (continued). 
Key: p-values generated through Mann-Whitney non-parametric tests of significance.  
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7.5 DISCUSSION 
In this study of Egyptian subjects, a urinary metabolic profile was identified which 
distinguished patients with HCC from healthy controls and patients with cirrhosis with a 
sensitivity and specificity of 100%/93% and 81%/71%, respectively. Discriminatory 
metabolites were identified as glycine, TMAO, hippurate, citrate, creatinine, creatine and 
carnitine (Shariff et al., 2011). In the previous chapter (Chapter 6) it was observed that in 
Nigerian subjects with HCC, the metabolites creatinine, creatine, carnitine and acetone were 
discriminatory between disease and healthy groups (Shariff et al., 2010). These results 
suggest that despite differences in aetiology (HBV in Nigeria and mostly HCV in Egypt) 
HCC induces similar metabolite alterations in urine (Table 7-6). These two studies constitute 
the only 
1
H NMR spectroscopy studies of urine conducted in two different populations 
identifying similar metabolite profiles.  
 
Urinary creatine was significantly elevated in HCC subject urine, compared to healthy 
controls and cirrhosis subjects. Similar findings were observed in the Nigerian patient study. 
Creatine has a direct function in cellular energy transport, interacting directly with ATP to 
produce phosphocreatine and ADP. It may therefore be the case that creatine, an essential 
component of the energy transfer process, is elevated in rapidly growing cells, such as HCC. 
 
Urinary carnitine levels were elevated in patients with HCC urine compared to healthy 
controls and cirrhosis subjects, although not to a level of significance. Chen and colleagues, 
using hydrophilic interaction chromatography (HILIC) and reversed phase liquid 
chromatography (RPLC MS), also observed elevated urinary carnitine levels in HCC subjects 
(Chen et al., 2009). As described in previous chapters, carnitine is indispensable for energy 
metabolism, enabling fatty acids to enter the mitochondria for β-oxidation (Vaz and Wanders, 
2002). 
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Table 7-6. Discriminatory metabolites from 
Nigerian and Egyptian urine studies. 
 
Key: 
▲
indicates significant univariate 
differences between HCC and healthy groups; 
 
■
indicates significant univariate differences 
between HCC and cirrhosis groups. 
 
 
 
 
The serum and plasma metabolic profiling studies presented in previous chapters (Chapters 
3 - 5) identified alterations in lipid metabolism, perhaps as an indication of subversion of 
lipids for use as cellular membrane components, rather than for energy production.  
 
Urinary creatinine levels were reduced in HCC subjects, compared to healthy controls and 
cirrhosis subjects, with a trend towards significance (p=0.12 and 0.33). Similar observations 
were made in the Nigerian subjects with HCC. Chen and colleagues also observed reduced 
urinary creatinine levels in HCC subjects (Chen et al., 2009).   Lower total body creatinine 
may be due to lower muscle mass, as previously described (Chapter 6) (Barr et al., 2005). 
The muscle mass of these subjects was not formally recorded though is likely that the “dry 
weight” of patients was reduced, as most subjects with HCC were visibly cachectic.  
 
Urinary glycine levels were significantly reduced in HCC subjects compared to healthy 
volunteers (p<0.001), but not compared to cirrhosis subjects (p=0.88). Glycine is a key 
component of a central methylation reaction within cells. Glycine N-methyltransferase 
(GNMT) catalyses the transfer of the methyl group of S-adenosylmethionine (SAMe) to 
glycine to form S-adenosylhomocysteine (SAH) and sarcosine (Ogawa et al., 1998). S-
adenosylmethionine is synthesised from methionine and ATP, catalysed by the enzyme 
Nigerian urine Egyptian urine 
Creatinine
▲■
 Creatinine 
Creatine
▲
 Creatine
▲■
 
Carnitine
▲■
 Carnitine 
Acetone Glycine
▲
 
 TMAO
▲
 
 Hippurate
▲
 
 Citrate
▲
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methionine adenosyltransferase (MAT) (Lu and Mato, 2008) (Figure 7-5) and acts as a 
methyl donor, inducing the methylation of nucleic acids, proteins and phospholipids. 
Chromosomal hypermethylation of a number of genes, involved in proliferative, apoptotic, 
cell adhesion and DNA repair, has been described in HCC tissue (Tischoff and Tannapfe, 
2008). Hypermethylation of CpG islands or promoter sequences has the consequence of gene 
silencing, which, if the genes act in a tumour suppressor role, may induce malignancy. Gene 
knockout animal models of MAT and GNMT are predisposed to liver pathology and HCC 
(Liao et al., 2009; Martinez-Chantar et al., 2002).  In a recent study of 262 urine and plasma 
samples of patients with prostate carcinoma, sarcosine was found to be elevated in patients 
with tumours (Sreekumar et al., 2009). It was observed that the addition of sarcosine to 
benign prostate cells induced a malignant phenotype and addition of glycine had the same 
effect, although to a lesser extent.  In a rat model of galactosamine-induced hepatotoxicity, 
glycine supplementation was shown to protect against liver damage (Coen et al., 2007). It 
therefore appears that glycine may play a part in hepatocarcinogenesis, but its exact role is as 
yet undefined. 
Methods
SAMe + GLYCINE SAH + SARCOSINE
METHIONINE
GNMT
MAT
METHYLATION
Figure 7-5. Schematic of glycine involvement in cellular methylation reactions. 
Key: MAT, methionine adenosyltransferase; SAMe, S-adenosylmethionine; GNMT, Glycine 
N-methyltransferase; SAH, S-adenosylhomocysteine.  
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Urinary TMAO levels were reduced in patients with HCC compared to healthy controls 
(p<0.001), but not compared to cirrhosis subjects (p=0.18). TMAO is an aliphatic amine and 
the oxidation product of trimethylamine (TMA) and derived from mainly dietary sources, 
through the action of gut microbes (al-Waiz et al., 1992). It may be that the low urinary 
TMAO observed in our group of HCC patients reflects suppressed gut microbial activity.  
 
Urinary hippurate levels were significantly reduced in HCC subjects, compared to healthy 
controls (p<0.001), but not compared to cirrhosis subjects (p=0.66). Hippurate is an acyl 
glycine that is formed by conjugation of benzoate with glycine in liver and kidney 
mitochondria (Schachter and Taggart, 1953). Benzoate is formed via the metabolism of gut 
microbes from dietary aromatic compounds (Nicholson et al., 2005; Rechner et al., 2002). It 
is possible that the decreased hepatic function in patients with HCC (as evidenced by lower 
albumin and higher bilirubin levels) translates into less efficient benzoate conjugation and 
subsequently lower urinary hippurate excretion levels. In this way, hippurate may be seen as 
a surrogate marker of liver function.    
 
Urinary citrate levels were significantly reduced in HCC subjects compared to healthy 
controls (p<0.001) and non-significantly reduced compared to cirrhosis subjects (p=0.12).  
Citrate is a tri-carboxylic acid (TCA) cycle intermediate and reduced urinary levels may 
indicate altered mitochondrial aerobic respiration due to heightened physiological stress of 
cancer cells, which would be in agreement with Warburg’s hypothesis (Warburg et al., 1924). 
In a study of urinary metabolic changes following partial hepatectomy in male Sprague-
Dawley rats, Bollard and colleagues observed initially decreased urinary citrate levels 
compared to control animals (Bollard et al., 2010). It was hypothesised that these changes 
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may be due to markers of physiological stress and heightened energy demand, which may 
similarly occur in HCC subjects.    
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7.6 CONCLUSIONS 
The urinary metabolic profile of HCC in this cohort of Egyptian patients (Shariff et al., 2011) 
bears similarity to that identified in the Nigerian cohort described in Chapter 6 (Shariff et 
al., 2010). In both, levels of the metabolites creatine, carnitine and creatinine were altered. 
These changes indicate the effects of the tumour on human physiology (creatinine and 
creatine), tumour respiration (carnitine and citrate), gut bacterial metabolism (hippurate and 
TMAO) and in the form of glycine, a metabolite that may be involved with tumourogenesis 
itself through aberrant DNA methylation.  
 
For validation, studies in larger populations with accurately characterised patients including 
earlier stage HCC (Okuda stage I) are required to confirm or refute these results. In follow up 
studies, anthropometric measurements would be desirable to investigate the relationship of 
altered metabolites, cancer cachexia and tumourogenesis. 
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8 URINARY METABOLIC PROFILING OF HEPATOCELLULAR 
CARCINOMA IN A UNITED KINGDOM COHORT USING PROTON 
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 
8.1 ABSTRACT 
Introduction: Previous chapters have described urinary 
1
H NMR studies of patients with 
HCC from Nigeria and Egypt. The aims of this study were to assess whether similar 
discriminatory urinary 
1
H NMR metabolic profiles occur in a UK patient cohort where 
aetiologies of liver disease are of greater diversity. Methods: UK patients with HCC and 
cirrhosis were analysed using a 600 MHz 
1
H NMR system. Multivariate analysis and median 
group MR spectra comparison allowed identification of metabolites altered between groups. 
Metabolite identification was achieved through literature reference and statistical total 
correlation spectroscopy (STOCSY). Results:  Fifty-two patients were recruited. Following 
exclusions, 13 samples from HCC patients and 25 from those with cirrhosis were selected for 
analysis. At 200 IUml
-1
, AFP displayed a diagnostic sensitivity of 27%. Multivariate analysis 
generated diagnostic models with a sensitivity/specificity of 53.6%/96%. p-cresol sulphate 
(p=0.04), creatinine (p=0.03), citrate (p=0.21) and hippurate (p=0.52) were reduced in the 
urine of patients with HCC. Carnitine (p=0.31) and formate (p=0.44) were elevated. 
Conclusions: Multivariate models of urine metabolic profiles were not as diagnostically 
sensitive as those from Nigerian and Egyptian studies. Nevertheless, they still  outperformed 
AFP. Reduced levels of creatinine, citrate and hippurate and elevated carnitine bears 
similarities to findings from the Nigerian and Egyptian groups. Alterations in levels of p-
cresol sulphate is a novel finding and may indicate an altered sulfonation capacity of the liver 
in patients with HCC.   
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8.2 INTRODUCTION 
Liver disease is the fifth commonest cause of death in the UK (The British Association for 
the Study of the Liver and The British Society of Gastroenterology, 2009). In contrast to 
other chronic conditions, such as cancer and cardiovascular disease, the mortality rate of liver 
disease is rising. Improvements have been made in the treatment of decompensated liver 
disease including endoscopic variceal band ligation, primary prophylactic beta-blockade, 
spontaneous bacterial peritonitis antimicrobial prophylaxis, pharmacotherapy for 
encephalopathy, treatment of hepatorenal syndrome, alcoholic hepatitis and intensive care of 
liver failure. Patients with cirrhosis are therefore living longer and are more likely to develop 
HCC. Data from developed nations including European countries, Japan and the US, have 
shown that incidence of HCC in cirrhosis at 1 year is 4 – 7% when associated with HCV, 2 – 
4% with HBV and 0.2 – 2% with alcohol induced liver disease (Fattovich et al., 2002). 
Despite surveillance guidelines (Bruix and Sherman, 2005; Ryder,  2003), the 5-year 
mortality for HCC in the developed world is poor. From the US, the Surveillance 
Epidemiology and End Results (SEER) database documented a 9.9% 5-year survival for 
HCC, compared to over 60% for all tumours. A retrospective SEER-database based study 
from the US between 1994 - 2001, reported 6-monthly regular surveillance rates of only 17% 
in patients over 65 years with cirrhosis (Davila et al., 2010). Similar rates were found in a 
survey of cirrhotic patients attending Imperial College NHS Healthcare trust between 2007 – 
2011 (Rajasooriar, G, BSc thesis, 2010, supervised by Shariff, M). This highlights the 
problems patients may have in attending recurrent hospital and clinic appointments for 
radiological procedures and blood tests, in particular for those that live greater distances from 
medical centres. A simple, non-invasive urine test to gauge risk of HCC would be invaluable 
for this population. It would potentially allow surveillance in the community by the local 
General Practitioner or even the patient themselves.  
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In comparison to the studies reported of Nigerian and Egyptian patients (Chapters 4, 5, 6 and 
7) (Shariff et al., 2010; Shariff et al., 2011), the aetiological variation of patients in the UK 
with HCC is greater, including viral hepatitis, alcohol and NASH. The collection of samples 
in the UK also allowed detailed patient and disease demographics to be collated. It was 
therefore possible to accurately stage and grade liver disease. In this respect, the study was 
designed to limit confounding factors such as the presence of cirrhosis, age and gender, to 
allow focus on cancer-specific urinary biomarkers to be isolated.  
 
Based on this, the main aims of this study were to: 
1. Identify tumour specific urinary metabolite changes in well matched patients with 
HCC on the background of cirrhosis and those with cirrhosis alone. 
2. Compare findings to previous similar studies in Nigerian and Egyptian cohorts. 
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8.3 METHODS 
8.3.1 Patient Selection 
Patients were recruited from outpatient and inpatient settings at St Mary’s Hospital, Imperial 
College NHS Trust, London, UK between October 2008 and March 2011. All subjects gave 
written and informed consent, in accordance with local Research Ethics Committee approval.  
Hepatocellular carcinoma was diagnosed with two confirmatory imaging modalities and 
cirrhosis with either histological or radiological confirmation. Tumour staging was according 
to the BCLC staging system (Bruix and Sherman, 2005) which is based upon tumour size and 
multiplicity, patient performance status, the presence or absence portal vein invasion, the 
presence or absence of portal hypertension and Child-Pugh scores of liver function (Child 
and Turcotte, 1964; Pugh et al., 1973) (Figure 8-1). Patients with cirrhosis were graded 
according to the Child-Pugh score. At the time of sample collection, participant height, 
weight, medical, drug, smoking and alcohol intake history were recorded. A 24-hour dietary 
history was also recorded paying attention to foodstuffs known to produce prominent NMR 
signals, such as vanilla (vanillin) and fish (acetic acid) (Figure 8-2).  Exclusion criteria 
included those patients not meeting the diagnostic criteria cited above for HCC and cirrhosis, 
those patients with HCC who had undergone curative resection or transplant, patients co-
infected with HIV and those samples identified as outliers on principal component analysis.  
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Figure 8-1. Barcelona Clinic Liver Cancer algorithm (Bruix and Sherman, 2005). 
 
 
Figure 8-2. UK patient demographics and dietary questionnaire.  
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8.3.2 Sample collection 
15 mL of random, non-fasted urine were collected into preservative-free universal containers 
and placed immediately on ice or into a refrigerator at 4 ºC. Five to 10 mL of urine was 
transferred to 15 mL falcon tubes and centrifuged within 1 – 2 hrs at 4 ºC, 1000 rpm for 10 
min. The supernatant was then transferred as 2 mL aliquots into 2 mL microvial tubes and 
stored at -80 ºC until analysis.   
 
8.3.3 Sample preparation  
Urine samples were thawed at room temperature and 400 μL were transferred to 1.5 mL 
microvial tube to which 200 μL of phosphate buffer solution (pH 7.4), containing 1 mM of 
TSP, sodium azide 3 mM (as a bacterial biocidal agent to inhibit bacterial growth and 
contamination) and D2O 20%. Samples were centrifuged for 5 min at 13,000 rpm and 550 μL 
of supernatant were transferred to 5 mm NMR tubes (Norell, Landisville, New Jersey, USA). 
 
8.3.4 Proton nuclear magnetic resonance spectroscopy 
Samples were run in a random non-grouped order under automation on a Bruker DRX-600 
NMR system operating at 600.44 Hz 
1
H frequency (Bruker Biospin, Rheinstetten, Germany). 
at the department of Biomolecular Medicine, Imperial College London. The system was 
tuned, matched and frequency locked onto deuterated hydrogen as the nucleus of interest. A 
representative sample was utilised to set shim gradients to ensure a homogenous magnetic 
field across the sample, a 90º pulse length and the water suppression offset parameters. These 
settings were saved and utilised for the whole sample set.  Pulse programme and acquisition 
parameters were set according to optimised protocols for urine from the department of 
Biomolecular Medicine (Beckonert et al., 2007). Spectra were acquired at 300 K using a one-
dimensional (1-D) noesypr1d pulse sequence with water presaturation during the relaxation 
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delay (RD) and mixing time (tm) using the following pulse programme: -RD-90º_t-90º-tm-
90º-acquire; where RD = 2.0 s and tm = 0.1 s. For each sample, 128 FIDs were collected into 
32, 000 data points with a spectral width of 20 ppm. A line broadening function of 0.3 Hz 
was applied prior to Fourier transformation. Spectra were manually phased, baseline 
corrected and referenced to TSP at 0 ppm using TOPSPIN v2.0 (Bruker Biospin, 
Rheinstetten, Germany). Spectral peaks were assigned with reference to the literature 
(Clayton et al., 2009; Holmes et al., 1997; Wishart et al., 2007).   
 
8.3.5 Spectral processing 
Proton NMR spectra were exported to MATLAB R2010 (MathWorks, Natick, 
Massachusetts, U.S.A) and to avoid influence on analyses from water suppression aberration, 
the water region from 4.5 ppm – 6 ppm was excluded. Spectra were aligned to negate the 
effect of pH dependent variation in metabolite resonances which may occur despite sample 
buffering. To remove the effect of differential urine concentrations, data were normalised 
using median fold-change normalisation. Median spectra for both clinical groups were 
generated to allow direct visual comparison of average spectra and allow the selection of 
regions that were visually divergent, in addition to those identified by multivariate analysis, 
for peak integration.  
 
8.3.6 Statistical Total Correlation Spectroscopy (STOCSY) 
Using in-house software for use in MATLAB, developed at the department of Biomolecular 
Medicine, Imperial College London, the spectral database could be interrogated for correlated 
peaks across the whole spectrum. Peaks that co-varied with high correlation could be 
identified by input of one peak region of interest. Correlation factors could be varied from 0 – 
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1. This method was utilised to identify unknown peaks to extract the total spectrum for an 
individual metabolite.  
 
8.3.7 Multivariate and univariate statistical analysis 
Full resolution data were used for analyses. Data matrices were generated in MATLAB 
containing ppm variables as columns and sample identities as rows. After water exclusion, 
this amounted to a matrix of 28,238 variables and 43 observations. This matrix was exported 
to SIMCAP-12 (Umetrics, Umea, Sweden) for multivariate analysis and variables from 0.2 – 
10.0 ppm were used for analysis, thus removing any influence from variation in TSP 
concentration between samples. Data were mean-centred and PCA was performed first to 
model variation and identify outliers. Pareto scaled data and unit variance data were also 
generated, but both tended to model noise rather than signal. Therefore, only mean-centred 
data were used for further analysis. After outliers were identified and excluded,     PLS-DA 
was performed to identify the discriminant strength of the model and to generate a loadings 
plot from which metabolites could be identified which most greatly contributed to differences 
between the groups. In SIMCAP-12, PLS-DA models are generated through seven-fold cross 
validation. In this method, every 7
th
 sample is excluded (1
st
, 7
th
, 14
th
, 21
st 
and so on), a model 
generated from the remaining samples and the excluded “training set” predicted back into the 
model. This is repeated for all the samples (grouping the 2
nd
, 9
th
, 16
th
 and 3
rd
, 10
th
, 17
th
 and so 
on) until all the samples have been excluded once. The results are averaged to produce a 
model that is externally cross-validated, similar to the cross validation algorithms described 
in previous chapters.  
 
Spectral peaks that were most contributory to PLS-DA models and those peaks that appeared 
divergent on comparison of median spectra were selected for peak integration. Comparison of 
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integrals was performed using GraphPad Prism (La Jolla, California, USA) using Mann-
Whitney non-parametric tests of significance, as normal Gaussian distribution could not be 
assumed, p-values of <0.05 were considered significant.  
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8.4 RESULTS 
8.4.1 Subject recruitment, exclusion and demographics 
A total of 51 patients were recruited: 19 with HCC and 32 with cirrhosis. From the HCC 
cohort, two patients were excluded as they had undergone curative orthotropic liver 
transplant or curative hepatic resection prior to sample collection; one patient was excluded 
as they were co- infected with HIV and a further three samples were excluded following 
PCA, the details of which are given in the results section. The total number of HCC samples 
after exclusions was therefore 13. From the cirrhosis cohort, four patients were excluded 
owing to insufficient radiological or biopsy evidence of cirrhosis status and two samples were 
excluded following PCA, leaving a total of 25. Median ages were similar in both groups, 61 
yrs for HCC and 58 yrs for cirrhosis patients. There were proportionally more males in the 
HCC group (85% versus 56%) but this was not statistically significant (p=0.26). Body mass 
indices were comparable, 25.9 kg/m
2
 in the HCC group and 27.3 kg/m
2
 in the cirrhosis group, 
again the difference not reaching significance (p = 0.23) (Table 8-1).  
 
Table 8-1. UK patient demographics. 
Characteristic HCC Cirrhosis p-value 
N 13 25  
Median age (range) (years) 61 (29 – 82) 58 (28 – 79) 0.55
a
 
Male n (%) 11 (85%) 14  (56%) 0.26
b
 
Median body mass index (kg/m
2
) 25.9 27.3 0.23
a
 
Child-Pugh A  4 (40%) 17 (74%)  
Child-Pugh B 3 (30%) 4 (17%)  
Child-Pugh C 1 (10%) 2 (9%)  
Non-cirrhotic 2 (20%) 0  
Unknown due to insufficient data 3 2  
Key: 
a
Mann-Whitney test for non-parametric data, 
bFisher’s exact test for categorical data. 
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There were greater numbers of Child’s-Pugh grade A patients in the cirrhosis group (74% 
versus 40%), but cumulatively, grade A + B patients accounted for the majority of patients in 
both groups: 70% in the HCC cohort and 91% in the cirrhosis cohort. Aetiologies of liver 
disease are displayed in Table 8-2. The majority of patients had either chronic HCV, HBV or 
alcohol related disease.   
 
Disease stages of HCC are displayed in Table 8-3. Three tumours were BCLC stage A, five 
grade C and two grade D. Three tumours could not be staged owing to insufficient data.  
 
Table 8-2. Hepatocellular carcinoma and cirrhosis aetiological factors. 
Aetiology HCC Cirrhosis 
HCV 6 6 
HBV 3 3 
Alcohol 2 9 
NASH 0 2 
Haemochromatosis 1 1 
HCV + Alcohol 1 2 
HBV + Alcohol 0 0 
NASH + Alcohol 0 1 
Idiopathic 0 1 
Total 13 25 
 
Table 8-3. Barcelona Clinic Liver Cancer stages of hepatocellular carcinoma.  
Stage Number 
A 3 (30%) 
B 0 
C 5 (50%) 
D 2 (20%) 
Unknown due to insufficient data 3 (30%) 
Total 13 
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8.4.2 Serum biochemical analysis 
Median AFP levels were significantly higher in the HCC group (18.1 IU mL
-1
 versus 4.6 IU 
mL
-1, 
Table x3.5). Using an AFP cut off level of 20 IU mL
-1
, sensitivity and specificity were 
45% and 95%, respectively and at 200 IU mL
-1
, were 27% and 100%, confirming the poor 
sensitivity of AFP for HCC in this cohort (Table 8-4). Table 8-5 displays the median serum 
biochemistry profiles of the cohorts, which for serum creatinine, ALT, bilirubin and INR are 
similar, with the exception of albumin which was lower in the HCC group compared to the 
patients with cirrhosis (30 gL
-1
 and 35 gL
-1
, respectively). 
 
Table 8-4. Alpha fetoprotein diagnostic sensitivity and specificity. 
 Sensitivity Specificity 
AFP cut off 20 (IU mL
-1
) 45% 95% 
AFP cut off 200 (IU mL
-1
) 27% 100% 
AFP cut off 400 (IU mL
-1
)) 27% 100% 
 
 
Table 8-5. Serum biochemistry profiles of subject cohorts. 
 HCC  
Median (range) 
Cirrhosis  
Median (range) 
p-values 
Serum Samples (n) 13 25  
AFP (IU mL
-1
) 18.1 (1.2-1230)
+
 4.6 (1.8-29.2)
+++
 <0.01 
Creatinine (mmol L
-1
) 79 (59 – 96)
++
 71 (48 – 132) ++ 0.26 
ALT (IU L
-1
) 43.5 (7-147)
++
 37 (8-193)
+
 0.7 
Bilirubin (μmol L-1) 10 (5-79)
++
 17 (6-87)
+
 0.08 
Albumin (g L
-1
) 30 (22-40)
++
 35 (19-48)
++
 0.02 
INR (IU) 1.1 (1-1.5)
+++
 1.2 (1-3.1)
+++
 1 
Key: p-values calculated using Mann-Whitney tests of significance. 
+
2 measurements 
missing,  
++
3 measurements missing,
+++
4 measurements missing. 
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8.4.3 Median spectra  
Median overlaid spectra from HCC and cirrhosis groups are shown in Figure 8-3, displaying 
high colinearity.  
 
 
Figure 8-3. Median proton nuclear magnetic resonance urine spectra. 
Key: HCC (black) and cirrhosis (red). 
 
8.4.4 Multivariate statistical analysis 
The initial PCA scatter plot is displayed in Figure 8-4 clearly demonstrating two HCC and 
one cirrhosis outlying samples, positioned outside the Hotelling’s T2 limit. Examination of 
the MR spectra of these samples identified glycosuria in one HCC sample, with dominant 
peaks from 3.2 ppm to 4.0 ppm (Figure 8-5) which were the major contributor to PC1, in 
addition to a triplet at 1.24 ppm. Principal component 2 was heavily weighted by resonances 
at 1.18 ppm (triplet), 3.65 ppm (quadruplet) and 1.14 ppm (doublet).  The cirrhosis and 
remaining HCC outlying samples displayed dominant resonances at 1.18 ppm (triplet) and 
3.65 ppm (quadruplet), which correspond to ethanol resonances (Figure 8-6). Of note, the 
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patient from whom one of these samples was from admitted to consumption of five cans of 
Guiness in the 24 hrs prior to sampling (equivalent to 11.5 units or 115 g of ethanol).  
 
 
Figure 8-4. Principal components analysis all UK urine samples. 
Key: HCC samples (■); cirrhosis samples (●). Outliers indicated in red circles. 
 
Principal components analysis, following exclusion of outlying samples, identified further 
significantly outlying samples. Two outliers in this analysis revealed heavy influence from 
glucose metabolites. One of these patients, although not formally diagnosed as diabetic, had a 
high capillary glucose level (18.2 mmolL
-1
) at the time of sampling. The other had no 
documented diagnosis of diabetes. These samples were excluded and a third PCA scatter plot 
was generated with R
2
 and Q
2
 values of 0.51 and 0.31, respectively (Figure 8-7).  
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Figures 8-5 and 8-6. Urine magnetic resonance spectra displaying marked glucose and 
ethanol resonances.  
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Figure 8-7. Principal components analysis following exclusions.  
Key: HCC samples (■); cirrhosis samples (●). (R2 = 0.51 and Q2  = 0.31). 
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To identify discriminatory metabolites between the two groups, PLS-DA was performed.  In 
a two component model, model fitting was poor (R
2
 = 0.48) with negative Q
2 
values, 
suggesting that, as a predictive tool, the model would be poorly predictive (Figure 8-8). The 
misclassification matrix generated from these analyses is displayed in Table 8-6, and results 
in a diagnostic sensitivity of HCC of 53.6% and specificity of 96%, highlighting the model’s 
poor predictability. The most influential variables, from PLS-DA loadings plot and visual 
comparison of median spectra are summarised in Table 8-7.   
 
Figure 8-8. Partial least squared discriminant analysis of UK urine samples. 
 Key: HCC samples (■); cirrhosis samples (●). (R2 = 0.48, Q2 negative). 
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Table 8-6. Misclassification matrix from partial least squared discriminant analysis. 
 Predicted as HCC Predicted as Cirrhosis Total 
HCC 7 6 13 
Cirrhosis 1 24 25 
 
 
Table 8-7. Discriminatory metabolites comparison between subject cohorts. 
Discriminatory metabolite HCC median 
(arbitrary units) 
Cirrhosis median 
(arbitrary units) 
p-values  
 
↑ Carnitine (3.24 ppm) 1.16 x 107 9.37 x 106 0.31 
↑ Formate (8.5 ppm) 6.36 x 106 3.13 x 106 0.44 
↓ Citrate doublet (2.56 ppm) 4.65 x 107 7.33 x 107 0.21 
↓ Citrate doublet (2.68 ppm) 5.39 x 107 7.20 x 107 0.25 
↓ Hippurate (3.97 ppm) 4.25 x 107 4.68 x 107 0.52 
↓ Hippurate (7.56 ppm) 3.94 x 106 4.45 x 106 0.69 
↓ p-cresol sulphate (2.35 ppm) 1.15 x 107 2.61 x 107 0.06* 
↓ p-cresol sulphate (7.21 ppm) 6.68 x 106 1.32 x 107 0.04* 
↓ Creatinine methyl (3.05 ppm) 4.50 x 108 5.01 x 108 0.26 
↓ Creatinine methylene (4.06 ppm) 2.83 x 108 3.62 x 108 0.03* 
p-values calculated using Mann-Whitney tests of significance.  
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8.4.5 Univariate statistical analysis  
Influential metabolite peak integrals are displayed in Table 8-7 and Figure 8-9. Metabolites 
elevated in the urine of patients with HCC were carnitine (3.24 ppm, p=0.31) and formate 
(8.5 ppm, p=0.44), although neither result reached significance. Urinary metabolites reduced 
in patients with HCC included citrate double doublet (2.56 ppm and 2.68 ppm, p=0.21 and 
p=0.25, respectively) and both the aliphatic and aromatic resonances of hippurate (3.97 ppm, 
p=0.52 and 7.56 ppm, p=0.69), neither of these results reaching significance. Peaks at 2.35 
ppm (p=0.06) and 7.21 ppm (p=0.04) were significantly reduced in patients with HCC and 
were identified as arising from the same metabolite when a STOCSY analysis was performed 
(Figure 8-10). This metabolite was identified as p-cresol sulphate from the literature 
(Clayton et al., 2009), the resonance at 2.35 representing the methyl signal and that at 7.21, 
the aromatic signal. A comparison of the median spectral integrals of the 7.21 ppm region is 
displayed in Figure 8-11. Finally, urinary creatinine was found to be reduced in patients with 
HCC, at both the creatinine methyl singlet at 3.05 ppm (p=0.26) and significantly, at the 
methylene singlet at 4.06 ppm (p=0.03) (Figure 8-12).  
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Figure 8-9. Median value scatter plots of discriminatory variables. 
p-values calculated using Mann-Whitney tests of significance. 
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Figure 8-9. Median value scatter plots of discriminatory variables. 
p-values calculated using Mann-Whitney tests of significance. 
 
 
Figure 8-10.  
STOCSY analysis 
of region at 2.35 
ppm, revealing 
correlation with 
double doublet at 
7.21 ppm. 
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Figure 8-11. Comparison of median spectra of creatinine (4.06 ppm). 
 
Figure 8-12. Comparison of median spectra of p-cresol sulphate (7.21 ppm). 
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8.5 DISCUSSION 
This is the first reported study to identify HCC specific urinary 
1
H NMR markers in a closely 
matched group of patients with HCC. Similar to the studies of Nigerian and Egyptian patient 
cohorts, reduced urinary creatinine, citrate and hippurate and elevated carnitine levels were 
found in patients with HCC in comparison to those with cirrhosis, albeit not to levels of 
statistical significance. The study presented here also identified significant reductions in 
urinary p-cresol sulphate, a metabolite which was not discriminatory in previous studies. 
 
Study patients were well matched, the majority being Child-Pugh stage A and B. In these 
patients, serum AFP, the most widely used marker for HCC, displayed poor diagnostic 
sensitivity (27%) at a cut off of 200 IU mL
-1
, while urinary multivariate analysis, despite 
displaying poor fitting and predictive parameters, produced a superior sensitivity (53.6%). 
Diagnostic specificity was similar for both tests (100% for AFP and 96% for multivariate 
models). These results compare poorly to both the Nigerian and Egyptian urinary 
1
H NMR 
studies, which displayed multivariate model sensitivities and specificities approaching >90%. 
The reasons for poorer discrimination in this UK cohort may be due to a number of factors. 
Firstly, the cohorts for this study were intentionally selected to be well matched, both for 
demographic and physical status and for aetiology of liver disease. No healthy control group 
was included as the metabolic profiles of healthy patients have been shown to be very 
different to those of diseased groups, which may be due to global metabolic and hepatic 
function rather than tumour specific changes. Furthermore, the stage of the tumours tended to 
be higher in the Nigerian and Egyptian cohort, compared to the UK cohort. It is therefore 
possible that the close matching of cirrhosis and HCC patients, with ≥70% in both groups 
being Child-Pugh stage A or B,  resulted in higher similarity of spectra.  Certainly, BMI was 
similar in both groups, so it is unlikely that cancer cachexia, which may have been a 
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prominent factor in causing altered spectral profiles in the Nigerian and Egyptian group, had 
a great influence on discriminatory profiles in this study. Nevertheless, PLS-DA and median 
MR spectral comparison identified a number of spectral regions elevated or reduced in the 
HCC compared to the cirrhosis cohorts.  
 
Urinary p-cresol sulphate, identified through STOCSY analysis, was significantly reduced in 
the HCC cohort at 7.21 ppm (p=0.04). This corresponded to the aromatic resonances of the 
molecule. The methyl group, on the benzene ring, resonated at 2.35 ppm, and comparative 
median values approached significance (p=0.06). This finding was not evident in the 
Nigerian and Egyptian groups. p-cresol is a product of colonic bacterial metabolism of 
tyrosine. Certain bacteria, such as Clostridium difficile, are particularly high producers.  
Sulfonation to p-cresol sulphate occurs in the liver. Clayton and colleagues in 2008, observed 
that healthy human subjects with high pre-test urinary p-cresol sulphate levels sulfonated 
acetaminophen (paracetamol) to the less toxic acetaminophen glucuronide to a lesser extent 
than those with lower pre-test p-cresol sulphate levels (Clayton et al., 2009). This was 
proposed to be due to the competitive inhibition of p-cresol sulfonation in the presence of 
paracetamol. This study was performed in healthy patients, so it is not possible to surmise 
whether this would translate in higher likelihood of drug induced liver toxicity, although 
sulfonation of hepatically metabolised drugs is a common occurrence and it is possible that p-
cresol sulphate is a surrogate marker of liver function, lower levels reflecting reduced 
sulfonation in those patients with HCC and worse liver function. 
 
Urinary creatinine was reduced in patients with HCC, the methylene (CH2) singlet at 4.06 
ppm significantly reduced (p=0.03), while the methyl singlet (CH3) at 3.05 ppm, non-
significantly reduced (p=0.26). Similar findings were present in both the Nigerian and 
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Egyptian cohorts of patients. Chen and colleagues, using HILIC and RPLC MS, also 
observed reduced urinary creatinine levels in HCC subjects (Chen et al., 2009).   Creatinine is 
a breakdown product of creatine phosphate in muscle and is eliminated from the body by 
glomerular filtration and partial tubular excretion. Renal impairment will cause a rise in 
serum creatinine and a concomitant rise in urine creatinine. Serum creatinine levels were 
similar in both groups, so is unlikely to have contributed to urinary differences. Lower total 
body creatinine may be due to reduced muscle mass. Although the BMI of each group was 
non-significantly different (HCC = 25.9 kg/m
2
 and cirrhosis = 27.25 kg/m
2
, p=0.23) it may be 
that the slight difference in weight is due to reduced muscle mass in HCC patients, which is 
reflected in lower urinary creatinine levels.  A study of urinary creatinine in a US population 
observed that lower muscle mass was a major contributing factor to lower urinary creatinine 
levels (Barr et al., 2005) . 
 
Formate (8.5 ppm, p=0.44) was non-significantly elevated in the HCC group and was not 
identified as a discriminatory metabolite in the Nigerian or Egyptian groups. Formate is a 
small 46 Da carboxylic acid that is endogenously produced as the product of 1-carbon 
metabolism and from dietary fibre digestion by the gut microbiome (Holmes et al., 2008).  As 
with glycine, which was found to be reduced in patients with HCC in the Egyptian cohort, 
formate, through the 1-carbon metabolism pathway, may be involved in the methylation 
status of the cell. In an international study of urinary metabolic profiles and blood pressure, 
Holmes and colleagues described a positive correlation of blood pressure and urinary 
formate, proposing that formate affects blood pressure through aberration of sodium chloride 
reabsorption in the renal tubules. Blood pressure data was not collected on the subjects in this 
study, although cirrhosis tends to induce a relatively low blood pressure state owing to 
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decreased systemic vascular resistance, and higher portal pressures causing shunting of fluid 
into the third space.  
 
Urinary citrate levels (2.56 ppm and 2.68 ppm, p=0.21 and p=0.25, respectively) were 
reduced in the HCC cohort, although not to a level of significance. This finding is similar to 
that of the Egyptian cohort and may represent a repression of oxidative phosphorylation in 
the mitochondria, as predicted by the Warburg hypothesis (Warburg et al., 1924; Warburg,  
1958).  In addition, a previous study in Sprague-Dawley rats by Bollard and colleagues 
observed reduced urinary citrate after partial hepatectomy, proposed to be a marker of 
heightened energy demand and cellular stress, as would be the case in patients with HCC 
(Bollard et al., 2010). 
  
Urinary hippurate levels (3.97 ppm, p=0.52 and 7.56ppm, p=0.69), an aromatic acyl glycine, 
that is formed by conjugation of benzoate with glycine in liver and kidney mitochondria 
(Schachter and Taggart, 1953), was non-significantly reduced in the urine of patients with 
HCC. Hippurate was similarly reduced in the urine of the Egyptian cohort of HCC patients.  
Benzoate is formed via the metabolism of gut microbes from dietary aromatic compounds 
(Nicholson et al., 2005; Rechner et al., 2002), but it is possible that the decreased hepatic 
function, as evidenced by higher Child-Pugh scores in patients with HCC translates into less 
efficient benzoate conjugation and subsequently lower urinary hippurate excretion levels. In 
this way, hippurate may be seen as a surrogate marker of hepatic function, however, 
alterations in the urinary level of this metabolite have also been reported in inflammatory 
bowel disease (Williams et al., 2009) and pneumonia (Slupsky et al., 2009) questioning its 
specificity for a particular disease.    
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There were several areas where the study could have been improved. Firstly, the number of 
patients was low and it is therefore difficult to draw firm conclusions from the data. Although 
Imperial College NHS Healthcare Trust treats many patients with HCC, it was not possible to 
sample all of them owing to low recruitment rates. This was improved by contacting patients 
by mail and telephone to arrange suitable dates for sampling. Despite this, many patients 
declined to partake owing to their frail physical state and the difficulty in attending hospital. 
Based on the study presented here, however, recruitment of HCC patients for urinary 
metabolic profiling is underway as a UK Clinical Research Network listed study (UKCRN ID 
8457, htttp://public.ukcrn.org.uk/Search/ StudyDetail.aspx Study 8357). This will provide a 
much larger cohort of subjects allowing validation of the results described here, Secondly, 
although tumour stages were less advanced than that of the Nigerian and Egyptian cohorts, it 
would have been preferable if more very early tumours could have been recruited for study. 
This would not have been possible in the time-frame of this study as early tumours remain 
rarely detected owing to the poor sensitivity of current surveillance techniques of US and 
AFP. As part of the UKCRN Nationwide study, patients with cirrhosis are being recruited 
and followed up. A small proportion of these patients will develop HCC and it will be 
possible to compare pre- and post-HCC urinary profiles to isolate markers of early disease. 
Finally, as in the Egyptian and Nigerian study, many samples had to be excluded owing to 
certain metabolites overwhelming the spectral profiles resulting in bias of multivariate 
analysis. In this study, ethanol and glucose (glycosuria) were the main factors for exclusion. 
For future studies it would, therefore, be important to ensure that diabetes is not present in 
subjects, and if it is, then serum glucose levels are recorded prior to sampling. Excessive 
alcohol consumption would also be an exclusion criteria.  
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8.6 CONCLUSIONS 
This is the first urinary 
1
H NMR spectroscopy metabolic profiling study of HCC to be 
performed in a UK population. Overall, the findings provide further insight into the metabolic 
pathogenesis of liver disease and HCC and corroborate some of the findings highlighted in 
earlier studies in Nigerian and Egyptian cohorts. Similarities include reduced urinary 
creatinine, citrate and hippurate and raised carnitine, albeit not to significant level. This study 
has also identified p-cresol sulphate as a discriminatory urinary metabolite in this UK cohort, 
significantly reduced in patients with HCC compared to those with cirrhosis. The explanation 
for this is not clear but may be due to altered liver function.  
 
Larger cohort numbers are required for validation of these data. Based on the study presented 
here, recruitment of patients with HCC for urinary metabolic profiling is now underway as 
part of the UKCRN portfolio of studies. This will hopefully confirm the alterations described 
by this study and prove that urine does indeed possess diagnostic capabilities. 
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9 THE URINARY METABOLIC PROFILING OF 
HEPATOCELLULAR CARCINOMA IN A NIGERIAN PATIENT 
COHORT USING ULTRA HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY MASS SPECTROMETRY 
 
9.1 ABSTRACT 
Introduction: Mass spectrometry has been utilised for the identification of urinary 
biomarkers of HCC in several previously published studies. The study presented here utilises 
UPLC-MS for metabolic profiling of urine samples from the same Nigerian cohort of 
subjects recruited for 
1
H NMR studies. The aims were to examine whether the metabolite 
profiles detected by UPLC-MS could also distinguish these patients, provide validatory data 
and identify metabolites altered in the urine of patients with HCC. Methods: Liquid 
chromatography was performed using a 1.7 μm high strength silica column and mass 
spectrometry run in positive and negative ion mode using a quadrupole time of flight system. 
Univariate and mulitivariate analysis identified discriminatory ions and tandem fragmentation 
MS was employed for metabolite identification. Results: A number of discriminatory ions 
were identified, however, it was only possible to identify acetylcarnitine (204 Da) and an ion 
weighing 229 Da, eluting at 1.14 mins, likely representing leuacylproline. Acetylcarnitine 
levels were raised in the urine of patients with HCC compared to cirrhosis (p<0.001) and 
healthy volunteers (p=0.07). Conclusions: These data complement the matched 
1
H NMR 
spectroscopy study in confirming elevation in urinary carnitine molecules, in this case, 
acetylcarnitine. This result provides insight into the altered energy metabolism processes of 
HCC. In particular it may suggest a subjugation of fatty acid metabolism to provide lipid 
building blocks for rapidly dividing tumour cells.   
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9.2 INTRODUCTION 
The use of ultra performance liquid chromatography mass spectrometry (UPLC-MS) has 
been validated in cancer biomarker identification and metabolic profiling (Antoniello et al., 
1998; Jeng et al., 2009; Motyl et al., 1993; Psychogios et al., 2011; Tamura et al., 1986; 
Want et al., 2010). It is complimentary to 
1
H NMR spectroscopy displaying higher sensitivity 
(picomolar versus micro/nanomolar range) and has the ability to detect metabolites that 
1
H 
NMR spectroscopy may not (Psychogios et al., 2011). 
  
Liquid and gas chromatography MS have been utilised in the identification of urinary 
biomarkers of HCC since the 1980s, although the majority of these studies had limitations. In 
1986, Tamura and colleagues detected elevated levels of urinary pseudouridine using high 
performance (HP) LC in patients with HCC. Pseudouridine is a C-glycoside isomer of the 
nucleoside uridine and it is the most prevalent of the over one hundred different modified 
nucleosides found in RNA. In this study, in combination with serum AFP, urine 
pseudouridine levels displayed an 83% sensitivity for HCC diagnosis (Tamura et al., 1986). 
Urinary pseudouridine levels have also been shown to be elevated in other malignancies, such 
as non-Hodgkin’s lymphoma (Motyl et al., 1993), probably as an indicator of overall cellular 
proliferation of tumour growth and not a specific attribute to HCC.  
 
In 2009, based on a further HPLC-based study in Taiwanese subjects, the nucleosides, 
adenosine, cytidine and inosine were proposed as urinary markers of HCC (Jeng et al., 2009). 
When combined with serum AFP, sensitivity for tumour diagnosis was 80%, however, the 
study was only conducted with one healthy subject group as controls and no patients with 
cirrhosis, substantially reducing the validity of the findings.  
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In 1998, using RPLC, Antionella and colleagues reported increased urinary levels of free and 
acetylated polyamines in patients with HCC compared to healthy controls and patients with 
cirrhosis (Antoniello et al., 1998). These polyamines were identified as putrescine, spermine 
and spermidine which are required for cellular proliferation, although their exact role is 
unclear. Putrescine acts on SAMe to produce spermine which in turn acts on further SAMe 
molecules to produce spermidine (Wishart et al., 2007).  Unfortunately, as with other 
markers, polyamines were found not to be sensitive enough for accurate early tumour 
detection and may not be specific to HCC.  
 
There have been only two LC-MS studies reporting global urine metabolic profiling of 
hepatocellular carcinoma. The first was performed by Chen and colleagues in 2008 using 
UPLC-MS coupled with both RPLC and HILIC, on urine samples from 21 patients with HCC 
compared to 24 from healthy controls (Chen et al., 2009).  In this study, HILIC was found to 
be complimentary to RPLC as polar compounds, such as creatinine, were superiorly retained 
on the hydrophilic HILIC chromatography column. Multivariate analyses, in the form of PCA 
and PLS-DA, were utilised for biomarker identification. Twenty four metabolites (16 from 
HILIC and eight from RPLC) were identified as having greatest influence on PLS-DA 
loadings plots. Of these, four were authenticated with standards and MS-MS fragmentation 
studies: creatinine and N-methyl nicotinic acid, both of which were reduced in patients with 
HCC; and carnitine and acetylcarnitine, which were elevated in patients with HCC. The 
remaining influential metabolites, which were not authenticated, included nine carnitine 
derivatives: hypoxanthine, proline betaine, leuacylproline, phenylacetylglutamine and four 
unidentified analytes. The alteration in carnitines and acetylcarnitine were attributed to a 
decrease in mitochondrial β-oxidation of fatty acids. Decreased urinary creatinine was 
attributed to disordered hepatic metabolism of arginine, glycine and methionine. Lower N-
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methyl nicotinic acid urine levels were hypothesised to be caused by nicotinamide and 
nicotinic acid hepatic metabolism alterations. This study, although one of the first to describe 
urinary metabolic profiling in HCC, provided no demographic features of the participants. It 
is accepted that age, sex and nutritional status may heavily confound metabolic profiling 
studies. Furthermore, the stage and grade of HCC were not reported. Patients with advanced 
HCC may be more successfully discriminated from those with early disease owing to the 
global physiological effects advanced tumours will have on the body.  The second study, also 
performed in China in 2009, profiled 20 urine samples from male patients with HCC in 
comparison to 20 samples from healthy male controls using GC-MS (Wu et al., 2009).  This 
modality has the advantage of being highly sensitive to even very small polar metabolites 
(Pasikanti et al., 2008) and the disadvantage of requiring lengthy derivitisation steps to form 
volatile analytes. Identification of metabolites was performed with reference to the National 
Institute of Standards and Technology database and confirmed with comprehensive standard 
authentification, identifying 103 metabolites. Principal components analysis was utilised to 
identify discriminatory metabolites. Octanedioic acid, glycine, tyrosine, threonine and 
butanedioic acid were reported to be elevated in patients with HCC. Other metabolites, 
including primidine, xylotol and hypoxanthine, were reduced. A diagnostic model using 18 of 
the identified metabolites, using cross validated Y-values, was subjected to area under the 
curve analysis and generated an area of 0.93. Metabolite alterations were attributed to 
heightened cellular proliferation (hypoxanthine), glycolysis (glycine and xylotol) and nucleic 
acid turnover (primidine). Efforts were made to control for gender and age, however, there 
was no description of tumour stage or grade and an adequate control group of patients with 
cirrhosis was not included. Furthermore, PCA may not be the most appropriate multivariate 
tool for this purpose. It is an unsupervised model that does not seek to discriminate between 
groups but describes the maximum variation across all the samples, plotted in orthogonal 
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components. Certainly, from the scores plots displayed in this study, the first component does 
not split the groups. If the loadings were used from this component then the metabolites 
identified may be those of greatest variation in all the samples, rather than those different 
between the two groups. Nonetheless, these two studies were the first to identify that 
metabolic profiling of urine using LC or GC MS can potentially identify discriminatory 
patterns.   
 
In Chapter 6, it was shown that in a cohort of Nigerian subjects, 
1
H NMR spectroscopy of 
urine can provide discriminatory metabolite profiles of patients with HCC (Shariff et al., 
2010). The aims of the study presented here were to examine whether the metabolite profiles 
detected by UPLC-MS could also distinguish these patients, provide validation data and 
identify any other metabolites altered in the urine of patients with HCC, compared to well 
matched healthy and cirrhosis control subjects.  
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9.3 METHODS 
9.3.1 Patient selection 
The study protocol was in concordance with the ethical guidelines of the 1975 Declaration of 
Helsinki and approved by the research ethics committee of the University of Jos, Nigeria. The 
metabolic profiling protocol was approved by the research ethics committee of Imperial 
College London, UK. Subjects were recruited as previously described (Chapters 4 and 5). 
 
9.3.2 Serum biochemical tests 
Serum AFP, urea, creatinine, ALT, ALP, total bilirubin and albumin levels were measured at 
St Mary’s Hospital, Paddington as previously described (Chapter 8). Median levels were 
compared using unpaired Mann-Whitney tests of significance. 
 
9.3.3 Urine sample collection 
Urine samples were collected, transported and stored as previously described (Chapter 6).  
 
9.3.4 Sample preparation 
150 μL aliquot of each urine sample was added to 150 μL of sterile H2O. The samples were 
centrifuged at 13 000 g for 10 mins to remove particulates. 250 mL of the resultant diluted 
urine was transferred into 96-well plates for analysis. 5 μL of each urine sample were pooled 
to constitute three quality control (QC) samples which were run at the beginning (the 10 first 
runs), after every 10
th
 sample and at the end of the experiment, in both positive and negative 
ion modes. The QCs served as measures of retention time drift and subsequent reliability of 
the data as interpreted by initial PCA. Samples were run in random, non-grouped order over a 
total of 35 hrs. 
 
210 
 
9.3.5 Chromatographic conditions 
Chromatographic separations were performed on a Waters 2.1mm x 100mm ACQUITY
TM 
1.7 µm HSS T3 column (Waters, Elstree, UK) maintained at 40 ºC in an ACQUITY
TM
 UPLC 
system (Waters MS Technologies, Manchester, UK) based at Imperial College London.  
 
Samples were maintained at 4 ºC prior to injection of 5 µL onto the column. A 12 min 
gradient was employed with mobile phase A of 0.1a% formic acid (FA) in water and mobile 
phase B 0.1% FA in acetonitrile. The composition was increased linearly from 0 to 15% B 
over 1 min, then to 50% B over the next 2 min, 95% B over the next 3 mins, remained 95% B 
until 9.9 mins then returned to 100% A over 0.2 min, and then re-equilibrated over the next 
1.9 min prior to injection of the next sample. Analytes elute at different times dependent on 
their polarity and hence solubility in the aqueous (water) or organic (acetonitrile) solvents. 
Formic acid was added to provide a source of protons in RPLC-MS and to reduce the pH of 
the mobile phase, to suppress the ionisation of weak organic acids and thereby improve 
retention.   
 
9.3.6 Mass spectrometry 
Mass spectrometry experiments were performed on a Micromass LCT Premier™ (Waters MS 
Technologies, Manchester, UK) with electrospray ionisation (ESI) operated in both positive 
and negative modes. The mass spectrometer was calibrated using a solution of sodium 
formate. All analyses were acquired using the lock spray to ensure accuracy and 
reproducibility; 200 pg mL
-1
 leucine-enkephalin (m/z 556.2771) in H2O:ACN (50:50) was 
used as the lock mass with a flow rate of 30 mL
-1
. Data were collected in positive and 
negative ion centroid mode, the lockspray frequency was set at 200 sec, and data were 
averaged over 10 scans. The mass spectrometer was operated with a capillary voltage of 
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2.4 kV for negative mode and 3.2 kV for positive ion mode, cone voltage of 35 V, nebulizer 
gas flow of 900 L/h, desolvation temperature of 350 °C, and source temperature of 120 °C. 
The instrument was set to acquire over the mass range m/z 50-1000 with acquisition time of 5 
scans sec
-1
 and an interscan delay of 100 ms. These settings have been  validated for the 
analysis of urine using UPLC-MS (Want et al., 2010). 
 
9.3.7 Tandem mass spectrometry (MS-MS) 
Fragmentation experiments were therefore undertaken to identify the most discriminatory 
variables. Tandem mass spectrometry (MS-MS) was performed using a quadrupole TOF 
Premiere
TM
 instrument (Waters MS Technologies, Manchester, UK). Chromatographic 
conditions were the same as preceding MS experiments and survey scans were performed for 
masses identified through multivariate and XCMS analysis. A collision ramp was set for the 
argon filled collision cells from 5 – 30 eV to ensure passage and fragmentation of the parent 
ion selected by the quadrupole. Fragmentation patterns and retention times were then 
interrogated to identify candidate molecules using online databases for identification 
(http://www.hmdb.ca/ and http://metlin.scripps.edu/metabolites_list.php) (Wishart et al., 
2007). Acetylcarnitine standard was purchased from Sigma-Aldrich (Gillingham, UK), and 
made up to 1g mL
-1
 concentration for authentification experiments.  
   
9.3.8 Data pre-processing 
Data underwent peak-picking, retention time correction and grouping using XCMS (Scripps 
Center for Mass Spectrometry, La Jolla, California, USA) (Smith et al., 2006)
 
as previously 
described (Chapter 5). 
 
 
212 
 
9.3.9 Multivariate analysis 
The data matrix was exported to SIMCA (Umetrics, Umea, Sweden) for PCA and PLS-DA as 
described in earlier chapters. All date were mean centred prior to multivariate analysis and 
outliers were excluded on the basis of causing heavy bias to the loadings components.  
9.3.10 Univariate analysis 
Data were exported to GraphPad Prism (La Jolla, California, USA) for univariate analysis in 
the form of Mann-Whitney t-tests comparison of medians between groups, assuming non-
parametric distribution of data.  
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9.4 RESULTS 
9.4.1 Subject recruitment, exclusion and demographics 
A total of 47 Nigerian subjects, in three cohorts, were recruited for study: 18 patients with 
HCC; 12 patients with cirrhosis; and 17 healthy Nigerian controls. The majority of subjects 
recruited for this study were the same as the parallel 
1
H NMR urine study (Chapter X). As a 
method of comparison, Table 9-1 outlines the baseline demographics of each subject group. 
Multivariate analysis identified a number of outlying samples which were excluded based on 
unrepresentative metabolite profiles as described in the following sections. Different samples 
were outlying in the two ion modes, leading to their exclusion. Two demographic data tables 
are therefore displayed. 
 
Three HCC and one healthy control samples were excluded from positive ion mode studies 
following multivariate analysis in the form of PCA, leaving 15 HCC, 12 cirrhosis and 16 
healthy control samples. Subject demographics are shown in Table 9-2. All patients in the 
HCC and cirrhosis groups were HBsAg positive (ELISA, 3
rd
 generation). All control subjects 
were HBsAg negative with normal hepatic function.  
 
In negative ion mode, one sample from a patient with HCC and one healthy control sample 
were excluded following PCA, leaving 17 HCC, 12 cirrhosis and 16 healthy control samples 
(Table 9-4). Of the remaining samples, all the cirrhosis subjects and 16/17 (94%) were 
HBsAg positive. The single HCC patient negative for HBsAg had idiopathic liver disease. 
All subjects denied taking prescribed or non-prescribed medication, nutrient or vitamin 
supplements to direct questioning.  
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These data are directly comparable to multivariate analysis data as samples that were 
excluded following PCA, on the basis of outlying and biased influence upon factors, were 
also excluded from the baseline demographics.    
In both ion modes, patients with HCC were older than those with cirrhosis and healthy 
controls, albeit, not significantly. Patients with HCC and cirrhosis had deranged hepatic 
biochemistry compared to healthy controls, as would be expected. All of the patients with 
HCC had vastly elevated serum AFP levels. In both ion modes, serum creatinine was not 
significantly different between the groups (Tables 9-3 and 9-5).  
 
Table 9-1. Comparison of subject demographics in 
1
H NMR and UPLC MS studies.  
 HCC Cirrhosis  Healthy 
 
1
H NMR UPLC MS 
1
H NMR UPLC MS 
1
H NMR UPLC MS 
N 18 18 10 12 14 17 
Median 
age (yrs) 
46.5 47 37 40 37 45 
Male n   12 12 8 9 7 8 
Ethnicity Nigerian Nigerian Nigerian Nigerian Nigerian Nigerian 
HB sAg+ 17/18 17/18 10/10 12/12 0 0 
Median 
AFP 
12474 19422 6 6 1.7 1.6 
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Table 9-2. Demographic profiles for samples used in positive ion mode. 
Characteristic HCC Cirrhosis Healthy  p-value 
N 15 12 16 - 
Median age 
(range) (years) 
45 (25 – 85) 40 (23 – 65) 37 (18 – 80) a0.74 and b0.79 
Male n  (%) 9/15 (60%) 9/12 (75%) 7/16 (44%) - 
Ethnicity Nigerian Nigerian Nigerian - 
HB sAg+ 15 (100%) 12 (100%) 0 - 
Key: p-values: 
a
 and 
b
 denote Mann-Whitney tests of HCC versus healthy and HCC versus 
cirrhosis, respectively. 
 
 
 
 
 
Table 9-3.  Serum biochemistry profiles for samples used in positive ion mode.  
 HCC  
Median 
(range) 
Cirrhosis  
Median 
(range) 
Healthy 
Median 
(range) 
p-values  
Serum Samples (n) ***15 **11 *11  
AFP (IU mL
-1
) 15,522  
(2.1–30,000) 
6.0 (2.9 – 
1,825) 
1.7 (1.0 – 6.9) a and b<0.001 
Creatinine (mmol 
L
-1
) 
74 (18 – 166) 76 (51 - 143) 74 (29 – 203) a0.90 and b0.80 
ALT (IU L
-1
) 42.5 (11 – 476) 37 (15 – 132) 22 (7 – 41) 
a
0.006 and 
b
0.83 
ALP (IU L
-1
) 11.5 (5.8 – 
24.9) 
10.5 (5.9 – 
980) 
8.1 (5.3 – 92.2) a0.60 and b0.78 
Bilirubin (μmol L-1) 47.8  
(14.4 – 318.4) 
28.8 (9.1 – 
67.1) 
6.5 (2.8 – 30.3) a<0.001 and 
b
0.27 
Albumin (g L
-1
) 28.7  
(15.7 – 59.3) 
27.8 (18 – 
39.5) 
49.3  
(29.3 – 79.2) 
a
0.005 and 
b
0.81 
Key:*Five serum samples missing; **one serum sample missing; ***three HCC samples 
insufficient for ALT, ALT, bilirubin and albumin measurements. 
a
 and 
b
 denote Mann-Whitney 
tests of HCC versus healthy and HCC versus cirrhosis, respectively. 
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Table 9-4. Demographic profiles for samples used in negative ion mode. 
Characteristic HCC Cirrhosis Healthy p-value 
N 17 12 16  
Median age 
(range) (years) 
45.0 40.0 37.0 
a
0.42 and 
b
0.52 
Male n (%) 11/17 (64.7%) 9/12 (75%) 8/16 (50%) - 
Ethnicity Nigerian Nigerian Nigerian - 
HB sAg+ 16/17 (94%) 12 (100%) 0 - 
Key: p-values: 
a
 and 
b
 denote Mann-Whitney tests of HCC versus healthy and HCC versus 
cirrhosis, respectively. 
 
 
Table 9-5. Serum biochemistry profiles for samples used in negative ion mode. 
 HCC  
Median 
(range) 
Cirrhosis  
Median 
(range) 
Healthy  
Median 
(range) 
p-values  
Serum Samples (n) 17*** 11** 11*  
AFP (IU mL
-1
) 15,522  
(2.1-30,000) 
6.0 (2.9-1825) 1.4 (1.0-6.9)- 
a 
and
 b
<0.001 
Creatinine (mmolL
-1
) 77 (18-166) 76 (51-143) 76 (29-615) 
a
0.80 and 
b
0.96 
ALT (IU L
-1
) 46 (11-476) 37 (15-132) 22 (8-41) 
a
0.003 and 
b
0.60 
ALP (IU L
-1
) 11.5 (5.8-24.9) 10.5 (5.9-
980.4) 
6.4 (5-92.2) 
a
0.27 and 
b
0.88 
Bilirubin (μmol L-1) 30.7  
(14.4-318.4) 
28.8 (9.1-67.1) 4.7 (2.8-30.3) 
a
<0.001 and 
b
0.44 
Albumin (g L
-1
) 30 (15.7-59.3) 27.8 (18-39.5) 48 (29.3-79.2) 
a
0.006 and 
b
0.51 
Key:*Five serum samples missing; **one serum sample missing; ***three HCC samples 
insufficient for ALT, ALT, bilirubin and albumin measurements. 
a
 and 
b
 denote Mann-Whitney 
tests of HCC versus healthy and HCC versus cirrhosis, respectively. 
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9.4.2 Positive ion mode data 
Positive and negative ion mode chromatographs are displayed in Figure 9-1, highlighting 
that complementary data that can be generated from the same sample.  
 
 
Figure 9-1. Ultra-performance liquid chromatography mass spectrometry total ion 
chromatograms from a patient with hepatocellular carcinoma. 
 
9.4.2.1 Multivariate statistical analysis 
XCMS processing of initial data results in the output of a matrix of variables (2,915 m/z (M) 
:RT (T) readings, or “analytes”). Principal components analysis of all three groups and QCs 
displayed group clustering with four outlying samples (Figure 9-2). Quality control samples 
were well clustered. The “drift” in the first few QC samples is to be expected as the column 
equilibrates to the experimental run. Tight QC clustering is observed thereafter indicating 
minimal retention time drift. The experimental data can, therefore, be reliably attributed to 
sample metabolic characteristics rather than retention time aberrations. Outliers in this PCA 
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correspond to one healthy control and three HCC samples. Examination of the loadings plots 
for these samples identified large contributions from variables M332-T249, M229-T94, 
M481-T258, M437-T250 and M525-T264. Examinations of the loadings plots of the outlying 
healthy control and HCC samples revealed markedly raised levels of these variables, 
confirming the disproportional influence from the presence of these samples in the model. 
These four samples were therefore excluded from the dataset. The identity of these analytes 
was not investigated further so it is not possible to comment on the reasons these samples 
displayed such altered levels. It is noteworthy that these outliers were different to those 
identified in the Nigerian urine 
1
H NMR spectroscopy study, which was attributed to 
paracetamol metabolites.  
 
 
 
Figure 9-2. Positive ion mode: principal components analysis. 
Key: Hepatocellular carcinoma (■), cirrhosis (●), healthy controls (●) and quality controls 
(▲). Outlying samples are circled in red. PC = principal component.  
 
The PCA scores plot displayed in Figure 9-3A represents healthy controls and HCC samples 
following exclusion of outlying samples. Group clustering is observed. The cumulative R
2
, or 
the explained variance, with a two principal component model was 0.57, suggesting the 
PC 2 
Hotelling’s T2 limit 
PC 1 
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model is well fitted. Two component PLS-DA displayed clear separation of cohorts with 
good model fitting (R
2
 = 0.66) and predictability (Q
2
 = 0.53).  Analysis of the loadings plot 
and the variable importance list (regression vectors), identified the most influential analytes 
in the multivariate model (Table 9-6).  
 
Principal components analysis of patients with HCC and patients with cirrhosis, following 
outlying sample exclusion, also displayed clustering of disease groups (Figure 9-3B). PLS-
DA analysis revealed good separation of the samples with an R
2
 value of 0.64 and Q
2
 of 0.43. 
The variable importance list of the most influential variables in this model is displayed in 
Table 9-6. It is noteworthy that there was marked similarity between variables in both 
models.  
 
  
Figure 9-3. Positive ion mode: principal components analysis following exclusions.  
Key: Hepatocellular carcinoma (■), healthy controls (●), cirrhosis (●). PC = principal 
component.  
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Table 9-6. Positive ion mode discriminatory variables.  
HCC versus Healthy Controls  HCC versus Cirrhosis 
M229-T94 M204-T67  
M204-T67 M229-T94 
M302-T208 M302-T208 
M332-T249 M332-T249 
M478-T199 M478-T199 
 
 
9.4.2.2 XCMS generated univariate statistical analyses 
The data matrix produced by XCMS is ordered in terms of statistical significance, by means 
of a student’s t-test, of variables most altered between two designated groups. The five most 
significant variables are displayed in Table 9-7.  
 
 
Table 9-7.  Positive ion mode discriminatory variables comparisons generated by 
XCMS driven univariate analysis. 
HCC versus Healthy Controls  p-value HCC versus Cirrhosis p-value 
M565-T29 <0.001 M180-T77 <0.001 
M577-T27 <0.001 M335-T41 <0.001 
M597-T27 <0.001 M457-T193 <0.001 
M429-T29 <0.001 M875-T194 <0.001 
M595-T27 <0.001 M913-T194 <0.001 
p-values calculated using *student’s t-test. 
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9.4.3 Negative ion mode 
9.4.3.1 Multivariate statistical analysis 
Figure 9-4 displays all group PCA, including QC samples, displaying some grouping of 
samples and two outlying samples based on Hotelling’s T2 index. Analysis of the loadings 
plots of the all group PCA and the contribution plots from the outlying samples identified 
heavy bias from variables M230-T167 and M187-T258, which were markedly raised in the 
two outlying samples. These samples were therefore excluded from any further analyses.  
 
Subsequent PCA of HCC and healthy control samples (Figure 9-5A) revealed some 
clustering, albeit not as marked as compared to positive mode data. The R
2
, or cumulative 
variance of this model was 0.46, reflecting poorer model definition. PLS-DA of these two 
groups produced a less robust model compared to positive mode data, with R
2
 and Q
2
 values 
of 0.40 and 0.22. The variable importance list of the most influential variables in this model 
is displayed in Table 9-8.  
 
Principal components analysis of HCC and cirrhosis samples were less well clustered, 
displaying an R
2
 of 0.47 and PLS-DA displayed R
2
 and Q
2
 levels of 0.47 and -0.06, 
respectively, suggesting poorer predictability of the model (Figure 9-5B). The variable 
importance list of the most influential variables in this model is displayed in Table 9-8. 
Similar to positive mode data, three of the influential variables were the same in both 
analyses. 
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Figure 9-4. Negative ion mode: principal components analysis.  
Key: Hepatocellular carcinoma (■), cirrhosis (●), healthy controls (●) and quality controls 
(▲). Outlying samples are circled in red. PC = principal component.  
 
 
 
Figure 9-5. Negative ion mode: principal components analysis following exclusions.  
Key: Hepatocellular carcinoma (■), healthy controls (●), cirrhosis (●). PC = principal 
component.  
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Table 9-8.  Negative ion mode discriminatory variables.  
HCC versus Healthy Controls  HCC versus Cirrhosis 
M357-T235 M187-T258 
M243-T61 M173-T203 
M187-T258 M410-T280 
M527-T236 M243-T61 
M410-T280 M189-T185 
 
 
9.4.3.2 XCMS generated univariate statistical analyses 
The data matrix produced by XCMS is ordered in terms of statistical significance, by means 
of a student’s t-test, of variables most altered between two designated groups. The five most 
significant variables for negative mode studies, are displayed in Table 9-9.  
 
Table 9-9. Negative ion mode discriminatory variables comparisons generated by 
XCMS driven univariate analysis. 
HCC versus Healthy Controls p-value HCC versus Cirrhosis p-value 
M481-T29 <0.001 M957-T194 <0.001 
M583-T30 <0.001 M914-T41 <0.001 
M335-T31 <0.001 M356-T35 <0.001 
M449-T30 <0.001 M700-T39 <0.001 
M409-T32 <0.001 M963-T194 <0.001 
p-values calculated using student’s t-test. 
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9.4.4 Variable identification and authentification 
Based on PLS-DA and XCMS data, variables most significantly altered between groups were 
selected for MS-MS fragmentation studies. These are displayed in Table 9-10.   
 
 
Table 9-10. Variables selected for tandem mass spectrometry studies.  
Positive mode Negative mode 
M204-T67 M357-T235 
M229-T94 M243-T61 
M302-T208 M187-T258 
M180-T77 M173-T203 
 
Variables M180-T77, M357-T235 and M243-T61 produced poor chromatographic peaks and 
fragmentation patterns that could not be identified. Variables M302-T208, M187-T258 and 
M173-T203 produced distinct chromatographic peaks and fragmentation patterns; however, 
no match could be identified from databases or from a literature search. Variables M204-T67 
and M229-T94 displayed clear chromatographic peaks and fragmentation patterns (Figures 
9-6 and 9-7). Figure 9-8 depicts the relative median abundance values for these variables in 
the three subject groups. Both variables are elevated in patients with HCC, reduced in healthy 
controls and negligible in patients with cirrhosis. 
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Figure 9-6. Total ion chromatogram and fragmentation spectrum of mass 204.  
A. Total ion chromatogram for mass 204 m/z displaying a main elution peak at 0.96 minutes 
and B. Tandem mass spectrometry fragmentation spectrum of parent mass 204 m/z.  
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Figure 9-7. Total ion chromatogram and fragmentation spectrum of mass 229.  
A. Total ion chromatogram for mass 229 m/z displaying a main elution peak at 1.14 minutes 
and B. Tandem mass spectrometry fragmentation spectrum of parent mass 229 m/z. 
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Figure 9-8. Relative concentration of variables M204-T67 and M229-T94. 
p-values calculated using Mann-Whitney tests for non-parametric data.  
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Fragmentation experiments on mass 204 m/z displayed main fragments at 85.034 m/z and 
145.05 m/z.  Online databases confirmed this to be likely to represent acetylcarnitine, an 
acetic acid ester of carnitine.  
 
Fragmentation spectra of mass 229 m/z revealed masses at 142.09 m/z, and 70.08 m/z. No 
match could be identified from online databases. Chen and colleagues, in an RPLC/HILIC 
MS urine study also identified a mass at 229.15 m/z elevated in patients with HCC which was 
attributed to leuacylproline, without standard authentification, a proline cycle metabolite 
(Chen et al., 2009).  
 
9.4.5 Standard authentification 
The chromatographic trace and fragmentation pattern of mass 204 m/z is compared to that of 
an acetylcarnitine standard in Figure 9-9. The elution peak of the standard occurs at 1.10 min 
(66 sec) and is slightly delayed in comparison to the sample which elutes at 1.0 min (60 sec). 
This is likely to be due to the complex nature and multiple components of the sample, as 
opposed to the pure compound standard, affecting elution rates. The fragmented mass 
spectrum of mass 204 is highly correlative in both the standard and the sample, displaying 
peaks at 145.05 m/z and 85.04/5 m/z, confirming this molecule to be acetylcarnitine.   
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Figure 9-9. Total ion chromatogram and mass spectrum of acetylcarnitine. 
A. Total ion chromatogram of mass 204 m/z in urine of subject with hepatocellular 
carcinoma (black) and authenticated standard (red). B. Mass spectrum of fragmented mass 
204 m/z in urine of subject with hepatocellular carcinoma (black) and authenticated standard 
(red). 
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9.5 DISCUSSION 
In contrast to 
1
H NMR spectroscopy, UPLC-MS displays higher sensitivity and detects 
differing metabolites. Metabolite identification, however, remains more involved, in part 
owing to lack of comprehensive databases and the more complex nature of ionised 
metabolites which may be detected whole or fragmented. Given these differences, urine 
UPLC-MS metabolic profiles, in both positive and negative ion modes, could distinguish 
patients with HCC from those with cirrhosis and healthy controls with robust PCA and PLS-
DA models. The loadings plots and regression vectors for these models and the XCMS 
generated data, identified influential analytes that were altered in HCC samples. As it is not 
possible to identify metabolites solely based on TOF-MS readings, and chromatographic 
retention times will deviate between experiments, fragmentation MS-MS was undertaken. 
Subsequently, the single metabolite that could be accurately identified and authenticated was 
acetylcarnitine.   
 
Univariate statistical analysis confirmed that urinary acetylcarnitine (204 Da) was elevated in 
patients with HCC compared to those with cirrhosis (p<0.001) and healthy controls (p=0.07). 
These results bear similarity to the urinary levels of carnitine detected by 
1
H NMR 
spectroscopy in both Nigerian (Shariff et al., 2010) and Egyptian studies (Shariff et al., 2011) 
(Chapters 6 and 7). Chen and colleagues also reported elevated carnitine and acetylcarnitine 
urinary levels in patients with HCC using HILIC and RPLC separations with MS (Chen et 
al., 2009). The same group reported elevated carnitine and acetylcarnitine in the serum of 
patients with HCC (Yin et al., 2009). Acetylcarnitine is an acetylated ester of carnitine that is 
intimately involved in the β-oxidation of fatty acids and transport of acetyl Co-A into the 
mitochondria for this purpose. Carnitine levels may rise with increased carnivorous 
consumption. Although dietary histories were not obtained in this Nigerian cohort, given that 
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the local diet very rarely contains meat, owing to its relatively high cost, it is unlikely that 
differences in meat consumption are responsible for the above observations. Urinary 
acetylcarnitine may therefore be a surrogate marker for alterations in oxidation of fatty acids 
by the body. Figure 9-10 schematically illustrates fatty acid β-oxidation (Vaz and Wanders, 
2002). Long chain fatty acids are present as Co-A esters in the cellular cytosol and are trans-
esterified to carnitine, catalysed by carnitine palmitoyltransferase I (CPT I) allowing the 
passage of the resultant long chain fatty acid acylcarnitine esters through the outer 
mitochondrial membrane. The specific carrier protein, carnitine-acylcarnitine translocase 
(CACT) transports the esters through the inner mitochondrial membrane where they are 
trans-esterified back to long chain acyl-CoA, catalysed by CPT II. Carnitine that is released 
can be transported back into the cytoplasm via CACT or acetylated by carnitine 
acetyltransferase to produce acetylcarnitine which can also enter the cytosol via the CACT 
transporter.  
 Carnitine 
Discussion
CPT
β-OXIDATION
Carnitine
Long chain 
acylcarntine
CYTOSOL
Fatty acids
MITOCHONDRIA
Long chain 
acycarnitine
CACT
CAT
Carnitine
Acetylcarnitine
 
Figure 9-10. Fatty acid β-oxidation and carnitine and acetylcarnitine transport.  
Key: CPT= carnitine palmitoyltransferase; CACT= carnitine-acylcarnitine translocase; 
CAT= carnitine acetyltransferase. 
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Peroxisome proliferator-activated receptor α (PPARα) activation is an established mechanism 
of fatty acid oxidation stimulation through the induction of genes encoding proteins involved 
in the transport and synthesis of acylcarnitine. Patterson and colleagues administered 
fenofibrate, a PPARα agonist, to healthy human volunteers for 14 days (Patterson et al., 
2009). Using UPLC-MS, urine was analysed at intervals and displayed depleted levels of 
acetylcarnitine by day 7, suggesting that increased fatty acid oxidation results in depleted 
urinary levels of acetylcarnitine. It is therefore theoretically possible that increased urinary 
acetylcarnitine is an indicator of decreased fatty acid oxidation. A mechanistic pathway of 
suppression of fatty acid acid oxidation in tumour cells was suggested by Debarardinis and 
colleagues in a study of interleukin-3-deprived hematopoietic cells. In this study, it was 
observed that phosphatidylinositol 3-kinase and Akt signalling, genes which have previously 
been found to be constitutively active in gastrointestinal and ovarian malignancies, 
suppressed expression of CPT I, thereby reducing the transport of fatty acids into the 
mitochondria for β-oxidation (Deberardinis et al., 2006). They proposed that decreased fatty 
acid oxidation allows fatty acids to be available as building blocks for phospholipids in cell 
membranes of the rapidly proliferating tumour. This is certainly an attractive notion as it also 
gives basis to the theory proposed by Weinberg and Chandel that rather than oxidative 
phosphorylation being subjugated for wholly energy demand reasons, it occurs for the 
provision of glycolytic intermediates to the pentose phosphate pathway to provide nucleotide 
substrates for the growing tumour (Weinberg and Chandel, 2009). In the same manner, 
repression of β-oxidation provides fatty acids for the construction of cell membranes (Figure 
9-11). Indeed, in the advanced stages of malignancy, energy reserves are low, so a reasonable 
explanation must exist as to why β-oxidation of fatty acids is suppressed.  
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Figure 9-11. Altered glycolytic and fatty acid metabolism in tumour cells for the 
generation of cellular substrates.  
Key: PPP= pentose phosphate pathway; TCA= tricarboxylic acid cycle; CPT I= carnitine 
palmitoyltransferase I. 
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9.6 CONCLUSIONS 
This study has validated that UPLC-MS urinary metabolic profiles could generate metabolic 
profiles capable of distinguishing between patients with HCC from healthy controls and 
patients with cirrhosis.  These data compliment the matched 
1
H NMR spectroscopy study in 
confirming elevation in urinary carnitine molecules, in this case, acetylcarnitine. This result 
provides insight into the altered energy metabolism processes of HCC. In particular, it may 
suggest a subjugation of fatty acid metabolism to provide lipid building blocks for rapidly 
dividing tumour cells. Unfortunately, no further metabolites could be identified and this 
highlights the disadvantage of UPLC-MS. Despite its higher sensitivity, in comparison to 
1
H 
NMR spectroscopy identification of metabolites is far more involved and of lower yield. 
Nevertheless, acetylcarnitine, which is distinguishable from carnitine, was not detected by 
1
H 
NMR spectroscopy due to its lower abundance in urine. This strengthens the argument of the 
complementary nature of these two modalities in identifying as many discriminatory 
metabolites as possible.  
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10  THE URINARY METABOLIC PROFILING OF 
HEPATOCELLULAR CARCINOMA USING ULTRA PERFORMANCE 
LIQUID CHROMATOGRAPHY MASS SPECTROMETRY IN A UK 
POPULATION 
10.1 ABSTRACT 
Introduction: The study presented here describes UPLC-MS urinary metabolic profiling of 
UK patients with HCC and cirrhosis, in an attempt to validate previous findings. Methods: 
Urine sample chromatography was performed using a 1.7 µm high strength silica column. 
Mass spectrometry was performed in both positive and negative ionisation modes. Data were 
processed using XCMS, multivariate and univariate statistical analysis. Molecular species 
were identified using tandem mass spectrometry fragmentation experiments. Results: 
Following exclusions, 15 samples from aetiologically diverse patients with HCC, 24 (positive 
mode) and 26 (negative mode) samples from patients with cirrhosis were used for analyses. 
Multivariate urinary metabolic profile models displayed diagnostic sensitivity and specificity 
values of 80% and 95.8% of HCC diagnosis in positive mode and 93.3% and 96.2% in 
negative mode. Discriminatory urinary metabolites included elevated acetylcarnitine 
(p=0.83), reduced dimethylheptanoylcarnitine (p=0.097) and p-cresol sulphate (p=0.05). 
Conclusions: This study has provided evidence that UPLC-MS can identify a discriminatory 
urinary metabolic profile between patients with HCC and those with cirrhosis induced by a 
highly diverse range of aetiologies. This would suggest HCC-associated urinary metabolic 
changes are independent of the underlying disease. Further evidence was also provided of the 
role perturbed fatty acid oxidation and altered gut microbial activity, in the form of altered 
carnitine and p-cresol sulphate levels. 
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10.2 INTRODUCTION 
In the previous chapters, UPLC-MS urinary metabolic profiling in a Nigerian population 
identified elevated acetylcarnitine as a discriminatory molecule. The population in this 
Nigerian study was aetiologically homogeneous, being mostly HBV infected. The findings 
reported in the study described in this chapter are of patients recruited in the UK, the same 
group that were enrolled into the parallel 
1
H NMR study (Chapter 8). The aetiologies of 
these UK patients were more diverse, including alcohol and NASH induced liver disease. 
Furthermore, the control group selected is composed entirely of patients with cirrhosis 
matched for liver disease stage and aetiology.  
 
The primary aim of this study was to identify HCC urinary biomarkers that are tumour 
specific and not as a result of liver disease aetiology and severity. The secondary aim was to 
identify any corroboratory findings to previous studies from other populations.  
 
  
236 
 
10.3 METHODS 
10.3.1 Patient selection 
Samples from patients recruited for the UK urinary 
1
H NMR study (Chapter 8) were used 
for parallel UPLC-MS studies.  All patients gave written informed consent in accordance 
with local Research Ethics Committee approval. Patients with HCC had been diagnosed with 
two confirmatory imaging modalities and patients with cirrhosis with biopsy or US, MRI or 
CT confirmation. Patients with HCC were staged according to the Barcelona Clinic Liver 
Cancer (BCLC) staging system (Bruix and Sherman, 2005). Patients with cirrhosis were 
staged according to the Child-Pugh staging system (Child and Turcotte, 1964; Pugh et al., 
1973). 
 
10.3.2 Blood laboratory tests 
Serum AFP, creatinine, ALT, total bilirubin, albumin and INR levels were measured at St 
Mary’s Hospital, London as previously described (Chapter 5). Median and interquartile 
ranges (IQR) were calculated for each assay and median levels were compared using 
unpaired Mann-Whitney tests of significance. 
 
10.3.3 Urine sample collection and preparation 
15 mL of random urine was collected from each volunteer and prepared for storage at -80ºC 
as described previously.   150 μL urine samples were prepared for UPLC-MS as described in 
Chapter 9.  5 μL of each urine sample were pooled to constitute three QC samples which 
were run at the beginning (the initial 10 runs), after every 10
th
 sample and at the end of the 
experiment, in both positive and negative ion modes. Samples were run in random, non-
grouped order. 
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10.3.4 Chromatographic conditions 
Chromatographic separations were performed on a Waters 2.1mm x 100mm ACQUITY
TM 
1.7 µm HSS T3 column (Elstree, Herts, UK) maintained at 40 ºC in an ACQUITY
TM
 UPLC 
system (Waters MS Technologies, Manchester, UK) . The samples were maintained at 4 ºC 
prior to injection of 5 µL onto the column. A 12 mins gradient was employed with mobile 
phase A of 0.1a% formic acid (FA) in water and mobile phase B 0.1% FA in acetonitrile. The 
composition was increased linearly from 0 to 15% B over 1 min, then to 50% B over the next 
2 mins, 95% B over the next 3 mins, remained 95% B until 9.9 mins then returned to 100% A 
over 0.2 min, and then re-equilibrated over the next 1.9 mins prior to injection of the next 
sample.  
 
10.3.5 Mass spectrometry 
Mass spectrometry experiments were performed on a Micromass LCT Premier™ (Waters MS 
Technologies, Manchester, UK) with ESI operated in both positive and negative modes. Data 
were collected in positive and negative ion mode centroid mode, the lockspray frequency was 
set at 200 s, and data were averaged over 10 scans. The mass spectrometer was operated with 
a capillary voltage of 2.4 kV for negative mode and 3.2 kV for positive ion mode, cone 
voltage of 35 V, nebulizer gas flow of 900 L/h, desolvation temperature of 350 °C, and 
source temperature of 120 °C. The instrument was set to acquire over the mass range m/z 50-
1000 with acquisition time of 5 scans s
-1
 and an interscan delay of 100 ms.  
 
 
10.3.6 Tandem mass spectrometry and feature identification 
Tandem mass spectrometry (MS-MS) was performed on a Quadrupole Time of Flight 
(QTOF) Premiere
TM
 instrument (Waters MS Technologies, Manchester, UK). 
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Chromatographic conditions were the same as preceding MS experiments and survey scans 
were performed for masses identified through multivariate analysis. A collision ramp was set 
for the argon filled collision cells from 5 – 30 eV to ensure passage and fragmentation of the 
parent ion selected by the quadrupole. Fragmentation patterns and retention times were then 
interrogated to identify candidate molecules using online databases for identification 
(http://www.hmdb.ca/ and http://metlin.scripps.edu/metabolites_list.php).  
 
10.3.7 Data pre-processing 
Data underwent peak-picking, retention time correction and grouping using XCMS (Scripps 
Center for Mass Spectrometry, La Jolla, California, USA) (Smith et al., 2006) as previously 
described (Chapter 5). 
 
10.3.8 Multivariate analysis 
The data matrix was exported to SIMCA (Umetrics, Umea, Sweden) for PCA and PLS-DA. 
All date were mean centred prior to multivariate analysis and outliers were excluded on the 
basis of exceeding the Hotelling’s T2 distance and causing heavy bias to the loadings 
components.  
 
10.3.9 Univariate analysis 
Data were exported to GraphPad Prism (La Jolla, California, USA) for univariate analysis in 
the form of Mann-Whitney t-tests comparison of medians between groups, assuming non-
parametric distribution of data. Fisher’s exact test was used to compare categorical data.  
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10.4 RESULTS 
10.4.1 Subject recruitment, exclusion and demographics 
A total of 50 patients were recruited, comprising two groups: 19 with HCC and 31 with 
cirrhosis. Prior to analysis, three patients were excluded from the HCC group: one who had 
undergone curative liver transplantation and thus no longer had HCC; a second who had 
undergone curative hepatic resection and a third who was co-infected with human 
immunodeficiency virus (HIV), the safety protocols at the department of biomolecular 
medicine prohibiting the analysis of HIV infected samples. From the positive and negative 
mode studies, a further sample was excluded following multivariate analysis from both ion 
mode data, the details of which are given below, leaving a total of 15 HCC samples. From the 
cirrhosis group, four patients were excluded prior to analysis, owing to insufficient 
radiological or biopsy evidence of cirrhosis; three samples were excluded following 
multivariate analysis of positive mode data, and one excluded after analysis of negative mode 
data, leaving a total of 24 and 26 in positive and negative mode groups, respectively. Subject 
samples used for the parallel 
1
H NMR study (Chapter 8) were almost the same as those used 
for this study. As a means of comparison, Table 10-1 details the subject demographics from 
each study.  
 
Subject demographics for positive and negative mode studies are displayed in Tables 10-2 
and 10-3. These data are directly comparable to multivariate analysis data as samples that 
were outlying according to PCA were excluded from both subsequent multivariate analysis 
and baseline demographics. Different samples were outlying in the two ion models; therefore 
two demographic data tables are displayed. 
 
 
 
 
240 
 
Table 10-1. Comparisons of subjects recruited for 
1
H NMR and UPLC MS studies. 
 HCC Cirrhosis 
 
1
H NMR UPLC MS 
1
H NMR UPLC MS 
N 13 15 25 26 
Median age (yrs) 61 61 58 60 
Male n   11/13 12/15 14/25 17/26 
HCV 6 7 6 7 
HBV 3 3 3 4 
Alcohol 2 3 9 9 
NASH 0 0 2 2 
HCV + Alcohol 1 1 2 2 
HBV + Alcohol 0 0 0 0 
NASH + Alcohol 0 0 1 1 
Haemochromatosis 1 1 1 1 
Idiopathic 0 0 1 0 
Median AFP 18.1 21 4.6 4.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
241 
 
Table 10-2. Demographic profiles for samples used in positive ion mode. 
Characteristic HCC Cirrhosis p-value 
N 15 26 - 
Median age (range) (years) 61 60 0.9
a 
Male n (%) 12 (80%) 17 (65%) 0.48
b 
Median body mass index (kg/m
2
) 26.3 27.2 0.24
a 
Child-Pugh A  5 (33%) 17 (65%) - 
Child-Pugh B 4 (27%) 5 (19%) - 
Child-Pugh C 1 (7%) 2 (8%) - 
Non-cirrhotic 2 (13%) 0 - 
Unknown due to missing data 3 (20%) 2 (8%) - 
Key: 
a
Mann-Whitney test for non-parametric data; 
bFisher’s exact test for categorical data. 
 
 
 
Table 10-3. Demographic profiles for samples used in negative ion mode. 
Characteristic HCC Cirrhosis p-value 
N 15 24 - 
Median age (range) (years) 61 60 0.9
a 
Male n (%) 13/15 (87%) 15/24 (63%) 0.15
b 
Median body mass index (kg/m
2
) 26.3 26.5 0.42
a 
Child-Pugh A  5 (33%) 16 (67%) - 
Child-Pugh B 4 (27%) 4  (17%) - 
Child-Pugh C 1 (7%) 2 (8%) - 
Non-cirrhotic 2 (13%) 0 - 
Unknown due to missing data 3 (2%) 2 (8%) - 
Key: 
a
Mann-Whitney test for non-parametric data; 
bFisher’s exact test for categorical data. 
 
 
 
 
In both groups, median age and BMI were similar: 61 years and 26.5 kg/m
2
 in the HCC 
groups; 60 years and 26.5 – 27.2 kg/m2. There were proportionally more males in the HCC 
groups but not significantly (p=0.48 and 0.15). The majority of both cohorts consisted of 
Child-Pugh stage A and B patients (60% for HCCs and 84% for patients with cirrhosis).  
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Aetiological factors are displayed in Table 10-4 and 10-5 and graphically, for positive mode 
samples, in Figure 10-1.  
 
Table 10-4. Positive ion mode aetiological factors. 
Aetiology HCC Cirrhosis 
HCV 7 (46%) 7 (29%) 
HBV 3 (20%) 4 (17%) 
Alcohol 3 (20%) 8 (33%) 
NASH 0 2 (8%) 
Haemochromatosis 1 (7%) 1 (4%) 
HCV + Alcohol 1 (7%) 1 (4%) 
HBV + Alcohol 0 0 
NASH + Alcohol 0 1 (4%) 
Idiopathic 0 0 
Total 15 24 
 
 
 
Table 10-5. Negative ion mode aetiological factors. 
Aetiology HCC Cirrhosis 
HCV 7 (46%) 7 (27%) 
HBV 3 (20%) 4 (15%) 
Alcohol 3 (20%) 9 (35%) 
NASH 0 2 (8%) 
Haemochromatosis 1 (7%) 1 (4%) 
HCV + Alcohol 1 (7%) 2 (8%) 
HBV + Alcohol 0 0 
NASH + Alcohol 0 1 (4%) 
Idiopathic 0 0 
Total 15 26 
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 Figure 10-1. Pie chart of aetiological factors (positive mode). 
 
HCV and alcohol induced liver disease were the major aetiological factors for both groups 
accounting for 66-73% of patients in all ion mode groups and patient cohorts. BCLC stages 
of HCC are depicted in Table 10-6.  
 
Table10-6. Positive ion mode Barcelona Clinic Liver Cancer staging.  
Stage Positive mode (n) Negative mode (n) 
A 5 5 
B 0 0 
C 7 7 
D 2 2 
Unknown due to missing data 1 1 
Total 15 15 
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10.4.2 Serum biochemical analysis 
Patient cohort biochemical profiles are displayed in Tables 10-7 and 10-8, displaying similar 
biochemical profiles in HCC and cirrhosis groups, the only significant differences occurring 
in median serum albumin  (35 gL
-1
 in cirrhosis and 30 gL
-1
 in HCC cohorts, p=0.02) and AFP 
(4.9 IU mL
-1
 in cirrhosis and 21 IU mL
-1
 in HCC cohorts, p <0.01). 
 
Table 10-7. Serum biochemistry profiles for samples used in positive ion mode. 
 HCC 
Median (range) 
Cirrhosis  
Median  (range) 
p-values 
Serum Samples (n) 15 24 - 
AFP (IU mL
-1
) 21 (5.7-1230)
++ 
4.9 (1.1-29.2)
+++
 <0.01
 
Creatinine (mmol L
-1
) 77.5 (59-96)
++ 
71 (48-132)
+
 0.22 
ALT (IU L
-1
) 45 (7-147)
++ 
35 (8-152)
+ 
0.37 
Bilirubin (μmol L-1) 11 (5-168)
++ 
17 (6-87)
+ 
0.37 
Albumin (g L
-1
) 30 (22-40)
++ 
35 (19-46)
++ 
0.02 
INR (IU) 1.1 (1-2)
+++ 
1.2 (1-3.1)
++ 
0.75 
Key: Mann-Whitney test was used for non-parametric data, 
 +
2 measurements missing,  
++
3 
measurements missing, 
+++
4 measurements missing. 
 
 
 
 Table 10-8. Serum biochemistry profiles for samples used in negative ion mode. 
 HCC 
Median (range) 
Cirrhosis Median  
(range) 
p-values 
Serum Samples (n) 15 26 - 
AFP (IU mL
-1
) 21 (5.7-1230)
++ 
4.9 (1.1-29.2)
+++ 
<0.01 
Creatinine (mmol L
-1
) 77.5 (59-96)
++ 
70 (48-132)
++ 
0.21 
ALT (IU L
-1
) 44 (7-147)
+++ 
35 (8-152)
+ 
0.43 
Bilirubin (μmol L-1) 11 (5-166)
++ 
16.5 (6-87)
+ 
0.36 
Albumin (g L
-1
) 30 (22-40)
++ 
35 (19-46)
++ 
0.02 
INR (IU) 1.1 (1-2)
+++ 
1.2 (1-3.1)
+++ 
0.7 
Key: Mann-Whitney test was used for non-parametric data, 
 +
2 measurements missing,  
++
3 
measurements missing, 
+++
4 measurements missing. 
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The sensitivity of serum AFP, at all cut-off values, was poor, at best identifying only 46.2% 
of HCCs using a cut-off value of 20 IU mL
-1
. This dropped to 23.1% using a cut-off value of 
200  IU mL
-1
. Specificity was high, at 95 - 100% for all cut-offs values (Table 10-9).  
 
 
Table 10-9. Serum alpha-fetoprotein diagnostic sensitivity and specificity.  
 Sensitivity Specificity 
AFP cut off 20 (IU mL
-1
) 46.2 95 
AFP cut off 200 (IU mL
-1
) 23.1 100 
AFP cut off 400 (IU mL
-1
)) 23.1 100 
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10.4.3 Chromatographic data  
Representative total ion chromatograms from positive and negative ion chromatograms are 
displayed in Figure 10-2, displaying the variation in metabolite elution times between ESI 
modes and patient groups. 
 
  
Negative ion mode
Negative ion mode
Positive ion mode
Positive ion mode
HCC
HCC
Cirrhosis
Cirrhosis
Figure 10-2. Representative positive and negative mode total ion chromatograms.   
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10.4.4 Multivariate statistical analysis 
Principal components analysis of positive ion mode data identified three cirrhosis and one 
HCC outlying samples which heavily biased principal components. Examination of the 
loadings plots and the individual contributions plots of these samples identified features M 
536 T293, M310 T316 and M172 T197 as major contributory features, elevated in these 
samples, causing them to be outliers. Given that the concentration of these features was 
unrepresentatively raised in these samples and not contributory to diagnostic biomarker 
profiles, their identity was not investigated further. Subsequent PCA is shown in Figure 8-3, 
displaying excellent clustering of QC samples indicating minimal retention time drift during 
the run.  
 
SIMCA-P+ 12.0.1 - 2011-08-19 13:35:49 (UTC+0) 
• HCC 
• Cirrhosis
• Quality controls
PC1
PC2
 
Figure 10-3. Principal components analysis of UK urine positive ion mode data. 
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Two group PCA models are displayed in Figure 10-4. In positive mode, little clustering is 
seen with poor R
2
 and Q
2
 values (0.3 and 0.04). In negative mode improved clustering is 
observed with only marginally improved R
2
 and Q
2
 values (0.4 and 0.04).  
SIMCA-P+ 12.0.1 - 2011-08-19 13:49:49 (UTC+0) SIMCA-P+ 12.0.1 - 2011-08-19 13:51:07 (UTC+0) 
PC1
PC2
PC1
PC2
Positive mode Negative mode
• HCC 
• Cirrhosis
Figure 10-4. Principal components analysis of UK urine positive and negative mode 
data. 
 
 
Partial least squared discriminant analyses, using 7-fold cross validation, revealed poor model 
parameters for positive mode data (R
2
= 0.2, Q
2
 negative). The misclassification matrix of this 
model is displayed in Table 10-10 displaying a sensitivity and specificity of 80% and 95.8% 
of HCC diagnosis. Negative mode data PLS-DA recorded improved model parameters (R
2
= 
0.6, Q
2
 = 0.2) with a sensitivity and specificity of 93.3% and 96.2% (Table 10-11).  
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Table 10-10. Positive ion mode misclassification matrix.  
 Predicted as HCC Predicted as Cirrhosis  
HCC 12 3 Sensitivity = 80% 
Cirrhosis 1 23 Specificity = 95.8% 
 
 
 
Table 10-11. Negative ion mode misclassification matrix. 
 Predicted as HCC Predicted as Cirrhosis  
HCC 14 1 Sensitivity = 93.3% 
Cirrhosis 1 25 Specificity = 96.2% 
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Analysis of the loadings plots of these models identified a number of features that were 
highly contributory to the model. The extracted ion chromatogram for each of these features 
was inspected to ensure that the peak detection of XCMS had genuinely detected a peak. A 
signal to noise ratio of 10 was used as cut off for detection of true peaks. Features selected 
are displayed in Table 10-12 alongside fragmentation data and probable identities based on 
fragmentation patterns.  
 
 
Table 10-12.  Discriminatory features identified from multivariate analysis.   
m/z feature Mode Fragment Da (abundance) ID 
M204 T61 Positive 85 (100), 145.1 (10), 60.1 (5) Acetylcarnitine 
M265 T229 Positive 130.1 (100), 84.1 (70), 91.1 
(50), 136.1 (20) 
No match 
M286 T297 Positive 85 ((100) No match 
M302 T334  Positive  85.1 (100), 243.2 (10) Dimethylheptanoylcarnitine 
M310 T316 Positive 85 (100), 121.1 (10), 79.1 (5) No match 
M187 T253 Negative 107 (100) p-cresol sulfate 
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10.4.5 Tandem mass spectrometry and univariate analysis 
Features selected from PLS-DA were subjected to tandem mass spectrometry and resultant 
fragmentation patterns were used for identification. Candidate features are displayed in Table 
10-12 alongside fragmentation data and probable identities. In positive mode, five features 
were identified and fragmented. Of note, four of these masses produced an 85 Da fragment, 
characteristic of carnitine compounds, as shown for acetylcarnitine in Chapter 9. Two 
features could be identified as acetylcarnitine and dimethylheptanoylcarnitine (C16H31NO4), a 
long chain acylcarnitine. Fragmentation patterns of these molecules are displayed in Figure 
10-5.  
 
In negative ion mode, one identifiable molecule was detected, M187 T253. On tandem mass 
spectrometry studies, this fragmented to masses at 187 Da, 107 Da and 79 Da, a typical 
fragmentation pattern of p-cresol sulphate (Want et al., 2010) (Figure 10-6). 
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Figure 10-5. Mass spectra of acetylcarnitine standard compared  to subject samples. 
Key: Acetylcarnitine standard (top), feature M204 T61 from urine sample (middle) and 
feature M302 T334 (bottom). 
 
 
Figure 10-6. Mass spectra of feature M187 T253, likely to be p-cresol sulphate.  
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10.4.6 Univariate statistical analysis 
The relative intensity levels for features M204 T61 and M302 T334 were compared for each 
group. Median levels were calculated and compared and these are represented as scatter bar 
charts in Figure 10-7. In positive mode, feature M204 T64 which represents acetylcarnitine, 
was elevated in the urine of patients with HCC, but not significantly (p=0.83). M302 T334, 
likely representing dimethylheptanoylcarnitine, was reduced, again not significantly 
(p=0.097).  In negative mode, M187 T253, which is likely to represent p-cresol sulphate, was 
significantly reduced in the urine of patients with HCC (p=0.05). This finding is in agreement 
with the parallel 
1
H NMR study which identified reduced urinary p-cresol sulphate in HCC 
patients, reported in Chapter 8.  
 
 
 
Figure 10-7.  
Scatter charts displaying group  
comparisons for features  
M204 T61 (acetylcarnitine),  
M302 T334 (dimethylheptanoylcarnitine) 
and M187 T253 (p-cresol sulphate). 
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10.5 DISCUSSION 
This pilot study has provided a number of informative findings relevant to the metabolic 
profiling of HCC. Firstly, there are no reported similar studies in a UK, European or US 
population and these results, therefore, provide novel insight into the urinary metabolic 
changes in a developed world population. It has also provided evidence that UPLC-MS can 
identify a discriminatory urinary metabolic profile between patients with HCC and those with 
cirrhosis induced by a highly diverse range of aetiologies, including alcohol and NASH 
induced liver disease. This would suggest that regardless of aetiology, alterations in 
metabolism are tumour-induced rather than aetiologically induced. 
 
Secondly, multivariate analysis, in the form of cross validated PLS-DA provided predictive 
models for HCC diagnosis which out-performed serum AFP in terms of sensitivity (80% - 
93.3% versus 23.1% - 46.2%). This result contrasts to that of the Nigerian population in 
which AFP was elevated, above 200 IU L
-1
, in all HCC patients. This is not surprising given 
the knowledge that flares of chronic HBV, even without HCC, may cause a rise in serum 
AFP. Given the majority of tumours in this study occurred on a background of HCV or 
alcohol induced liver disease, it is expected that many of them will be non- secreting 
tumours. It is poorly understood why certain aetiologies encourage AFP secreting tumours 
and others do not. This may be as a result of the originator cell of the tumour, perhaps in the 
presence of HBV, being less differentiated and therefore more akin to the fetal state. It would 
appear, however, that urinary metabolic profiles are less affected by liver disease aetiology.     
 
Identification of features remained challenging, but three discriminatory metabolites were 
characterised with reasonable accuracy. Acetylcarnitine was observed to be elevated in urine 
of patients with HCC, albeit not significantly (p=0.83). This finding is akin to those findings 
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in the parallel Nigerian UPLC-MS study (Chapter 9). In addition to this, 
dimethylheptanoylcarnitine, a long chain acylcarnitine was reduced in the urine of patients 
with HCC, again non-significantly (p=0.097).  These results support the theory that B-
oxidation of fatty acids is perturbed in HCC. A relative reduction in the level of long chain 
acylcarnitines could occur either through the decreased transesterification of long chain fatty 
acids by carnitine palmitoyl transferase 1 (CPT-1) in the outer mitochondrial membrane or an 
increased flux through the mitochondrial membrane with acetylcarnitine via  carnitine-
acylcarnitine translocase (CACT) (Figure 9-10). In either mechanism, it may be that 
alteration in oxidation of fatty acids may provide lipid substrates for cellular membranes in 
proliferating tumours.  
 
The identification of a significant reduction in urinary p-cresol sulfate in negative ion mode 
provides validatory confirmation to the parallel urinary 
1
H NMR study in the same UK 
cohort. As discussed in Chapter 8, this finding was not evident in the Nigerian and Egyptian 
groups. p-cresol is a product of colonic bacterial metabolism (Clayton et al., 2009) and it may 
be that because of dietary differences in Nigerian, Egyptian and UK populations, the gut 
microbiome is altered. This in turn may affect the production of urinary metabolites, such as 
p-cresol sulphate.  It has been shown that urinary p-cresol sulphate levels were reduced in 
patients with Crohn’s disease, a population where there are major alterations in the colonic 
gut microbiome (Williams et al., 2009). Functionally, this finding may also be indicative of 
an underlying hepatic metabolic derangement, lower levels of p-cresol sulphate reflecting 
reduced sulfonation in those patients with HCC and worse liver function (Chapter 8).  
 
Improvements in this study are possible. Sample numbers were small and this may explain 
why most metabolites identified displayed trends but not overt statistically significant 
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differences between groups. A larger study population number in follow up studies is 
essential. This would also allow subgroup analyses to be performed. In particular, it would be 
valuable to investigate whether the urinary metabolic profile of HCC patients with viral 
hepatitis differs from those with NASH, a condition intimately linked with the “metabolic 
syndrome”.  
 
Standard authenitification of metabolites would be desirable. Unfortunately, standards for p-
cresol sulphate and dimethylheptanoylcarnitine are not commercially available but can be 
constructed in the laboratory. Finally, given the identification of carnitine related molecules 
in this UK population and in the previously reported Nigerian population (Shariff et al., 
2010) it would be informative to perform a targeted carnitine and carnitine related molecule 
profile of urine from patients with HCC to identify any further alterations that may be present 
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10.6 CONCLUSIONS 
This study has provided evidence that UPLC-MS can identify a discriminatory urinary 
metabolic profile between patients with HCC and those with cirrhosis induced by a highly 
diverse range of aetiologies, including alcohol and NASH induced liver disease. This would 
suggest that HCC induces urinary metabolic changes independent of the underlying disease. 
Urinary UPLC-MS multivariate profiles also provided predictive models for HCC diagnosis 
which out-performed serum AFP in terms of sensitivity (80 - 93.3% versus 23.1 - 46.2%). 
 
Further evidence was also provided, in the form of altered carnitine moiety levels, of the role 
perturbed fatty acid oxidation may have in HCC. The identity of p-cresol sulphate, a gut 
microbial produced metabolite, also found in parallel 
1
H NMR studies to be reduced in the 
urine of patients with HCC. This provides some validation for the use of the complementary 
techniques of 
1
H NMR and UPLC-MS. 
. 
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11  CONCLUSIONS AND FUTURE WORK 
The results of these studies reveal altered biofluid metabolic profiles of HCC indicative of 
heightened basal metabolic rate, cellular turnover, deranged lipid metabolism, chromosomal 
methylation and altered gut microbe metabolism. The hypotheses of this thesis were firstly, 
that the presence of HCC results in altered blood and urinary metabolic profiles which can be 
characterised using 
1
H NMR and LC-MS and secondly, that these profiles can be modelled to 
allow accurate disease diagnosis. The latter hypothesis, for the individual populations studied, 
was upheld, with urinary metabolic profiles, in particular, displaying high diagnostic 
sensitivity and specificity. Whether the metabolites detected are directly from the tumour 
itself, or as a result of the tumour effects on its microenvironment or total body physiology 
remains unclear.   
 
The use of both 
1
H NMR spectroscopy and UPLC MS profiling highlighted the advantages 
and disadvantages of the techniques. Preparation for 
1
H NMR spectroscopy, both for blood 
and urine, involved few stages and interpretation of results was straightforward given the 
availability of well validated 
1
H NMR spectral databases. It also provided, in the urine of 
patients with HCC from Nigeria and Egypt (Chapters 6 and 7), the most accurate predictive 
results, albeit with relatively abundant metabolites (creatinine, creatine and carnitine) given 
the inherent poor sensitivity of 
1
H NMR spectroscopy in detecting low concentration 
metabolites. Preparation for UPLC MS, however, was labour intensive, involving many steps. 
This was particularly the case for lipidomic profiling of blood (Chapter 5). Identification of 
candidate metabolites was difficult owing to the need of further fragmentation experiments 
and paucity of well characterised databases. Metabolites detected, however, were different to 
that of 
1
H NMR and illuminating of the different metabolic pathways altered in the presence 
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of HCC. The multivariate results from UPLC MS studies, both in urine and blood, were less 
impressive than 
1
H NMR. The following sections summarise the findings from each 
experiment group in futher detail.   
 
11.1 FISHER RAT MODEL OF HCC 
The well-characterised Fisher rat model of HCC, induced by DEN and NMOR, was chosen 
because of the rapid onset of HCC, allowing studies to be undertaken in reasonable 
timeframes. Animals with tumours were over 100g lighter than healthy counterparts. Proton 
NMR spectra from these animals displayed marked and significant decreases in lipoproteins, 
unsaturated fatty acids, acetyl-glycoprotein, acetoacetate, and glucose (p≤0.001). Plasma 
citrate and formate levels were increased (p=0.02). Ultra performance LC-MS lipid profiling 
studies of plasma confirmed that multivariate statistical modelling was robust in classifying 
animals with HCC, distinct from healthy control animals. Features M496 T104 and M759 
T366 were identified as most contributory to multivariate models from animal studies, 
although the levels of these metabolites were not significantly different between HCC and 
control animals on univariate statistical comparison. M496 T104 is likely to represent LPC 
(24, 0, 0), a major cellular membrane component. M759 T366 could not be identified from 
available databases. The lipoprotein changes in the rat are likely to indicate a heightened 
basal metabolic rate, a marker of cancer cachexia, resulting in dramatic weight differences. 
These findings are not the same as for the human studies, where certain lipoproteins are 
increased and others diminished, in comparison to patients with cirrhosis and healthy 
volunteers.  
 
While revealing in their own right, the results from an animal model of HCC have 
limitations for translation into human studies. The pathophysiology, genotype, phenotype, 
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environmental, dietary and co-morbid factors in humans are impossible to replicate in an 
animal model and it is probably the interplay between all of these factors that results in the 
carcinogenic process and influences metabolic profiles in man (Holmes et al., 2008; 
Psihogios et al., 2008; Wolk et al., 2001). Furthermore, the onset of tumours in this 
particular animal model occurs as early as 10 weeks. This is due to the potency of the 
mutagens utilised. This is not akin to the human disease, which typically occurs decades 
after the introduction of an aetiological factor. A model, whereby the aetiological factor is 
more like the human disease may provide better translation. An example of such is a 
C57/Black 6 transgenic mouse model of HCC that contains the entire open reading frame of 
HCV under an albumin promoter, developed by the Pawlotsky group in France (Lerat et al., 
2002). This model displays liver-specific expression of the complete HCV RNA coding 
sequence. Since these animals are immune-tolerant to the viral proteins, there is no immune 
or inflammatory response to viral protein expression, similar to human disease. There is an 
increased rate of hepatocellular adenoma and carcinoma in these. Such models should be 
considered in future studies as the carcinogenic process is more translational when making 
species comparisons. 
 
11.2 HUMAN BLOOD METABOLIC PROFILING STUDIES 
The human 
1
H NMR blood metabolic profiling studies provided evidence of predominantly 
altered lipoprotein levels. Differences between patients with HCC, patients with cirrhosis and 
healthy volunteers were detected in levels of LDL (p=0.002 and 0.12), VLDL (p=<0.001 and 
0.77), lactate (p=0.03 and 0.12), N-acetylglycoproteins (p=<0.001 and 0.001) and 
acetoacetate (p=0.52 and 0.06).  Efforts were made to match groups as closely as possible; 
nonetheless the HCC group were older than the healthy controls. Although this difference 
was not significant, the confounding effect of age on lipoprotein resonances cannot be ruled 
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out. Nevertheless, these findings are still likely to indicate an altered production or 
consumption (decreased peripheral breakdown of VLDL) of lipoproteins.  
 
The serum lipidomic UPLC-MS studies identified LPC (24, 0, 0) as the lipid contributing 
most to multivariate discriminant models of HCC and cirrhosis. However, the results from 
Nigerian or UK groups did not produce significant results, which may have been because 
sample numbers in this study were small (n ≤10 in each group). This result was most marked 
in the UK group, displaying a reduction in LPC (24, 0, 0) levels in patients with HCC 
(p=0.4). A very recently published study observed similar changes in LPC (24, 0, 0)  levels in 
a group of 20 American patients with HCC using UPLC-MS and GC-MS (Patterson et al., 
2011). Lysophosphatidylcholine (24, 0, 0), is a major constituent building block of cellular 
membranes. Taken together with the blood and urine NMR data, this may indicate that lipids 
are being diverted from catabolism to anabolism in the form of tumour proliferation.  
 
There were inevitable limitations in these studies. First, although efforts were made to match 
HCC, healthy and cirrhosis groups, given the demographic make-up of HCC it is challenging 
to precisely match groups.  Secondly, as the UPLC-MS lipid profiling studies were 
performed as a pilot, partly to optimise the technique of lipid extraction, sample numbers 
were small. Larger studies are needed to tease out any significant differences between 
patients with HCC and controls. In retrospect, it would also have been illuminating to record 
markers of cancer cachexia (Tisdale,  2010) including percentage weight loss, adipose tissue 
loss, skeletal tissue loss, inflammatory and cytokine markers to definitively identify or refute 
any correlation with metabolite markers of HCC. The hypothesis that HCC cells secrete 
metabolite markers could also be explored further. A study comparing peripheral blood 
metabolic profiles to that of blood collected in proximity to the tumour (which could be 
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collected prior to trans-arterial chemo-embolisation therapy) in the same patient would be 
revealing. This would provide some proof, if metabolic characteristics were different, that the 
tumour itself is producing metabolite markers. Other cancers, which do not occur on the 
background of liver disease, were not included. It would not have been possible to distinguish 
which metabolic differences were due to HCC and which were due to cirrhosis when 
comparing HCC to other tumour types.     
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11.3 HUMAN URINE METABOLIC PROFILING STUDIES 
The human urine 
1
H NMR studies of Nigerian (Shariff et al., 2010), Egyptian (Shariff et al., 
2011) and UK cohorts (manuscript in progress), were the first to identify metabolite profiles 
of HCC which shared similarities between the different populations. Indeed, the diagnostic 
accuracy of urine profiles in Nigerian and Egyptian groups was far better than that of blood. 
Diagnostic sensitivity and specificity of discriminating urine profiles of HCC from healthy 
subjects ranged from 90 to 100% and 90 to 95%. This was only slightly reduced in 
discriminating patients with HCC from those with cirrhosis: 80 to 90% sensitivity and 70 to 
90% specificity. These results compare favourably to serum AFP, which carries a 39% to 
65% sensitivity and a 76% to 94% specificity for tumour diagnosis (Daniele et al., 2004). The 
UK urine study, in which patients with HCC were compared to those with cirrhosis, 
displayed poorer diagnostic power of metabolite profiles, with sensitivity dropping to 50%. 
This may have resulted from close matching of cirrhosis and HCC patients resulting in higher 
similarity of 
1
H NMR spectra.  Certainly, BMI was similar in both groups, so it is unlikely 
that cancer cachexia, which may have been a prominent contributor to altered spectral 
profiles in the Nigerian and Egyptian group, had a major influence in this study. Certain 
metabolites were similarly altered across the studies, such as a reduced urinary creatinine and 
raised creatine and carnitine levels. Reduced creatinine is likely to reflect reduced muscle 
mass in patients with cachexia, creatine to reflect increased energy consumption and 
carnitine, an alteration in fatty acid metabolism.  Of note, in both the UK and Nigerian 
UPLC-MS studies, acetylcarnitine was found to be increased in the urine of patients with 
HCC, corroborating altered carnitine profiles from 
1
H NMR spectroscopy studies. A previous 
study assessing the urine metabolic 
1
H NMR profiles of healthy volunteers after stimulation 
of β-oxidation of fatty acids with oral administration of fenofibrate, recorded decreased 
acetylcarnitine urine levels in treated subjects (Patterson et al., 2009). This suggests that β-
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oxidation is suppressed in patients with HCC. This would be in keeping with reduced LPC 
(24, 0, 0) levels in the blood of patients with the tumour if lipids were being diverted away 
from catabolism and instead incorporated into cellular membranes of rapidly proliferating 
cells.   
 
Certain urinary metabolites were discriminatory in the different populations. Urinary glycine, 
hippurate, citrate and TMAO were all decreased in the Egyptian patients with HCC. p-cresol 
sulphate was reduced in the urine of patients with HCC in the UK study, confirmed in both 
1
H NMR and UPLC-MS urine studies. Individual explanations for the altered levels of these 
metabolites are given in relevant chapters. These sets of metabolite are not part of the same 
metabolic pathway so it is unclear why in one population and not the other, they may be 
altered. Dietary, co-morbid and aetiological factors are sure to play a role but it is currently 
unclear how they would contribute to these particular metabolite differences.  
 
11.4 METABONOMICS IN OTHER CANCERS AND CACHEXIA 
The studies presented within this thesis, as with the majority of metabolite profiling studies, 
are limited to comparative disease groups. Metabolites are often the common endpoint of 
common mammalian pathways and it is probably the case that the same metabolites will be 
deranged in very different diseases. Metabonomics, therefore, is reliant upon the diagnostic 
accuracy of panels of biomarkers, the ratios of which are thought to be more specific to the 
disease in question. Examples of metabolic studies in non-HCC cancer, cachexia and other 
diseases are described to allow comparison.  
 
Serum metabolic profiling studies in patients with colorectal cancer (CRC), in age and gender 
matched individuals, have identified reduced glycine levels as discriminatory (Leichtle et al., 
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2012) and elevated acetylglycoproteins, acetate, formate and reduced citrate, creatine, and 
lactate were found to be highly discriminatory in patients with metastatic CRC (Bertini et al., 
2012). Furthermore, urine metabolic profiling studies of patients with CRC have identified 
reduced histidine (Qiu et al., 2010) and citrate, hippurate and p-cresol compared to matched 
healthy controls (Cheng et al., 2012). A study of GC MS profiles in serum of patients with 
recurrence of breast cancer after treatment identified altered levels of glycine and formate in 
addition to a number of other metabolites, as discriminatory (Asiago et al., 2010).  
 
There have been few human metabolic studies of metabolic profiles in cancer cachexia but a 
study of GC and LC MS serum profiles in a rat model of model of malnutrition, identified 
perturbations in levels of creatine, citrate and trimethylglycine (Wu et al., 2010).  
 
Finally, Williams and colleagues examined the 
1
H NMR urine profiles of patients with 
Crohn’s disease and compared these to healthy age and sex matched controls. Levels of 
hippurate and p-cresol were reduced in Crohn’s sufferers and in combination, were again 
highly discriminatory of disease in these groups (Williams et al., 2009). 
   
It is clear that certain metabolites, such as citrate, creatine, glycine, p-cresol sulphate and 
hippurate are altered in the cancer and non-cancer diseased state. This needs further 
investigation and comparative studies to allow control groups to include other diseases and 
cancers in age, sex and nutrition-matched analyses. Whether it would then be the case that the 
disease itself or cachexia/general illness are the discriminatory driving factors could be 
determined. Without these data, the diagnostic acumen of metabolic profiling will always be 
cast in doubt.    
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11.5 FUTURE DIRECTIONS 
For both blood and urine studies larger cohorts of patients with well-characterised 
anthropometric and liver disease stages are required for validation of the studies presented 
herein. It will also be essential to characterise the metabolic profiles of HCC in patients with 
early stage disease, when the tumour is asymptomatic. It would also be valuable to include 
positive controls, those patients with non-HCC tumours, to see whether there is similarity 
despite the presence of liver disease. Two ongoing projects, which are a direct result of the 
work of this thesis, address these issues. Firstly, the UK Clinical Research Network 
(UKCRN) has recently approved specimen collection for metabolic profiling of blood and 
urine in patients with HCC, with collaborative centres collecting samples from patients with 
HCC, cirrhosis and healthy volunteers (http://public.ukcrn.org.uk, UKCRN ID 8357). 
Parallel proteomics and genomics studies are also planned which will aid in identifying the 
underlying molecular basis of metabolic derangement. Secondly, as part of a European 
Commission FP7-funded study into the effect of prevention of liver fibrosis in HBV-infected 
patient population in West Africa (Banjul in Gambia, Dakar in Senegal, and Jos in Nigeria) 
led by the Liver Unit at Imperial College London, a metabolic profiling arm of the study will 
oversee sample collection from 800 patients with HCC over 5 years following an initial 
baseline screening programme of 13,000 subjects 
(http://ec.europa.eu/research/health/medical-research/cancer/fp7-projects/prolifica_en.html). 
From the perspective of continuing the work from my thesis, in addition to Gambia and 
Senegal, the study is located in the same centre in Jos in Nigeria, where my samples were 
collected.  These studies will include longitudinal sampling from those patients with 
established cirrhosis, a proportion of which will develop tumours during follow up. This will 
allow the assessment of very early stage tumours.  
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The work presented in this thesis has provided novel information on the ability of metabolic 
profiling of patient blood and urine to diagnose HCC and expose the effect HCC can have on 
human physiology. Certain questions remain on the nature and origin of these metabolic 
changes that follow-up studies aim to address.  
 
Hepatocellular carcinoma remains the third highest cause of cancer-related death, worldwide, 
affecting the developed and developing world. Urgent attention to developing novel methods 
of diagnosis, particularly in early stage HCC, is required to improve the prognosis from this 
challenging disease. Ultimately, a urinary dipstick test would be the goal for patients in 
resource-poor settings as screening at a village level would be simplified.  
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